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ABSTRACT 
 
 Mesoporous silica materials, discovered in 1992 by the Mobile Oil Corporation, have 
received considerable attention due to their superior textual properties such as high 
surface area, large pore volume, tunable pore diameter, and narrow pore size distribution. 
A general overview of recent developments of organofunctionalized hybrid mesoporous 
silica nanoparticles (MSNs) materials is presented, focusing on the use of MSNs as 
biocompatible, stimuli-responsive drug delivery devices and a description of the 
sophisticated systems with novel capping agents and controlled release mechanisms. 
 The potential of employing MSNs for drug delivery was further studied on the 
biological behaviors of these nanoparticles in blood vessels. The research demonstrated 
the size and surface effects on the interaction of MSNs with human red blood cell 
membranes, and proposed that appropriate surface modification of nanoparticles can 
improve their biocompatibility and diminish their dangerous side effects on red blood 
cells. 
 MSN materials have also been extensively applied in the field of catalysis. We have 
tethered a Pt(II) bipyridine catalyst onto MSNs in order to enhance its thermal stability 
and product selectivity. A detailed investigation on the catalytic activity showed that the 
catalytic performance was similar between the homogeneous and heterogeneous systems. 
However, the homogeneous system exhibited appreciable degradation after 16 hr at 100 
°C. Instead, using MSNs as scaffolds, this catalyst system retained its activity after 72 hr 
at 150 °C, demonstrating an increased thermal stability. 
 We also explored the feasibility of introducing a biocatalyst to function synergically 
with MSN supported inorganic catalyst. Supported Au-nanoparticle catalyst employed for 
direct alcohol oxidative esterification usually suffers from a slow alcohol oxidation rate. 
We designed a co-catalyst system by combining a biocatalyst, alcohol dehydrogenase 
enzyme and an inorganic catalyst, mesoporous silica nanoparticles supported Au 
nanoparticle to accelerate reaction tandemly. We identified several factors that affect the 
catalytic performance of the co-catalyst system. We then examined the catalytic 
capability of this co-catalyst system on the one-pot transformation of allyl alcohol into 
allyl acrylate ester. We expect that this system could lead to the development of a variety 
of catalyst pairs for a great scope of reactions. 
vii 
 
 We further explored the possibility of the intracellular co-delivery of a biocatalyst 
and its substrate using MSNs. We designed a gold nanoparticle-capped MSNs platform 
and demonstrated its ability to release luciferin from the interior pores of MSNs upon 
gold nanoparticle uncapping in response to disulfide-reducing antioxidants, and 
co-deliver bioactive luciferase from the PEGylated exterior surface of MSNs into Hela 
cells. The effectiveness of intracellular catalytical reactions was evaluated by measuring 
luminescence emission signals. We envision that our co-delivery systems could play a 
significant role in intracellular controlled catalysis and tumor imaging. 
 The research presented in this dissertation would provide MSNs with a great 
potential for various biomedical and catalytic applications. 
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CHAPTER 1. DISSERTATION ORGANIZATION 
 
 The dissertation is organized in seven chapters.  Chapter 1 describes the 
organization of the dissertation.  Chapters 2-6 consist of journal articles either published 
or submitted for publication.  Chapter 7 concludes this dissertation with summary of the 
results and discusses an outlook for future work. 
 Chapter 2 is an overview of the mesoporous silica nanoparticle family, from the 
synthesis and surface functionalization, to its applications in drug delivery and controlled 
release to both animal cells and plant cells. 
 Chapter 3 discusses the effects of size and surface functional groups of mesoporous 
silica nanoparticles on their interactions with human red blood cell membranes, which is a 
preliminary topic when employing them as intracellular drug delivery devices. 
 Chapters 4 to 6 describe catalytical applications of mesoporous silica nanoparticles. 
 Chapter 5 describes a co-catalyst system comprising an enzyme and a MSN 
supported gold-nanoparticle catalyst. The catalytic activity of the co-catalyst system was 
evaluated on the one-pot allyl alcohol oxidative esterification reaction, wherein an alcohol 
dehydrogenation reaction took place first on the biocatalyst and the products subsequently 
served as reactant for an esterification reaction catalyzed by Au catalyst.  
 We further explored the use of mesoporous silica nanoparticles to perform catalysis 
reactions intracellularly. Chapter 6 presents the design of an enzyme-substrate co-delivery 
system and demonstrates its in vitro application in triggering artificial intracellular 
reactions, converting biological energy into usable forms and controlling cell functions. 
 Finally, Chapter 7 is a brief conclusion of this dissertation, summarizing general 
accomplishments and potential future applications.
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CHAPTER 2. MESOPOROUS SILICA NANOPARTICLES 
FOR DRUG DELIVERY AND CONTROLLED RELEASE 
A manuscript submitted to the book Nanotechnology and Drug Delivery 
Xiaoxing Sun and Brian G. Trewyn 
 
ABSTRACT 
 The advancement of mesoporous silica nanoparticles with unique structural features 
as non-invasive and biocompatible carriers to deliver drug molecules into animal and 
plant cells has been well established in pharmaceutical research over the recent decade. 
Herein, we review synthetic approaches of mesoporous silica nanoparticles and current 
progress on the functionalization of mesoporous silica nanoparticles with organic 
components and inorganic nanoparticles plus a short survey of characterization methods 
frequently discussed. Utilizing these flexible functionalization methods, versatile 
mesoporous silica nanoparticle assemblies are fabricated and used as drug delivery 
devices via numerous mechanisms. We highlight the development of the design and 
synthesis of nanovalve and capping systems on mesoporous silica nanoparticles, where 
drugs are encapsulated in the pores and released in a controlled fashion by physical, 
chemical or biological external or internal stimuli. Moreover, when functionalized with 
specific cell and antigen targeting moieties, mesoporous silica nanoparticles can 
selectively deliver drugs to diseased cells, and hence enhance chemotherapy effectiveness 
and reduce side effects. Recent reports have also demonstrated paradigms of successful in 
vivo drug delivery systems using mesoporous silica nanoparticles as a scaffold. We 
further discuss investigations on the biocompatibility of mesoporous silica nanoparticles 
and on the internalization efficiency of mesoporous silica nanoparticles by animal and 
plant cells. 
 
1. Introduction 
 During the past several decades, a steadily growing number of drugs have been 
discovered. However, about 40 percent of newly designed drugs, especially those which 
are based on biomolecules such as peptides, oligonucleotides, proteins and DNA, often 
exhibit low bioavailability and are rejected by the pharmaceutical industry.1 Therefore, 
there is an increasing demand for the development of drug delivery systems to minimize 
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drug degradation, manipulate drug pharmacological profile, diversify drug administration 
routes, decrease detrimental drug side effects and target specific sites. To achieve these 
goals, numerous materials have been extensively investigated, such as amphiphilic block 
copolymers,2-4 liposomes,5 dendrimers,6,7 hydrogels,8,9 as well as inorganic 
nanoparticles.10,11 
 Among numerous drug delivery systems tested, mesoporous silica nanoparticles 
(MSNs) stand out to be a promising candidate, which have the potential to perform all the 
above-mentioned functions simultaneously. Typically, MSNs used as drug delivery 
systems are featured by their ordered arrays of 2D hexagonal micro- or mesopore 
structure, uniform particle sizes (80-500 nm), large surface areas (>1000 m2 g-1), high 
pore volumes (0.5-2.5 cm3 g-1), tunable pore diameters (1.3-30 nm), controllable particle 
morphology and both exterior and interior surfaces that could be independently modified 
with a variety of functional groups. In contrast to conventional polymer-based drug 
delivery systems, which usually suffer from problems such as low drug loading capacity 
and poor drug release control, MSNs-based drug delivery systems successfully avoid 
these issues. The high surface areas and pore volumes allow for a large payload of drug 
molecules. The pore environment and surface can be adjusted by functional groups 
favored by drug molecules in order to further enhance drug loading and releasing ability. 
The highly stable pore channels prevent encapsulated drug molecules from degradation in 
harsh environments during drug administration. The tunable particle morphology of MSN 
materials renders their superb biocompatibility at concentrations adequate for 
pharmacological applications. 
 Furthermore, the most remarkable advantage of MSN materials as drug delivery 
systems is their “zero premature controlled release” property. Namely, drugs are carried 
with precise control of location and time without leaching prior to reaching the targeted 
cells or tissues. This technique is realized by encapsulating drug molecules inside the 
pores of MSN materials followed by blocking the pore entrances with stimuli responsive 
agents, or so called “caps”. Hence, delivery of drug molecules takes place only when 
these caps leave the MSN assembly when triggered by external or internal stimuli that are 
manipulated manually at a desired location and time. In addition, it is also possible to 
deliver guest molecules repeatedly in small portions by reversibly switching the 
MSNs-based drug delivery system between “on” and “off” status. 
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 In this chapter, we review recent endeavors on the development of MSNs-based 
controlled release drug delivery systems, as well as investigations on their in vitro and in 
vivo applications. 
 
2. Synthesis of Mesoporous Silica Nanoparticles 
 The family of mesoporous silica materials was independently discovered by Kresge 
et al.12 at the Mobil Oil Company and the Kuroda group13 at Waseda University in the 
early 1990s. Since then, research in this field has tremendously expanded. Mesoporous 
silica materials with different mesophases have been synthesized by varying experimental 
conditions such as pH, temperature, templates and molar ratios.14,15 The earliest and most 
well known representative is MCM-41, exhibiting a 2D hexagonal mesopore arrangement 
(Fig. 1). Another example is SBA-15, sharing a 2D hexagonal structure, but it bears wider, 
tunable pore size range and greater hydrothermal stability than MCM-41. Both types of 
MSN materials have found applications as drug delivery devices.10,16-19 
 
 
Figure 1. (a) Transmission electron micrograph and (b) Scanning electron micrograph of 
MCM-41 material. 
 
 The key principle for synthesizing MSN materials is the condensation of silica 
precursors directed by self-assembled liquid-crystal arrays of surfactants. In-depth 
investigations have led to two proposed mechanisms involved in the formation of 
supramolecular aggregates of surfactants and subsequent generation of MSN materials.20 
In the liquid crystal templating mechanism (LCT), surfactants form liquid crystal 
(b) (a) 
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structures at concentrations above the critical micelle concentration (CMC) of the 
surfactant and serve as templates, without requiring the addition of silica precursors. 
While an alternative mechanism was proposed that the final mesopore ordering is a 
process of cooperative interaction between surfactants and silica precursors. For example, 
MSN materials could be prepared even at surfactant concentrations far below the CMC, 
in which case an ordered liquid crystal structure could develop under the second 
mechanism.21 
 In a typical surfactant-silica precursor interaction, tetramethyl- (TMOS) or 
tetraethyl-orthosilicate (TEOS) is normally added as silica precursors, and cationic 
alkyltrimethylammonium salts are used as templates under a basic reaction condition. 
Further exploration was conducted by the Stucky research group, where they employed a 
series of block-copolymer surfactants as structure directing agents to synthesize MSNs in 
acidic environments.22-25 A variety of strategies have been proposed to attain tunable pore 
sizes from less than 2 nm up to 30 nm, including the adjustment of the hydrocarbon chain 
length of small surfactant templates,26,27 the use of pore swelling agents such as 
mesitylene,26 or hydrothermal treatments.28 The control over the surfactant-silica 
interaction enables a versatile synthesis condition for MSN materials, and thus allows for 
the functionalization of other species into the silica framework. 
 
 
Figure 2. Surface functionalization of mesoporous silica nanoparticles by the (a) 
co-condensation method and (b) post-synthesis grafting method. 
 
(b) (a) 
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3. Surface Functionalization of Mesoporous Silica Nanoparticles 
 A notable advantage of using MSN materials as drug delivery systems is the relative 
ease to incorporate enormous variation of organic species with biocompatible MSN 
materials. The flexibility to modify MSN surfaces leads to the generation of a 
considerable number of MSN based hybrid materials that possess specific functions for 
drug delivery. Illustrations of these MSN derivatized materials and their functions will be 
discussed in later sections. The commonly used organic precursors are 
organotrialkoxysilanes [(R’O)3SiR] or organotrichlorosilanes [Cl3SiR]. Two popular 
pathways are available for surface functionalization (Fig. 2). One is to introduce 
organosilanes simultaneously with silica precursors during the synthesis of MSN 
materials (“co-condensation”) (Fig. 2a). The other pathway is to prepare unfunctionalized 
MSN materials and subsequently modify their surfaces with organosilanes (“grafting”) 
(Fig. 2b).  
 
3.1 Surfaces Functionalization by Co-condensation Method 
 Co-condensation is a direct synthesis method where organosilanes are condensed 
along with the silica precursors in the presence of surfactant templates. As a result, the 
organic groups are homogeneously distributed within the mesoporous structure. Also, it is 
possible to control mesoporous silica nanoparticle morphology by the introduction of 
different organosilanes (Fig. 3). Lin and coworkers proposed that interactions between 
organosilanes and surfactant molecules, such as electrostatic interaction, hydrophobic 
interaction or hydrogen bonding could contribute to the variation in particle 
morphology.29 They demonstrated that organosilanes with hydrophobic groups tend to 
intercalate their organic groups into the surfactant micelles and interact with the 
hydrophobic tails of surfactants, thus stabilizing the formation of long cylindrical micelles 
and giving rise to rod-shaped MSN materials. On the contrary, hydrophilic organosilanes 
would inhibit micelle growth and yield spherical particles with randomly oriented pore 
structures. As a result, by employing two organosilanes with opposite head group 
properties and varying their ratios, the surface functionality and particle morphology of 
MSN materials can be fine tuned with the co-condensation method.30 
 In order to preserve the pore structure and long-range pore ordering of MSNs, the 
amount of functional groups incorporated by the co-condensation method does not 
normally exceed 25 percent of surface coverage due to the difference in condensation 
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rates between organosilanes and silica precursors. The efficiency of loading depends on 
the nature of organic functional groups. A detailed study has been conducted by Lin and 
coworkers,31 where they summarized that the amount of chemically accessible functional 
groups is proportional to the interfacial electrostatic matching between the functional 
groups and the surfactant head groups. Functional groups possessing a stronger ability to 
compete with the silicate anions in binding with surfactant molecules would be more 
likely to appear at MSN surfaces than those weakly binding functional groups which are 
usually embedded within the silica frameworks and are hence inaccessible. Based on their 
result, the degree of surface functionalization can be adjusted by choosing appropriate 
organic functional groups. 
 
Figure 3. Field emission scanning electron microscopy (FE-SEM) images of (a) 
3-aminopropyl-MSN, (b) N-(2-aminoethyl)-3-aminopropyl-MSN, (c) 3-[2-(2-aminoethyl-
amino)ethylamino]propyl-MSN, (d) 3-ureidopropyl-MSN, (e) 3-isocyanatopropyl-MSN, 
(f) 3-cyanopropyl-MSN, (g) allyl-MSN, and (h) nonfunctionalized MSN. All images are 
presented using the same scale, with the scale bar = 3 μm. Reproduced with permission 
from ref. [29] Huh et al. 2003. Copyright 2003, American Chemical Society. 
 
3.2 Surface Functionalization by Post-synthesis Grafting Method 
 In the grafting method, major functionalization reactions take place between organic 
precursors and free silanol groups at the exterior surface and at the opening of the pores 
of MSNs. Compared to the co-condensed material, organosilane grafted MSN materials 
have better retained pore structures and are more thermally stable. However, in most 
cases, the degree of functionalization by the grafting method is lower than that of 
co-condensation method, owing to the limited number of free surface silanol groups. As 
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opposed to the homogeneous functional groups coverage obtained by the co-condensation 
method, it has been reported that most functional groups are preferentially attached to the 
external surface or the pore openings, since the silanol groups are more easily accessible 
there than the interior pore surface which suffer from lower diffusion rates of organic 
precursors.32 In certain situations such as when organic precursors are too big for the 
pores or they are unfavorable for the pore environment, their penetration to the inner sites 
of the pores is extremely impaired, leading to an unmodified internal surface. Taking 
advantage of this feature, it is feasible to selectively functionalize the external and 
internal surfaces of MSN materials with different functional groups. 
 
3.3 Multi-functionalization 
 To satisfy the need for constructing more complex MSN based drug delivery systems, 
it is desirable to be able to incorporate more than one type of functional group with the 
MSN. Co-condensing two different organosilanes with silica precursors could be a simple 
solution, but as mentioned previously, different hydrolysis rates of silanes would 
undermine the ordering of MSNs material and restrict the loading quantity. Furthermore, 
locations of the functional groups cannot be regulated accurately. Therefore, a 
co-condensation and post-synthesis grafting combined approach for selectively 
incorporating functional groups onto external and internal surface of MSN materials was 
developed by Lin and coworkers.33 A mercaptopropyl functionalized MSN material was 
first prepared by co-condensation method, yielding 90 percent of total thiol groups inside 
the pore channels, followed by 5,6-epoxyhexyltriethoxysilane (EHTES) grafted onto the 
outer surface of thiol-functionalized MSN materials with 43 percent surface coverage. 
The mercaptopropyl groups were converted to o-phthalic hemithioacetal (OPTA) groups 
and the 5,6-dihydroxyhexyl groups were used for a poly(lactic acid) coating. This 
assembly was reported as a detector for amino-containing neurotransmitters. In their 
study, both outer and inner surfaces of the MSN were modified without interacting with 
each other. Another strategy of sequential grafting was designed by the Ruiz-Hitzky 
group where external grafting with alkyl groups was carried out before removing 
surfactant templates so that the surfactant molecules would prevent the penetration of 
organic precursors into the pores.34 Templates were extracted afterward by refluxing the 
particles in an ammonium chloride containing n-heptane/ethanol mixture. This 
template-free material then received a second grafting with aryl groups. Since most of the 
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external silanol groups were consumed in the first grafting, a majority of aryl groups 
reacted mainly with silanol groups inside the pore channels, generating MSN materials 
functionalized with organic groups topologically located as desired.  
 In a recent paper reported by Lo and coworkers,35 a trifunctionalized MSN material 
was synthesized containing three distinct domains: the silica framework, the hexagonal 
pores and the outermost surfaces which were independently functionalized with contrast 
agents for imaging, drug payloads for cancer therapy and biomolecular ligands for cancer 
cell targeting, respectively. A near-infrared fluorescent contrast agent was co-condensed 
with TEOS for the optical tracking of MSN materials. The surfactant templates were then 
removed, followed by the grafting of nanochannels with a palladium-porphyrin based 
photosensitizer, which was exploited in photodynamic therapy. The third 
functionalization reaction occurred on the external surfaces with cRGDyK peptides that 
specifically bind to overexpressed integrins of cancer cells.  
 
4. Biological Performance of Mesoporous Silica Nanoparticles 
4.1 Intracellular Uptake of Mesoporous Silica Nanoparticles 
 To deliver encapsulated drug molecules into mammalian cells and perform 
therapeutic functions, MSN based drug delivery systems have to overcome the cell 
membrane boundary and be internalized by cells. Many research groups have 
demonstrated that MSN materials can be efficiently internalized by a variety of 
mammalian cells, including cancer cells (HeLa, CHO, lung, PANC-1, MCF-7, RIN-5F) 
and noncancer cells (liver, endothelial, skin fibroblast).36-40 However, thorough 
understanding of cellular internalization mechanisms has not been fully unveiled. At the 
size domain of MSN materials, particles have been found to enter cells through 
endocytosis pathways in the majority of cases.41 Various factors have been outlined to 
influence the kinetics and efficiency of intracellular endocytosis of MSN materials.  
 One of the factors dictating particle endocytosis is the surface functional group, as 
reported by Slowing et al38. The results showed that the surface functionalities not only 
regulate the uptake of MSN by HeLa cells, but also affect their ability to escape 
endosomal entrapment. Positively charged MSN materials exhibited better endocytosis 
efficiency than the negatively charged MSN, owing to a higher electrostatic affinity to the 
negatively charged cell membranes. On the other hand, the negatively charged particles 
possess superior endosomal escape ability, presumably due to a “proton sponge effect”. In 
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addition, folate groups on MSN materials could facilitate the HeLa cell uptake efficiency 
through a folate-receptor mediated endocytosis pathway. Therefore, as will be discussed, 
folic acid is widely used as a targeting ligand to regulate drug delivery accuracy. 
 The particle size and morphology also plays a role on the endocytosis of MSNs. The 
Lin research group observed a faster and higher intracellular uptake of smaller MSNs 
compared with larger ones42. This effect was further explored by Mou and coworkers43, 
indicating an optimal particle size of 50 nm to reach the maximum uptake of MSNs by 
HeLa cells. Also, distinct endocytosis efficiencies were found with spherical- and 
tubular-shaped MSNs. Their investigations may allow researchers to control the rate of 
drug delivery more accurately.  
 
4.2 Biocompatibility of Mesoporous Silica Nanoparticles 
 To evaluate the potential of MSNs as drug delivery devices, issues regarding the 
biocompatibility, biodistribution, retention and clearance of MSNs on cellular systems 
were examined by many research groups10,38,44-50. No significant cytotoxicity was 
observed of MSNs towards HeLa and CHO cells at dosage below 100 μg ml-1, even after 
6 d of incubation. A size- and concentration-dependent effect of MSNs on human 
dendritic cell viability was reported by Vallhov and coworker45. They found that smaller 
particles and lower concentrations affected human dendritic cells to a minor degree 
compared to the larger particles and higher concentrations, in terms of viability, uptake 
and immune regulatory markers, which is consistent with the in vitro results.  
 Likewise, a size- and morphology-dependent cytotoxicity of MSN materials on 
human red blood cells (RBCs) was confirmed by Haynes and Trewyn51,52. It was 
determined that in contrast to severe hemolytic activity of amorphous silica, MSNs 
showed high biocompatibility towards red blood cells at concentrations up to 100 μg ml-1, 
which is possibly attributed to restricted RBC access to silanol groups on the surface of 
the MSN structures. Furthermore, MSNs with particle size of 600 nm caused an 
echinocytic shape transformation of RBCs and a subsequent hemolytic effect. These 
findings suggest that careful control over the particle size and surface functionalities can 
minimize toxicity of MSNs.  
 Recent investigations on the in vivo biodistribution and circulation determined that 
silica nanoparticles accumulated mainly in the liver, kidney and urinary bladder after 
intravenous injection, and then partially excreted through the renal route48-50,53,54. It is 
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worth noting that Hyeon and coworkers observed an accumulation of nanoparticles less 
than 200 nm in tumor masses 24 hr after administration, which is probably due to an 
enhanced permeability and retention effect at tumor sites53. Interestingly, the blood 
circulation time can be regulated by different surface functional groups. It was also 
reported that no short-term toxicity effect of MSNs was observed on mice at a dosage 
below 200 mg kg-1, which is already significantly higher than the necessary dosage for 
drug delivery applications46,53. In a long-term study, accumulation of MSNs was observed 
in the liver for up to 3 months without apparent toxicity54. Therefore, although detailed 
information on the biocompatibility of MSNs still needs further investigations, there is 
little doubt that MSNs material will be a promising drug delivery device in clinical trials. 
 
5. Mesoporous Silica Nanoparticles for Drug Controlled Release 
 As mentioned in the first section, the large drug loading capability, the flexible 
surface modification, the rigid porous structures and the excellent biocompatibility of 
MSNs are ideal for drug delivery applications. Initial research of employing mesoporous 
silica materials for drug adsorption/desorption was conducted by Vallet-Regí at the 
beginning of this century16. They successfully demonstrated that 80% of previously 
loaded ibuprofen was released in three days. In order to achieve an accurate control of 
drug releasing rate, a “stimuli-triggered release” concept was brought forward 
simultaneously by Tanaka and coworkers and Lin and coworkers two years later10,55. In 
Tanaka’s approach, coumarin ligands were immobilized at the pore entrance and on the 
external surfaces by a grafting method. The uptake and release of guest molecules from 
pore voids were photo-regulated. The coumarin molecules underwent a dimerization 
reaction to completely seal the pore entrances when this sample was exposed to UV light 
(λ > 310 nm). Release of guest molecules was triggered by the cleavage of the coumarin 
dimers with UV light (λ = 250 nm) irradiation.  
 However, mesoporous silica samples prepared in Tanaka’s study have no defined 
morphology or monodispersed sizes so that the biocompatibility of these materials is 
unsatisfactory for drug delivery applications. The first example of using biocompatible 
MSNs as carriers and inorganic nanoparticles as caps to effectively deliver drug 
molecules into animal cells with zero premature release was developed in the Lin 
research group10. They prepared spherical mesoporous silica nanoparticles with a uniform 
particle diameter of 200 nm and pore size of 2.3 nm, and then functionalized them with 
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2-(propyldisulfanyl)ethylamine groups. This MSNs sample was soaked in a concentrated 
solution of vancomycin or ATP to allow the diffusion of cargo molecules into the pores. 
Water-soluble cadmium sulfide (CdS) nanocrystals with mercaptoacetic acid groups were 
then added to react with the terminal amino groups on the surface of the MSNs. Thus, the 
CdS nanocrystals were covalently bonded to the MSNs and blocked the pore entrances. 
The resulting vancomycin- or ATP-loaded, CdS-capped MSNs were washed to remove 
physisorbed molecules. A quantitative analysis of the amounts of each compound was 
monitored by HPLC and the loading efficiency of vancomycin and ATP was calculated to 
be 25 and 47 μmol g-1, respectively. The controlled release performance of this drug 
delivery system was evaluated. The material exhibited less than 1 percent drug release in 
buffer solution over a 12 hour period, suggesting a good pore blockage and minimal 
premature release. With the addition of disulfide reducing reagents such as dithiothreitol 
(DTT) or mercaptoethanol (ME) to cleave the CdS-MSN linkage, a rapid release was 
triggered and 85 percent of entrapped molecules were released within 24 hours. To 
further demonstrate its in vitro control release behavior, ATP-loaded, CdS-capped MSNs 
were cultured with astrocytes loaded with a calcium-chelating fluorescent dye. Perfusion 
application of ME led to a pronounced increase of intracellular calcium concentration, 
which was stimulated by ATP molecules carried by this drug delivery system. 
 
Figure 4. Design principle of mesoporous silica nanoparticles for controlled drug release. 
The capping agents block pore entrances and trap drug molecules by labile linkers which 
later respond to specific stimuli, triggering a drug release. 
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 Over the past decade, many research groups have made great endeavors in the 
development of MSNs based drug delivery systems with stimuli-responsive triggered 
release property (Fig. 4). A number of regulating mechanisms have been proposed and 
confirmed their feasibility for intracellular drug delivery with precise control of location 
and timing. The triggers or stimuli can be internal, meaning that they are already present 
in the living organism, or external, which requires a simple and convenient pathway for 
application. Internal stimuli are often unique to the targeted pathology, which enables 
drug delivery systems to respond specifically to the desired location and release drugs in a 
self-regulated fashion. External controls are mostly noninvasive and easy to manipulate, 
so that they could assist to localize the drug release and optimize the degree of the drug 
delivery process. Examples of these triggers include pH, light, redox potential, 
temperature, enzymes, etc. 
 
5.1 pH-triggered Release 
 A series of pH-responsive linkers have been exploited for controlled release 
applications by taking advantage of the acidic environment at tumor or inflammatory sites 
(pH ~ 6.8), endosomal or lysosomal compartments of cells (pH ~ 5-6) as well as the 
stomach (pH ~ 1.5-3.5). These pH-responsive linkers feature an inert respond to 
physiological pH and a robust release at low pH environment. 
 An early example of a pH-responsive release system was reported by Casacus et al., 
where they created a pH and anion controlled drug delivery system56. The MSN materials 
were prepared by the co-condensation of mercaptopropyltriethoxysilane with TEOS. A 
second grafting reaction was carried out with N-(3-triethoxysilylpropyl-2-aminoethyl)-eth
ylenediamine to get a preferential anchoring of amino groups on the external surfaces. At 
high pH values, the amines were deprotonated and were tightly packed through hydrogen 
bonding interactions so that the delivery system was at its “open gate” state. However, 
when the amines were protonated at low pH conditions, they repelled each other and 
covered the pore openings due to the coulombic repulsion effect between positively 
charged amine groups and the delivery system was monitored to its “close gate” state. In 
addition, a significant synergic effect was observed in the presence of anions, which 
could intercalate into the open-chain polyamines and seal the pore openings. This effect is 
clearly associated with the anion size and the strength of the polyamine-anion 
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electrostatic interaction. Employing this pH-responsive drug delivery system, they have 
successfully demonstrated pH-controlled release of squaraine and vitamin B2.57 
 A pH-responsive drug delivery system for protein drugs was designed by Kawi and 
coworkers.58 In order to encapsulate bulky proteins without denaturation, MSN materials 
with pore diameters above 10.5 nm and pore volumes around 1 cm3 g-1 were synthesized 
in this study. These MSN materials were further modified with amine groups by 
co-condensation and were loaded with a model protein, bovine serum albumin (BSA). 
The positively charged BSA loaded MSNs were then mixed with a solution of polyacrylic 
acid (PAA) at pH 5.35. The electrostatic assembly of PAA blocked the pore entrances and 
trapped the BSA proteins, the final loading amount of BSA was calculated to be 16.3 
percent. In pH 1.2 acidic medium, no release of BSA from the PAA-encapsulated sample 
was measured within 5 hours and released only 10 percent after 36 hours. However, in a 
phosphate buffer solution at pH 7.4, carboxyl groups on the PAA chains started to 
dissociate and repel each other, causing PAA to swell and dissolve into the buffer 
solution. As a result, 40 percent of the entrapped BSA was released from the sample, 
suggesting a good pH responsive capability of their material. Additionally, PAA was 
found to be able to protect proteins from enzymatic degradation. By comparing the 
UV-CD spectra of native and released BSA, they concluded that the BSA conformation 
has not been severely altered by the adsorption process, inferring a well-preserved protein 
activity. They envisioned that this material has the potential for the oral delivery of 
protein drugs to the target sites with higher pH, such as small intestine or colon. 
 Covalently-immobilized PAA on MSN materials was studied as a pH-sensitive drug 
delivery system by the Hong research group using a reversible addition-fragmentation 
chain transfer (RAFT) polymerization of acrylic acid (Fig. 5).59 In this example, 
5,6-Epoxyhexyltriethoxysilane was grafted on the MSNs, followed by the template 
removal. A RAFT agent, S-1-dodecyl-S-(α,α’-dimethyl-α’’-acetic acid)trithiocarbonate, 
was attached to the MSNs exterior surface through an esterification reaction with the 
hydroxyl groups. Finally, acrylic acid was allowed to polymerize under vacuum to form a 
covalently-bonded PAA nanoshell coating on the MSNs. The structure of PAA nanoshell 
was highly dependent on the pH value of the medium. At pH 8.0, the PAA nanoshell is 
deprotonated and soluble in aqueous solutions, thus forming an open state with accessible 
pore entrances. However, when the pH drops below 4.0, the PAA nanoshell becomes 
insoluble and collapses onto the surface of MSNs, rendering a compact layer. Fluorescein 
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was used to evaluate the pH-regulated drug release performance of the PAA coated 
MSNs. They observed both fluorescein uptake and release by PAA coated MSNs at pH 
8.0, but neither was detected with the same material at pH 4.0. Their results verified that 
the PAA coated MSNs can reversibly regulate the loading and releasing of guest 
molecules by adjusting pH values.  
 
Figure 5. Schematic graph of opening and closing of the core-shell structured 
nanoparticle triggered by pH. 
 
 The unique structural and physiochemical properties of pseudorotaxanes have been 
exploited for the fabrication of a series of pH-responsive drug delivery devices. In a 
system reported by Kim and coworkers, low molecular weight polyethyleneimine (PEI, 
Mn = 1100) and cyclodextrin (CD) were assembled onto the surface of MSNs as the rod 
and the ring components.60 PEI was grafted by a 1,1’-carbonyldiimidazol catalyzed 
reaction with carboxylic group functionalized MSNs. Calcein was then loaded as a guest 
molecule to the PEI-MSN hybrid material. Self-assembly of CDs (ring) with PEI (rod) 
was carried out under basic conditions, at which the CD was able to form hydrogen 
bonding with the deprotonated nitrogen atoms of PEI. Both α-CD and γ-CD showed 
effective blockage of the pores, whereas β-CD did not form a stable pseudorotaxane with 
PEI. The pH values of the suspensions of the calcein-loaded samples were adjusted from 
11 to 5.5 to examine the “dethreading” of CD and the consequent releasing of calcein. 
Only weak fluorescence intensity was observed at high pH value. But an immediate 
increase in the fluorescence intensity was measured upon acidification of the solution to 
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pH 5.5. The system provided an example of pseudorotaxane based MSNs for 
pH-regulated drug delivery. However, the harsh working condition remains a concern for 
practical applications. 
 Similar constitution of pseudorotaxane has been created by Stoddart and Zink and 
coworkers.61 The threading axis was a bisammonium stalk and cucurbit[6]uril (CB[6]) 
was used as the ring unit. Aminopropyl-functionalized MSNs were suspended in a 
methanol solution of propargyl bromide to obtain alkyne-terminated silica nanoparticles. 
After a loading with rhodamine B (RhB), the material was capped with 
CB[6]-disubstituted 1,2,3-triazole pseudorotaxanes by means of a CB[6]-catalyzed 
1,3-dipolar cycloaddition of alkyne groups on MSNs and 2-azidoethylamine. At neutral 
and acidic environments, the CB[6] encircle the bisammonium stalk tightly through 
ion-dipolar interactions. Raising the pH value results in deprotonation of the stalk and 
dethreading of CB[6], and subsequent unblocking of the pores. They also discovered that 
the use of a shorter stalk would bring the CB[6] ring closer to the surface of MSNs and 
strengthen its ability of preventing leakage. They proposed that their system can be tuned 
to operate under gentler pH by switching to other bisammonium ion centers with 
favorable pKa values. 
 The same research group later constructed a CB[6]-trisammonium pseudorotaxane 
based MSNs that could release guest molecules at either elevated or reduced pH values.62 
The trisammonium stalk consists of a tetra-methylenediammonium group and an 
anilinium group. The anilinium nitrogen atom is 106-fold less basic than the alkyl 
nitrogen atoms. Therefore, it stays unprotonated at neutral conditions, leaving the CB[6] 
ring residing on the tetra-methyleneammonium unit to block the pore channels. When the 
pH increased, all of the nitrogen atoms become deprotonated, resulting in the dethreading 
of the CB[6] ring. Otherwise, at lower pH with all nitrogen atoms protonated, the CB[6] 
moiety shuttles to the distal hexamethylenediammonium unit because its ion-dipole 
complexation is an order of magnitude greater of the six-carbon spacer than that of the 
four-carbon spacer. In both cases, the motion of CB[6] gives rise to the pore opening and 
controlled release of drugs. Furthermore, they demonstrated that the release profiles were 
different for aniline and p-anisidine functionalities due to their distinct pKa values. It is 
conceivable that the material sensitivity to specific pH values for their material can be 
rationally tuned by selecting appropriately substituted anilines. 
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5.2 Light-triggered Release 
 Light irradiation is a convenient remote control approach for site-specific drug 
delivery. The uptake and release of guest molecules can be rapidly induced upon 
exposure to light with certain wavelengths. After Tanaka and coworkers first 
demonstration of a coumarin functionalized MSN material to manipulate drug release as 
previously discussed, photochemical responsive linkers such as azobenzene, 
o-nitrobenzyl ester and thymine bases are incorporated onto the surface of MSNs to 
render them photochemically susceptible for light controlled release. 
 
Figure 6. Schematic representation illustrating the capping of MSNs by Py-β-CD based 
pseudorotaxane, and the dethreading of pseudorotaxane upon UV radiation. 
 
 By varying the stalk and ring components, the pseudorotaxanes approach was also 
applied to control drug release with light (Fig. 6). Zink, Stoddart and coworkers 
constituted a photosensitive pseudorotaxane of azobenzene derivative (AB) and 
β-cyclodextrin (β-CD).63 Unfunctionalized MSNs were grafted with 4-(3-triethoxylsilyl-
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propylureido)azobenzene (TSUA) groups or more water-soluble (E)-4-((4-(benzyl-
carbamoyl)phenyl)diazenyl)benzoic acid groups, as the pseudorotaxane stalks. Upon 
irradiation to 351 nm light, both azobenzene derivatives isomerized from the more stable 
trans form to a less stable cis configuration. β-CD or fluorescently labeled 
pyrene-β-cyclodextrin (Py-β-CD) were then introduced. The high binding affinity 
between trans-AB and β-CD locked the β-CD rings at the orifice. On the other hand, 
owing to the weak binding between cis-AB and β-CD, the isomerization of trans- to cis- 
AB stalks led to the dissociation of pseudorotaxanes, thus permitting the release of cargo 
molecules. Experimental data confirmed that the AB stalks and Py-β-CD assembly was 
stable without 351 nm UV radiation, whereas a complete Py-β-CD dissociation was 
determined when the sample was exposed to a 351 nm excitation beam for 400 minutes. 
Likewise, results from RhB loaded samples revealed that more than 90 percent of RhB 
was released from the laser light exposed sample, while less than 30 percent was released 
from the unexposed one, over a period of 7 hours. They concluded that their material was 
applicable to light-operated intracellular drug delivery systems.  
 Cyclodextrin was also employed by the Kim group to cover the porous reservoirs.64 
In their work, MSN materials were functionalized with aminopropyl groups, which were 
then treated with succinic anhydride in the presence of triethylamine to generate a 
carboxylic acid terminated MSNs sample. The sample was further functionalized by 
alkyne end groups through a coupling reaction with 2-nitro-5-(2-propyn-1-yloxy)-
benzenemethanol, producing a photosensitive o-nitrobenzyl ester moiety that would 
decompose upon UV light exposure at 350 nm. Following a calcein dye loading, the pores 
were capped with the mono-6-azido-β-CD, by the Huigsen 1,3-dipolar cycloaddition 
reaction. In order to test the feasibility of their approach, the fluorescence intensity of the 
CD-capped calcein-loaded MSNs sample suspension was monitored over time. Only a 
very weak signal was detected in the dark, indicating that the calcein molecules were 
retained inside the pores. When the sample was irradiated with UV light, a remarkable 
increase in the fluorescence intensity was observed due to the photolysis of o-nitrobenzyl 
ester linkage and the diffusion of CD and calcein molecules. Furthermore, they noted a 
periodic release behavior of their sample in response to successive UV irradiation over 
short periods of time. 
 Gold nanoparticles, for the demonstrated excellent biocompatibility, were used as 
pore-blocking caps in a research conducted by Lin and coworkers (Fig. 7).40 A 
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photoresponsive linker, thioundecyl-tetraethyleneglycolester-o-nitrobenzylethyldimethyl 
ammonium bromide, was immobilized onto the surface of Au nanoparticles (PR-AuNPs). 
These positively charged species then attached on the negatively charged MSN materials 
through the electrostatic interaction to produce a PR-AuNP capped MSNs system, the 
structure of which was later confirmed by transmission electron microscopy (TEM). A 
good capping efficiency was verified by the fact that no release of cargo was found even 
after 80 hours in the dark. Photoirradiation at 365 nm resulted in the cleavage of the 
o-nitrobenzyl ester containing linker, forming the negatively charged, 
thioundecyltetraethyleneglycolcarboxylate functionalized Au nanoparticles. Hence, the 
charge repulsion between Au nanoparticles and MSNs uncovered the pores and allowed 
the diffusion of guest molecules. In addition, intracellular studies were executed using an 
anticancer drug as cargo for the controlled release in human liver and fibroblast cells. 
Both cell lines were incubated with either drug-loaded sample or drug-free sample and 
were either exposed to light or kept in the dark. Only cells exposed to UV light with 
internalized drug-loaded MSNs caused significant cell death greater than 50 percent, 
suggesting that this system could indeed transport and release drug molecules inside live 
human cells under the control of photoirradiation. 
 
Figure 7. Schematic illustration of photo-induced controlled drug release of PR-AuNPs 
capped MSNs. 
 
 Thymine bases are a group of molecules that undergo photodimerization and revert 
back to monomeric thymines upon light irradiation above and below 270 nm, respectively. 
He et al. functionalized MSNs with thymine and loaded the cavities with a Ru(bipy)32+ 
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dye.65 Irradiation with 365 nm UV light led to the formation of a cyclobutane ring and 
thus covered the pore outlets. A reversed photoreaction was triggered by exposure to 240 
nm light, along with a release of 80 percent of loaded Ru(bipy)32+. Their study provided 
another illustration for light-triggered drug delivery. 
 
5.3 Redox Potential-triggered Release 
 The designs of redox responsive linkers are mainly based on the disulfide bond. It 
draws much interest in these systems because of its relative stability in plasma and is 
reversible. Intracellular antioxidant species levels are 100 to 1000 fold higher than that in 
the extracellular space, resulting in a high redox potential difference between the 
oxidizing extracellular space and the reducing intracellular space.66 This difference is 
more significant in cancer cells than that in healthy cells, which renders the disulfide 
linkage more vulnerable in cancer cells leading to potentially higher drug concentrations 
at tumor sites. Thus, the demand for both outstanding delivery efficiency and minimized 
cytotoxicity can be realized by MSN based drug delivery systems. 
 The feasibility of the redox-responsive linkage has been well established and reported 
in a number of recent publications. In addition to the original CdS-capped MSN materials, 
Lin and coworkers refined the system by replacing the CdS caps to more biocompatible 
superparamagnetic iron oxide (Fe3O4) nanoparticles.37 MSNs were functionalized with 
3-(propyldisulfanyl)propionic acid and incubated in a fluorescein solution. 3-amino-
propylsiloxyl coated Fe3O4 nanoparticles were then allowed to react with the carboxyl 
groups of MSNs to form a covalent amide bond. Less than 1 percent of fluorescein 
leaching was observed after 130 hr in a PBS suspension. A drastic release of 40 percent 
of loaded fluorescein was observed within 2 days upon the addition of DTT or 
dihydrolipoic acid, an antioxidant naturally present in the cells. A series of cell biological 
studies further confirmed successful endocytosis and intracellular fluorescein cargo 
release. Additionally, when a magnet was placed on the side of a cuvette, HeLa cells with 
internalized magnetic Fe3O4-capped MSNs were shown migrating across the cuvette. 
Confocal fluorescence microscopy images of the HeLa cells cultured with Fe3O4-capped 
MSNs for 10 hr revealed green fluorescent cell bodies, proving that the disulfide bond 
cleavage and uncapping process took place after the MSN materials were internalization 
by the cells.  
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 Not limiting to inorganic nanoparticles, polymers such as polyelectrolytes multilayers 
(PEM) have also been employed to inhibit premature release. Yang, Wang and coworkers 
synthesized MSNs with disulfide bond cross-linked multilayers of poly-(vinlypyrrolidone) 
and thiolated poly-(methacrylic acid) by through a layer-by-layer method.67 No detectable 
release of loaded FITC can be observed after a 24-hour incubation. Treatment with DTT 
caused the deconstruction of polyelectrolytes and the subsequent release of the 
encapsulated FITC. The PEM-MSNs were further conjugated with a cancer-specific DNA 
aptamer for cell targeting. A cell viability study results showed that doxorubicin (DOX) 
loaded PEM-MSN-aptamer samples led to more pronounced cancer cell death and 
non-cancer cell viability than the aptamer-free sample, demonstrating a redox-responsive 
controlled drug release system with targeted delivery ability. 
 
 
Figure 8. Graphical representaions of the assembly of the bistable [2]rotaxanes to form 
nanovalves and the possible positions (IN and OUT) regulated by the oxidation state. The 
cycle can be repeated several times. 
 
 A series of pseudorotaxanes have been developed in the Zink research group (Fig. 
8).68 In their first attempt, 1,5-dioxynaphthalene containing derivatives (DNPD) were 
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tethered to the surface of the MSNs, acting as the pseudorotaxane rod, followed by the 
assembly of cyclobis(paraquat-p-phenylene) (CBPQT4+), which noncovalently 
complexed with DNPD. The bulky CBPQT4+ tetracations thus obstruct the pore openings. 
The sample was loaded with a fluorescent dye, tris(2,2’-phenylpyridyl)iridium(III), to 
investigate the release behavior of this complex system. Upon addition of reducing agent, 
the pseudorotaxanes on the MSNs surface immediately dethreaded and opened up the 
pores. A fast increase in luminescence intensity was observed, indicating a rapid release 
of entrapped molecules.  
 The system was improved by including a second recognition site derived from 
tetrathiafulvalene (TTF).69 A much stronger binding affinity between CBPQT4+ and TTF 
exists than between CBPQT4+ and DNPD, which ensured that over 95 percent of the 
CBPQT4+ rings encircled the TTF station. However, oxidization of the TTF component to 
TTF2+ would destabilize such interaction and repel the CBPQT4+ rings to shuttle along the 
axis to the DNPD recognition sites. This process is reversible upon the addition of a 
reducing agent such as ascorbic acid so that the CBPQT4+ ring returns to the thermally 
favored TTF sites. They later established a general trend for the optimal design of their 
system: small guest molecules require short linkers and large guest molecules require 
long linkers. 
 
5.4 Temperature-triggered Release 
 The local temperature difference between tumor sites and nontumor sites has been 
shown to be useful as an internal trigger for the control release of drugs. It is desirable to 
design a temperature-responsive drug carrier that only releases drugs at temperatures 
above 37 °C, but keeps drugs encapsulated while in circulation. Poly(N-isopropyl-
acrylamide) (PNiPAm), a popular thermal-sensitive polymer, has been functionalized 
onto MSNs to modulate the transport of guest molecules.70-74 It holds a low critical 
solution temperature (LCST) close to 37 °C,75 below which the PNiPAm is hydrated and 
swollen so that it covers the cavities of MSNs. While at temperatures above LCST, the 
PNiPAm undergoes a conformation change to a hydrophobic, shrunken state in aqueous 
solution, and thus opening up the pore entrance.76,77 
 Initial studies were conducted by Lopez and coworkers, where they demonstrated 
three different approaches to prepare hybrid PNiPAm-functionalized MSNs.70-72 In their 
first method, PNiPAm was mixed with silica precursors at the condensation stage, giving 
23 
 
rise to a sample with random porosity.70 The product was found not feasible as a drug 
carrier due to its limited mass transport property. Their second mechanism was to form a 
copolymer of N-isopropylacrylamide (NiPAm) and 3-methacryloxypropyl-
trimethoxysilane through free radical polymerization.72 Then, the PNiPAm-silane 
copolymer was allowed to co-condense with TEOS to obtain PNiPAm-functionalized 
MSNs. But the particles were too large to be applied for intracellular application. So a 
third approach was proposed by growing PNiPAm on the external surface of 
pre-synthesized MSNs.71 This method is widely used because the size of MSNs can be 
very well controlled.73,74 Typically, a polymerization initiator, 1-(trichlorosilyl)-2-(m/p-
(chloromethyl)phenyl)ethane was grafted onto MSNs, followed by an in situ 
atom-transfer radical polymerization of monomers at a slow and uniform rate to prevent 
clogging of the pores with free polymers. Additionally, the degree of polymerization 
could be tuned. It was further demonstrated that the PNiPAm-coated MSNs material was 
capable to uptake fluorescein molecules at low temperatures and release them at 
temperatures above LCST. Investigations in the cell biological properties of 
PNiPAm-coated MSNs showed no acute cytotoxicity and good endocytosis efficiency on 
human breast carcinoma cells. Successful intracellular release of a fluorescent dye at 
elevated temperature was observed by confocal fluorescence microscopy. 
 Another thermal-responsive uncapping mechanism was developed based on DNA 
oligomers. The Bein group. attached biotin-labeled DNA double strands onto the external 
surface of MSNs by click chemistry.78 Avidin proteins were then coordinated with biotin 
and capped the pores of the nanoparticles. Upon temperature increase, the DNA double 
strands would dehybridize and release the biotin-avidin moiety into suspension, reaching 
an “open state”. By picking different lengths of DNA oligomers, they were able to control 
the temperature threshold for gate-opening. This DNA dehybridization induced 
uncapping mechanism enables a precise adjustment for desired applications. 
 
5.5 Enzyme-triggered Release 
 The development of smart, controlled-release delivery systems triggered by 
biomolecules such as enzymes is a very promising research direction, owing to their 
excellent biocompatibilities and their rapid and specific biological activities. 
 An enzyme-responsive cyclodextrin containing rotaxane was reported by Patel et al 
(Fig. 9).79 MSNs were functionalized with monoazide-terminated triethyleneglycol by a 
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two-step grafting process. After soaking the MSN materials in a solution of RhB, α-CD 
was threaded onto the triethyleneglycol chain and effectively blocked the pores. A bulky 
adamantyl ester-linked stopper group was tethered to the terminal azide groups by 
Huisgen cycloaddition, and hence interlocked α-CD to the rotaxane stalk. An enzyme 
triggered release was verified by the addition of porcine liver esterase which broke the 
ester bonds on the stopper groups and enabled α-CD rings to escape from the 
triethyleneglycol thread, therefore permitting the diffusion of cargo molecules. It is 
interesting to note that when the ester bond of the stopper group was replaced by amide 
bond, it was no longer activated by esterase cleavage, demonstrating a high selectivity of 
the enzyme. 
 
Figure 9. Esterase activated pore opening of α-CD containing rotaxane capped MSNs. 
 
 An extensively applied linker system is the biotin-avidin linker first prepared by Bein 
and coworkers, synthesizing biotinylated MSNs by a reaction of thiol-functionalized 
MSNs and biotin-maleimide.80 The avidin caps were then strongly complexed to the 
biotin terminals on the MSNs, forming a tight closure of the pores. The avidin-biotin 
linked MSNs exhibited zero release until the addition of protease trypsin, which digested 
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avidin by the tryptic hydrolysis process and led to the release of guest molecules. Release 
reached completion after 140 minutes following the treatment of trypsin. The 
biotin-avidin linker was also useful for the targeted drug delivery. 
 Another approach to develop enzyme-sensitive linkers was reported by Bernardos et 
al.81 MSNs as a starting material was loaded with [Ru(bipy)3]Cl2 for monitoring the 
enzyme-controlled release process. This sample was then capped with β-D-galactose and 
β-D-glucose disaccharides linked triethoxysilane. The capped sample was resuspended in 
a pH 7.5 buffer solution. Only a negligible release of cargo was observed after 5 hours. In 
contrast, the addition of β-D-galactosidase hydrolyzed the glycosidic bond, resulted in a 
decrease in the size of the capping agent, and induced [Ru(bipy)3]Cl2 cargo release. They 
also demonstrated that when the capped sample was treated with either digestive pepsin 
or denatured β-D-galactosidase, no release was observed, demonstrating that 
β-D-galactosidase was responsible for the dye release in their experiments. 
 
5.6 Other Stimuli 
 A novel biocompatible surfactant-assisted controlled release system was proposed by 
Tsai and Trewyn et al.82 The high cytotoxicity has always been a defect of the traditional 
cetyltrimethylammonium pore template, therefore the surfactant molecules have to be 
adequately removed before administration. To avoid this problem, a non-cytotoxic 
anionic surfactant, undec-1-en-11-yltetra(ethylene glycol) phosphate monoester (PMES), 
was developed to function as a structure directing agent. The presence of hydrophobic 
tails on the surfactants makes this material especially effective for the uptake of 
hydrophobic molecules. The MSNs with PMES (PMES-MSNs) sample possess a four 
fold greater loading ability for hydrophobic molecules in comparison to the calcined 
sample. Release of guest molecules occurred in conjunction with the diffusion of PMES 
surfactants when the drug-loaded PMES-MSNs were suspended in a PBS solution. The 
authors confirmed good biocompatibility and high cellular uptake efficiency for the 
PMES-MSN materials. In addition, an intracellular release of a hydrophobic drug 
(doxorubicin) was exemplified with Chinese Hamster Ovarian cells.  
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Figure 10. Schematic illustration of the glucose-responsive MSN based delivery system 
for controlled release of bioactive G-Ins and cAMP. 
 
 A glucose-responsive delivery system was fabricated by Lin and coworkers 
consisting of phenylboronic acid modified MSNs (BA-MSNs) and gluconic acid modified 
insulin (G-Ins) (Fig. 10).83 The G-Ins serving as caps were attached to BA-MSNs through 
reversible covalent bonding between the vicinal diols of G-Ins and the phenylboronic acid 
groups on BA-MSNs. Release of guest molecules can be triggered by introducing 
saccharides such as glucose, which forms much more stable cyclic esters with 
phenylboronic acid than the acyclic diols and hence substitutes G-Ins moieties. This 
system is especially promising for the treatment of diabetes because it responds only at 
diabetic glucose levels while remains intact at normal conditions. Moreover, cyclic 
adenosine monophosphate (cAMP), known as an insulin secretion stimulating agent, can 
be encapsulated inside the pores and released subsequent to G-Ins diffusion to achieve a 
synergic effect for the regulation of blood glucose levels. 
 The antigen-antibody pair is another strong and specific binding linker for controlled 
release. Climent et al. first anchored the outer surface of MSNs with a derivative of the 
hapten 4-(4-aminobenzenesulfonylamino)benzoic acid and the orifices were blocked 
when a polyclonal antibody of sulfathiazole bound to the surface functional group.84 The 
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delivery protocol of entrapped molecules occurred through a displacement reaction of the 
sulfathiazole-antibody pairs. Experimental results showed that release efficiency was 
closely associated with the concentration of sulfathiazole in the buffer solution. The 
delivery behavior was also determined to be antigen-specific, which makes their approach 
appealing for customizing controlled delivery devices. 
 A biomolecule-sensitive controlled release system was also reported by Yang and 
coworkers.85 This modulating scheme took advantage of specific aptamer-target 
interactions. Adenosine-functionalized MSNs were synthesized through amide coupling 
of amine-modified MSNs and adenosine-5’-carboxylic acid. ATP aptamer-immobilized 
gold nanoparticles were employed as capping agents since the aptamers recognized and 
attached to the adenosine moieties on the MSNs. The gold nanoparticle caps sufficiently 
inhibited cargo release in the absence of ATP molecules. In contrast, in the presence of 
aptamer target molecules, a competitive displacement reaction destroyed the 
aptamer-adenosine interaction and, thus, cleaved the gold caps from the exterior surface 
of the MSNs. Significant release of cargo was observed. A high specificity of 
ATP-aptamer affinity was evaluated by comparing the release profiles triggered by ATP, 
CTP, GTP and UTP. It is noteworthy that other than ATP molecules, the complementary 
oligonucleotides (cDNA) are also able to selectively and efficiently bind to aptamers and 
trigger the cargo delivery. 
 Ultrasound can serve as a noninvasive external stimulus to achieve localized drug 
delivery. In the work by Honma and coworkers, MSNs were coated with 
poly(dimethylsiloxane), which restricted the diffusion of drug molecules.86 On the other 
hand, ultrasound irradiation could enhance the permeability of water and drug molecules 
through the polymer layer, which is explained by the cavitation effect. Diffusion 
coefficient was four times higher for the ultrasound treated sample than that of the sample 
under nonultrasound conditions. Moreover, their material also revealed a regular pulsatile 
release pattern with repeated ultrasound irradiation.  
 The Martínez-Máñez and Stroeve research groups constructed a series of alkyl chain 
anchored MSNs to control delivery modulation.87 Pore outlets were decorated with 
alkylsilanes of variant chain length, as diffusion controllers. They demonstrated that 
longer alkyl chains led to a slower releasing rate. Therefore, mass transport can be 
regulated artificially. 
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 Releasing rates can also be tuned by controlling pore sizes. In a recent study by Gao 
et al., MSNs with pore sizes of 3.2 nm, 6.1 nm and 12.6 nm were prepared and all three 
materials were loaded with DOX, a typical chemotherapeutic agent.88 Through a series of 
investigations on in vitro cytotoxicity, cellular uptake efficiency, intracellular drug release 
behavior, permeability glycoprotein expression and ATP levels of a drug-resistant cell 
line (MCF-7/ADR), they claimed that MSNs with a larger pore size could suppress cancer 
cells more effectively due to a faster release of DOX and a better endocytosis efficiency 
than MSNs with smaller pores. 
 
5.7 Multiple Stimuli Triggered Release 
 Along with the extensive research conducted on single stimulus triggered drug 
delivery, multi-responsive controlled release systems have been developed to achieve 
complex release behaviors in either an independent or a synergistic fashion. 
 A dual pH and light controlled release system based on the combination of 
pH-sensitive pseudorotaxane and photo-sensitive nanoimpeller azobenzene was designed 
by Angelos et al.89 A silylated azobenzene derivative was co-condensed with TEOS to 
produce pore surface functionalized MSNs and CB[6]/bisalkylammonium containing 
pseudorotaxane was anchored on the exterior surface of MSNs. They illustrated that this 
material could function as AND logic gates, such that cargo delivery occurred only when 
it was triggered by both stimuli. They envisioned that it is possible to manually regulate 
delivery dosage with this system. 
 Another pH and photo-switch release approach was demonstrated by Aznar et al.90 
They employed a boronate ester linker formed between saccharide functionalized MSNs 
and boronic acid anchored gold nanoparticle caps. Two opening protocols were proposed 
to break the boronate ester linkage. One is to lower the pH value to 3; the other is to 
irradiate the material with a laser beam at 1064 nm, which induces plasmon resonance 
excitation in Au nanoparticles to produce a photothermal effect. Both triggers were 
shown to be able to generate a pulsatile release of guest molecules by administrating 
stimulus repeatedly. 
 In another pseudorotaxane based MSNs reported by Kim and coworkers, three 
independent stimuli were confirmed to be capable to sufficiently unblock the pore 
voids.91 The pseudorotaxane unit consisted of an o-nitrobenzene ester containing stalk 
and a β-CD ring. The stalk can either be ruptured by UV light irradiation or be 
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decomposed by lipase and the β-CD ring can be digested by α-amylase. Therefore, the 
release of guest molecules can be diversely triggered by enzymes or light individually, or 
by both to achieve a synergistic acceleration effect. 
 
 
Figure 11. Schematic illustration of a multiresponsive nanogated ensemble based on 
supramolecular polymeric network-capped mesoporous silica nanoparticle. 
 
 A tri-stimuli responsive delivery system was developed by Feng and coworkers 
involving the construction of a pyridyldithio-containing polymer functionalized MSNs 
that were disulfide bond linked to thiol-modified β-CD (Fig. 11).92 The β-CD moieties 
were further cross-linked by diazo-linkers to inhibit the release of entrapped molecules. 
Their assembly was expected to respond to UV light irradiation, as well as the addition of 
DTT or α-CD. Under a 365 nm UV light, the trans- configured diazo-linkers would 
transform into a cis-azobenzene and thus lose their high affinity to β-CD molecules. 
Addition of DTT would cleave the disulfide linkage between β-CD and MSNs. The 
introduction of excess α-CD would result in the formation of a more stable α-CD-diazo 
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cross-linkage and displace β-CD. In all three scenarios, the pore-blocking polymeric 
network was opened, leading to tri-stimuli triggered release. 
 The fact that magnetic nanocrystals are able to generate heat energy under 
high-frequency alternating magnetic field was applied in the design of 
temperature-responsive delivery systems by the Vallet-Regí group.93 Magnetic iron oxide 
nanocrystals were embedded inside the silica matrix of MSNs and the surface of MSNs 
was decorated with a thermosensitive copolymer of poly(ethyleneimine)-b-poly-
(N-isopropyl-acrylamide) (PEI/NIPAM). They demonstrated that this device could 
deliver proteins with preserved activity, triggered by a temperature increase, as well as an 
alternating magnetic field that heat up the local environment through encapsulated iron 
oxide nanocrystals. 
 
6. Targeted Drug Delivery of Mesoporous Silica Nanoparticles 
 Cell-specific targeting is highly attractive as an approach to spontaneously 
distinguish the site of disease diagnosis, and as a result, this technique reduces drug 
administration dosage and diminishes toxic side-effects of drugs during circulation. Both 
passive strategies and active surface decoration methods have been applied to the 
fabrication of novel MSNs based drug delivery systems for targeted release. 
 
6.1 Passive Routes 
 Passive accumulation of MSNs in tumor tissue can be realized by the enhanced 
permeability and retention (EPR) effect, a theory first postulated by Matsumura and 
Maeda in 1986.94 They hypothesized that the differential localization of macromolecules 
as well as particles of certain sizes is attributed to the tumor microenvironment, the 
relative slow elimination rate and poor lymphatic drainage. Effectiveness of the EPR 
effect can be mediated by the particle size, surface charge or hydrophobicity. Tamanoi 
and coworkers demonstrated a preferential accumulation of fluorescently labeled MSNs 
(100-130 nm in diameter) in tumors of mice, within 4 hours of an intravenous injection. 
The fluorescent signal then gradually decreased to the same level as the whole body after 
48 hr.95 Similar phenomenon was also reported by the Hyeon group that MSNs less than 
200 nm accumulated in tumor 24 hours after administration.53 
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6.2 Surface Decoration with Targeting Ligands 
 Efforts have been made to functionalize the surfaces of MSNs with cancer-specific 
targeting ligands for an enhanced MSNs uptake by cancer cells compared to 
noncancerous cells. One such ligand is folic acid,96-98 as folate receptors are known to be 
overexpressed in several types of human cancer, including ovarian, endometrial, 
colorectal, breast and lung.99 Using folic acid-conjugated MSNs (FA-MSNs), Sahlgren, 
Linden and coworkers observed that the total number of particles internalized by the 
HeLa cancer cells was about one order of magnitude higher than that of FA-MSNs 
internalized by noncancerous cells, although noncancerous cells normally do express 
folate receptors.96 Besides folic acid, other small cell nutrient molecules such as 
mannose,100 was also shown to selectively improve the uptake of MSNs by breast cancer 
cells. 
 Another group of targeting ligands is the RGD peptide, abbreviation for 
arginine-glycine-aspartic acid, which interacts with the highly overexpressed ανβ3 integrin 
receptor in metastatic cancers. Lo and coworkers verified an integrin-dependent 
endocytosis process of cyclic RGD (cRGD)-anchored MSNs by U87-MG cells.35 
Futhermore, Tamanoi, Zink and coworkers synthesized cRGD-modified MSNs, targeting 
metastatic cancer cells, as well as transferrin-modified MSNs, targeting transferrin 
receptor overexpressed primary cancer cells.101 They observed a positive interaction 
between targeting ligands and upregulated receptors, they also envisaged that by altering 
the surface groups, the MSN based drug delivery systems can be manipulated to target 
different stages of cancers.  
 Further research on the RGD peptide facilitated cancer cell delivery was conducted 
by the Trewyn group,102 where they determined that RGD modified MSNs remained in 
the endosomes for a longer period of time compared to MSNs without RGD ligand 
attached. Moreover, their results indicated that the conformation of the RGD peptide 
affects the uptake efficiency of RGD modified MSNs, where cyclic RGD peptides 
possess greater affinity to the cell membrane integrins and facilitate the endocytosis 
process better, comparing to linear RGD peptides. Other proteins or peptides such as 
monoclonal herceptin antibody or TAT peptide have also been immobilized onto MSNs 
and shown to increase the uptake efficiency by cancerous cells.103,104 
 Aptamers are recognized as molecule-specific targeting agents, so it is feasible to 
furnish MSNs with cell-specific aptamers for targeted delivery. In a work by Zhu et al., a 
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cancer-cell targeted DNA aptamer, sgc8, was selected as a recognition molecule.67 
Significant enhancement of Hela cell uptake of aptamer-conjugated MSNs comparing to 
aptamer-free MSNs was monitored by flow cytometry. 
 
7. In vivo and in planta delivery with Mesoporous Silica Nanoparticles 
7.1 In vivo Delivery 
 Despite the numerous studies that have demonstrated the in vitro therapy efficacy of 
MSNs based smart drug delivery systems, the feasibility of using MSNs for in vivo drug 
delivery has to be further evaluated. Recently, several groups have explored extended in 
vivo investigations. In Tamanoi’s experiments on mice, camptothecin (CPT)-loaded 
MSNs showed to be effective in suppressing tumor growth.95 For nude mice injected with 
CPT-loaded MSNs, the tumor significantly decreased in size or was completely 
eliminated by the end of treatment (52 days). Another important finding was that a 
targeting moiety functionalization dramatically increased tumor-suppressing effects of 
CPT-loaded MSNs.105 Folic acid-modified MSNs induced an enhanced tumor inhibition 
and faster tumor regression than unmodified MSNs, suggesting a good targeting efficacy 
of folic acid. 
 In vivo therapeutic efficacy of MSNs based drug delivery system was also assessed 
by Chen and coworkers.106 Mice with tumors of approximately 200 mm3 were treated 
with docetaxel-loaded MSNs (Dtxl-MSNs), taxotere or physiological saline for 17 days. 
They observed that Dtxl-MSNs treatment decreased tumor weight to only 28 percent 
compared to the control group, which was also significantly lower than the tumor weight 
of the taxotere group. The enhanced tumor suppression of Dtxl-MSNs may be attributed 
to the sustained drug release as well as intratumor drug accumulation due to the EPR 
effect. 
 
7.2 In planta Delivery 
 MSN systems have also been reported to overcome the rigid plant cell wall barrier 
and undergo plant cell internalization in a study by Lin, Wang and coworkers (Fig. 12).107 
First, they proved that MSNs functionalized with triethylene glycol (TEG-MSNs) was 
successfully internalized by tobacco mesophyll protoplasts. Using confocal fluorescence 
microscopy, they demonstrated TEG-MSNs can function as DNA delivery agents to 
efficiently carry green fluorescent protein (GFP) plasmid into protoplast cells and lead to 
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transgene expression. In depth applications for gene and guest molecules co-delivery with 
this system was inspected. A chemical trigger, β-estradiol, was loaded into inducible 
GFP-coated MSNs system and capped with gold nanoparticles by a redox-responsive 
disulfide linkage. Non-transgenic plants bombarded with this material exhibited gene 
transcription only after DTT triggered the release of β-estradiol. This methodology was 
also recently demonstrated and elaborated by the Wang and Trewyn research groups,108 
where they employed MSNs with large pore size (10 nm) to load and subsequently 
release active, non-denatured proteins, as well as plasmid DNA, to the same cell upon 
bombardment. Their findings indicated that MSNs based delivery system can be applied 
to plant science research to aid further investigations of plant genomics and gene 
function. 
 
 
Figure 12. DNA plasmid-coated gold nanoparticle-capped mesoporous silica 
nanoparticle for the simultaneous delivery of a gene and its promoter into plant cells. 
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8. Conclusion 
 The emergence of MSN materials has been appreciated by the biomedical and plant 
science field for the design of smart drug delivery devices. The unique characteristics of 
MSNs have created a fast growing number of stimuli-responsive release systems. A high 
degree of specificity and control in drug delivery is achieved by versatile uncapping 
mechanisms and new approaches for MSN synthesis. However, despite the encouraging 
progress, these systems are mostly investigated outside the biological system, and have 
not yet been proven for in vivo biomedical applications. Although ingenious work is 
required to conquer remaining challenges, it is reasonable to believe that these 
multifunctional MSNs drug delivery systems will promote the development in clinical 
and other biotechnological fields.
35 
 
REFERENCES 
1. Svenson, S. 2004. ACS Symposium Series. 879:2-23. 
2. Gref, R. and Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin, and R. 
Langer. 1994. Science. 263(5153): 1600-1603. 
3. Jeong, B. and Y.H. Bae, D.S. Lee, and S.W. Kim. 1997. Nature. 388:860-862. 
4. Discher, B.M. and Y.-Y. Won, D.S. Ege, J. C.-M. Lee, F.S. Bates, D.E. Discher, and 
D.A. Hammer. 1999. Science. 284(5417): 1143-1146. 
5. Torchilin, V.P. 2005. Nat. Rev. Drug Discov. 4(2):145-160. 
6. Gao, C. and D. Yan. 2004. Prog. Polym. Sci. 29(3):183-275. 
7. Lee, C.C. and J.A. Mackay, J.M.J. Frechet, and F.C. Szoka. 2005. Nat. Biotechnol. 
23(12):1517-1526. 
8. Peppas, N. A. and P. Bures, W. Leobandung, and H. Ichikawa. 2000. Eur. J. Pharm. 
Biopharm. 50(1):27-46. 
9. Peppas, N. A. and J.Z. Hilt, A. Khademohosseini, and R. Langer. 2006. Adv. Mater. 
18(11):1345-1360. 
10. Lai, C.Y. and B.G. Trewyn, D.M. Jeftinija, K. Jeftinija, S. Xu, S. Jeftinija, and 
V.S.-Y. Lin. 2003. J. Am. Soc. Chem. 125(15):4451-4459. 
11. Vivero-Escoto, J.L. and I.I. Slowing, B.G. Trewyn and V.S.-Y. Lin. 2010. Small. 
6(18):1952-1967. 
12. Kresge, C.T. and M.E. Leonowicz, W.J. Roth, J.C. Vartuli, and J.S. Beck. 1992. 
Nature. 359(6397):710-712. 
13. Inagaki, S. and Y. Fukushima, and K. Kuroda. 1993. J. Chem. Soc. Chem. Comm. 
8:680-682. 
14. Hoffmann, F. and M. Cornelius, J. Morell, and M. Froeba. 2006. Angew. Chem. Int. 
Ed. 45(20):3216-3251. 
15. Wan, Y. and D. Zhao. 2007. Chem. Rev. 107(7):2821-2860. 
16. Vallet-Regí, M. and A. Ramila, R.P. del Real, and J. Perez-Pariente. 2001. Chem. 
Mater. 13(2):308-311. 
17. Vallet-Regí, M. and F. Balas, and D. Arcos. 2007. Angew. Chem. Int. Ed. 
46(40):7548-7558. 
18. Trewyn, B.G. and S. Giri, I.I. Slowing, and V.S.-Y. Lin. 2007. Chem. Comm. 
31:3236-3245. 
19. Song, S.W. and K. Hidajat, and S. Kawi. 2005. Langmuir. 21(21):9568-9575. 
36 
 
20. Vartuli, J.C. and K.D. Schmitt, C.T. Kresge, W.J. Roth, M.E. Leonowicz, S.B. 
McCullen, S.D. Hellring, J.S. Beck, J.L. Schlenker, D.H. Olson, and E.W. Sheppard. 
1994. Chem. Mater. 6(12):2117-2326. 
21. Cai, Q. and W.-Y. Lin, F.-S. Xiao, W.-Q. Pang, X.-H. Chen, and B.-S. Zou. 1999. 
Micropor. Mesopor. Mater. 32(1-2):1-15. 
22. Huo, Q. and R. Leon, P.M. Petroff, and G.D. Stucky. 1995. Science. 
268(5215):1324-1327. 
23. Huo, Q. and D.I. Margolese, and G.D. Stucky. 1996. Chem. Mater. 8(5):1147-1160. 
24. Zhao, D. and J. Feng, Q. Huo, N. Melosh, G.H. Frederickson, B.F. Chmelka, and 
G.D. Stucky. 1998. Science. 279(5350):548-552. 
25. Zhao, D. and Q. Huo, J. Feng, B.F. Chmelka, and G.D. Stucky. 1998. J. Am. Chem. 
Soc. 120(24):6024-6036. 
26. Beck, J.S. and J.C. Vartuli, W.J. Roth, M.E. Leonowicz, C.T. Kresge, K.D. Schmitt, 
C.T.-W. Chu, D.H. Olson, E.W. Sheppard, S.B. McCullen, J.B. Higgins, and J.L. 
Schlenker. 1992. J. Am. Chem. Soc. 114(27):10834-10843. 
27. Widenmeyer, M. and R. Anwander. 2002. Chem. Mater. 14(4):1827-1831. 
28. Sayari, A. and P. Liu, M. Kruk, and M. Jaroniec. 1997. Chem. Mater. 
9(11):2499-2506. 
29. Huh, S. and J.W. Wiench, J.-C. Yoo, M. Pruski, and V.S.-Y. Lin. 2003. Chem. Mater. 
15(22):4247-4256. 
30. Huh, S. and J.W. Wiench, B.G. Trewyn, S. Song, M. Pruski, and V.S.-Y. Lin. 2003. 
Chem. Comm. 18:2364-2365. 
31. Radu, D.R. and C.-Y. Lai, J. Huang, X. Shu, and V.S.-Y. Lin, 2005. Chem. Comm. 
10:1264-1266. 
32. Lim, M.H. and A. Stein. 1999. Chem. Mater. 11(11):3285-3295. 
33. Radu, D.R. and C.-Y. Lai, J.W. Wiench, M. Pruski, and V.S.-Y. Lin. 2004. J. Am. 
Chem. Soc. 126(6):1640-1641. 
34. De Juan, F. and E. Ruiz-Hitzky. 2000. Adv. Mater. 12(6):430-432. 
35. Cheng, S.-H. and C.-H. Lee, M.-C. Chen, J.S. Souris, F.-G. Tseng, C.-S. Yang, C.-Y. 
Mou, C.-T. Chen, and L.-W. Lo. 2010. J. Mater. Chem. 20(29):6149-6157. 
36. Radu. D.R. and C.-Y. Lai, K. Jeftinija, E.W. Rowe, S. Jeftinija, and V.S.-Y. Lin. 
2004. J. Am. Chem. Soc. 126(41):13216-13217. 
37 
 
37. Giri, S. and B.G. Trewyn, M.P. Stellmaker, and V.S.-Y. Lin. 2005. Angew. Chem. Int. 
Ed. 44(32):5038-5044. 
38. Slowing, I.I. and B.G. Trewyn, and V.S.-Y. Lin. 2006. J. Am. Chem. Soc. 
128(46):14792-14793. 
39. Slowing I.I. and B.G. Trewyn, and V.S.-Y. Lin. 2007. J. Am. Chem. Soc. 
129(28):8845-8849. 
40. Vivero-Escoto, J.L. and I.I. Slowing, C.-W. Wu, and V.S.-Y. Lin. 2009. J. Am. Chem. 
Soc. 131(10):3462-3463. 
41. Prokop, A. and J.M. Davidson. 2008. J. Pharm. Sci. 97(9):3518-3590. 
42. Trewyn, B.G. and J.A. Nieweg, Y. Zhao, and V.S.-Y. Lin. 2008. Chem. Eng. J. 
137(1):23-29. 
43. Lu, F. and S.-H. Wu, Y. Hung, and C.-Y. Mou. 2009. Small. 5(12):1408-1413. 
44. Chung, T.-H. and S.-H. Wu, M. Yao, C.-W. Lu, Y.-S. Lin, Y. Hung, C.-Y. Mou, 
Y.-C. Chen, and D.-M. Huang. 2007. Biomaterials. 28(19):2959-2966. 
45. Vallhov, H. and S. Gabrielsson, M. Stromme, A. Scheynius, and A.E. Garcia-Bennett. 
2007. Nano Lett. 7(12):3576-3582. 
46. Hudson, S.P. and R.F. Padera, R. Langer, and D.S. Kohane. 2008. Biomaterials. 
29(30):4045-4055. 
47. Jiang, W. and B.Y.S. Kim, J.T. Rutka, and W.C.W. Chan. 2008. Nature. Nanotechnol. 
3(3):145-150. 
48. He, X. and H. Nie, K. Wang, W. Tan, X. Wu, and P. Zhang. 2008. Anal. Chem. 
80(24):9597-9603. 
49. He, Q. and Z. Zhang, F. Gao, Y. Li, and J. Shi. 2011. Small. 7(2):271-280. 
50. Huang, X. and L. Li, T. Liu, N. Hao, H. Liu, D. Chen, and F. Tang. 2011. ACS Nano. 
5(7):5390-5399. 
51. Lin, Y.-S. and C.L. Haynes. 2010. J. Am. Chem. Soc. 132(13):4834-4842. 
52. Zhao, Y. and X. Sun, G. Zhang, B.G. Trewyn, I.I. Slowing, and V.-S.Y. Lin. 2011. 
ACS Nano. 5(2):1366-1375. 
53. Kim, J. and H.S. Kim, N. Lee, T. Kim, H. Kim, T. Yu, I.C. Song, W.K. Moon, and T. 
Hyeon. 2008. Angew. Chem. Int. Ed. 47(44):8438-8441. 
54. Wu, S.-H., Y.-S. Lin, Y. Hung, Y.-H. Chou, Y.-H. Hsu, C. Chang, and C.-Y. Mou. 
2008. Chembiochem. 9(1):53-57. 
55. Mal, N.K. and M. Fujiwara, and Y. Tanaka. 2003. Nature. 421(6921):350-353. 
38 
 
56. Casasus, R. and M.D. Marcos, R. Martínez-Máñez, J.V. Ros-Lis, J. Soto, L.A. 
Villaescusa, P. Amorós, D. Beltran, C. Guillem, and J. Latorre. 2004. J. Am. Chem. 
Soc. 126(28):8612-8613. 
57. Bernardos, A. and E. Aznar, C. Coll, R. Martínez-Máñez, J. Barat, M.D. Marcos, F. 
Sancenon, A. Benito, and J. Soto. 2008. J. Controlled Release. 131(3):181-189. 
58. Song, S.-W. and K. Hidajat, and S. Kawi. 2007. Chem. Comm. 42:4396-4398. 
59. Hong, C.-Y. and X. Li, and C.-Y. Pan. 2009. J. Mater. Chem. 19(29):5155-5160. 
60. Park, C. and K. Oh, S.C. Lee, and C. Kim. 2007. Angew. Chem. Int. Ed. 
46(9):1455-1457. 
61. Angelos, S. and Y.-W. Yang, K. Patel, J.F. Stoddart, and J.I. Zink. 2008. Angew. 
Chem. Int. Ed. 47(12):2222-2226. 
62. Angelos, S. and N.M. Khashab, Y.-W. Yang, A. Trabolsi, H.A. Khatib, J.F. Stoddart, 
and J.I. Zink. 2009. J. Am. Chem. Soc. 131(36):12912-12914. 
63. Ferris, D.P. and Y.-L. Zhao, N.M. Khashab, A. Hussam, J.F. Stoddart, and J.I. Zink. 
2009. J. Am. Chem. Soc. 131(5):1686-1688. 
64. Park, C. and K. Lee, and C. Kim. 2009. Angew. Chem. Int. Ed. 48(7):1275-1278. 
65. He, D. and X. He, K. Wang, J. Cao, and Y. Zhao. 2012. Langmuir. 28(8):4003-4008. 
66. Saito, G. and J.A. Joel, and K.-D. Lee. 2003. Adv. Drug Deliv. Rev. 55(2):199-215. 
67. Zhu, C.-L. and X.-Y. Song, W.-H. Zhou, H.-H. Yang, Y.-H. Wen, and X.-R. Wang. 
2009. J. Mater. Chem. 19(41):7765-7770. 
68. Nguyen, T.D. and Y. Liu, S. Saha, K.C.-F. Leung, J.F. Stoddart, and J.I. Zink. 2007. 
J. Am. Chem. Soc. 129(3):626-634. 
69. Nguyen, T.D. and H.-R. Tseng, P.C. Celestre, A.H. Flood, Y. Liu, J.F. Stoddart, and 
J.I. Zink. 2005. Proc. Nat. Acad. Sci. USA. 102(29):10029-10034. 
70. Rao, G.V.R. and M.E. Krug, S. Balamurugan, H. Xu, Q. Xu, and G.P. Lopez. 2002. 
Chem. Mater. 14(12):5075-5080. 
71. Fu, Q. and G.V.R. rao, L.K. Ista, Y. Wu, B.P. Andrzejewski, L.A. Sklar, T.L. Ward, 
and G.P. Lopez. 2003. Adv. Mater. 15(15):1262-1266. 
72. Fu, Q. and G.V.R. Rao, T.L. Ward, Y. Lu, and G.P. Lopez. 2007. Langmuir. 
23(1):170-174. 
73. You, Y.-Z. and K.K. Kalebaila, S.L. Brock, and D. Oupicky. 2008. Chem. Mater. 
20(10):3354-3359. 
39 
 
74. Yang, Y. and X. Yan, Y. Cui, Q. He, D. Li, A. Wang, J. Fei, and J. Li. 2008. J. Mater. 
Chem. 18(47):5731-5737. 
75. Heskins, M. and J.E. Guillet. 1968. J. Macro. Sci. 2(8):1441-1455. 
76. Pelton, R. 2000. Adv. Colloid Interfac. 85(1):1-33. 
77. Li, D. and Y. Cui, K. Wang, Q. He, X. Yan, and J. Li. 2007. Adv. Func. Mater. 
17(16):3134-3140. 
78. Schlossbauer, A. and S. Warncke, P.M.E. Gramlich, J. Kecht, A. Manetto, T. Carell, 
and T. Bein. 2010. Angew. Chem. Int. Ed. 49(28):4734-4737. 
79. Patel K. and S. Angelos, W.R. Dichtel, A. Coskun, Y.-W. Yanng, J.I. Zink, and J.F. 
Stoddart. 2008. J. Am. Chem. Soc. 130(8):2382-2383. 
80. Schlossbauer, A. and J. Kecht, and T. Bein. 2009. Angew. Chem. Int. Ed. 
48(17):3092-3095. 
81. Bernardos, A. and E. Aznar, M.D. Marcos, R. Martínez-Máñez, F. Sancenon, J. Soto, 
J.M. Barat, M. Jose, and P. Amorós. 2009. Angew. Chem. Int. Ed. 48(32):5884-5887. 
82. Tsai, C.-H. And J.L. Vivero-Escoto, I.I. Slowing, I.-J. Fang, B.G. Trewn, and V.S.-Y. 
Lin. 2011. Biomaterials. 32(26):6234-6244. 
83. Zhao, Y. and B.G. Trewyn, I.I. Slowing, and V.S.-Y. Lin. 2009. J. Am. Chem. Soc. 
131(24):8398-8400. 
84. Climent, E. and A. Bernardos, R. Martínez-Máñez, A. Maquieira, M.D. Marcos, N. 
Pastor-Navarro, R. Puchades, F. Sancenon, J. Soto, and P. Amorós 2009. J. Am. 
Chem. Soc. 131(39):14075-14080. 
85. Zhu, C.-L. and C.-H. Lu, X.-Y. Song, H.-H. Yang, and X.-R. Wang. 2011. J. Am. 
Chem. Soc. 133(5):1278-1281. 
86. Kim, H.-J. and H. Matsuda, H. Zhou, and I. Honma. 2006. Adv. Mater. 18(23):3083-
3088. 
87. Aznar, E. and F. Sancenon, M.D. Marcos, R. Martínez-Máñez, P. Stroeve, J. Cano, 
and P. Amorós. 2012. Langmuir. 28(5):2986-2996. 
88. Gao, Y. and Y. Chen, X. Ji, X. He, Q. Yin, Z. Zhang, J. Shi, and Y. Li. 2011. ACS 
Nano 5(12):9788-9798. 
89. Angelos, S. and Y.-W. Yang, N.M. Khashab, J.F. Stoddart, and J.I. Zink. 2009. J. Am. 
Chem. Soc. 131(32):11344-11346. 
90. Aznar, E. and M.D. Marcos, R. Martínez-Máñez, F. Sancenon, J. Soto, P. Amorós, 
and C. Guillem. 2009. J. Am. Chem. Soc. 131(19):6833-6843. 
40 
 
91. Park, C. and H. Kim, S. Kim and C. Kim, 2009. J. Am. Chem. Soc. 131(46):16614-
16615. 
92. Liu, R. and Y. Zhang, and P. Feng. 2009. J. Am. Chem. Soc. 131(42):15128-15129. 
93. Baeza, A. and E. Guisasola, E. Ruiz-Hernandez, and M. Vallet-Regí. 2012. Chem. 
Mater. 24(3):517-524. 
94. Matsumura, Y. and H. Maeda. 1986. Cancer Res. 46(12):6387-6392. 
95. Lu, J. and M. Liong, Z. Li, J.I. Zink, and F. Tamanoi. 2010. Small. 6(16):1794-1805. 
96. Rosenholm, J.M. and A. Meinander, E. Peuhu, R. Niemi, J.E. Eriksson, C. Sahlgren, 
 and M. Linden. 2009. ACS Nano 3(1):197-206. 
97. Wang, L.-S. and L.-C. Wu, S.-Y. Lu, L.-L. Chang, I.-T. Teng, C.-M Yang, and 
J.-A.A. Ho. 2010. ACS Nano 4(8):4371-4379. 
98. Guo, R. and L.-L. Li, W.-H. Zhao, Y.-X. Chen, X.-Z. Wang, C.J. Fang, W. Feng, 
T.-L. Zhang, X. Ma, M. Lu, S.-Q. Peng, and C.-H. Yan. 2012. Nanoscale 
4(11):3577-3583. 
99. Sudimack, J. and R.J. Lee. 2000. Adv. Drug Deliv. Rev. 41(2):147-162. 
100.Brevet, D. and M. Gary-Bobo, L. Raehm, S. Richeter, O. Hocine, K. Amro, B. Loock, 
P. Couleaud, C. Frochot, A. Morere, P. Maillard, M. Garcia, and J.-O. Durand. 2009. 
Chem. Comm. 12:1475-1477. 
101.Ferris, D.P. and J. Lu, C. Gothard, R. Yanes, C.R. Thomas, J.-C. Olsen, J.F. Stoddart, 
F. Tamanoi, and J.I. Zink. 2011. Small. 7(13):1816-1826. 
102.Fang, I.-J. and I.I. Slowing, K.C.-W. Wu, V.S.-Y. Lin, and B.G. Trewyn. 2012. 
Chem-Eur. J. 18(25):7787-7792. 
103.Tsai, C.-P. and C.-Y. Chen, Y. Hung, F.-H. Chang, C.-Y. Mou. 2009. J. Mater. Chem. 
19(32):5737-5743. 
104.Pan, L. and Q. He, J. Liu, Y. Chen, M. Ma, L. Zhang, and J. Shi. 2012. J. Am. Chem. 
Soc. 134(13):5722-5725. 
105.Lu, J. and Z. Li, J.I. Zink, and F. Tamanoi. 2012. Nanomedicine 8(2):212-220. 
106.Li, L. and F.-Q. Tang, H.-Y. Liu, T.-L. Liu, N.-J. Hao, D. Chen, X. Teng, and J.-Q. 
He. 2010. ACS Nano 4(11):6874-6882. 
107.Torney, F. and B.G. Trewyn, V.S.-Y. Lin, and K. Wang. 2007. Nature Nanotechnol. 
2(5):295-300. 
108.Martin-Ortigosa, S. and J.S. Valenstein, V.S.-Y. Lin, B.G. Trewyn and K. Wang. 
2012. Adv. Func. Mater. (in press).
41 
 
CHAPTER 3. INTERACTION OF MESOPOROUS SILICA 
NANOPARTICLES WITH HUMAN RED BLOOD CELL 
MEMBRANES: SIZE AND SURFACE EFFECTS 
A paper published in ACS Nano, 2011, 5, 1366-1375 
Yannan Zhao, Xiaoxing Sun, Guannan Zhang, Brian G. Trewyn, Igor I. Slowing, and 
Victor S.-Y. Lin 
 
ABSTRACT 
 The interactions of mesoporous silica nanoparticles (MSNs) of different particle sizes 
and surface properties with human red blood cell (RBC) membranes were investigated by 
membrane filtration, flow cytometry and various microscopic techniques.  Small 
MCM-41-type MSNs (~100 nm) were found to adsorb to the surface of RBCs without 
disturbing the membrane or morphology.  In contrast, adsorption of large SBA-15-type 
MSNs (~600 nm) to RBCs induced a strong local membrane deformation leading to 
spiculation of RBCs, internalization of the particles, and eventual hemolysis.  In addition, 
the relationship between the degree of MSN surface functionalization and the degree of 
its interaction with RBC, as well as the effect of RBC-MSN interaction on cellular 
deformability were investigated.  The results presented here provide a better 
understanding of the mechanisms of RBC-MSN interaction and the hemolytic activity of 
MSNs, and will assist in the rational design of hemocompatible MSNs for intravenous 
drug delivery and in vitro imaging. 
 
1.  Introduction 
 Recent advancements in particle size and morphology control of mesoporous 
materials have led to the creation of nano- and submicron-sized mesoporous silica 
nanoparticles (MSNs).1-5  The MSN materials with well-ordered cylindrical pore 
structures such as MCM-41 and SBA-15, have attracted special interest in the biomedical 
field.1  The large surface areas and pore volumes of these materials allow the efficient 
adsorption of a wide range of molecules, including small drugs,6-10 therapeutic 
proteins,11-13 antibiotics,14, 15 and antibodies.16  Therefore, these materials have been 
proposed for use as potential vehicles for biomedical imaging, real-time diagnosis, and 
controlled delivery of multiple therapeutic agents.6-8, 10, 17-25   
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 Despite the considerable interest in the biomedical applications of MSNs, relatively 
few studies have been published on the biocompatibility of the two most common types 
of MSNs (MCM-41 and SBA-15).26-29  Asefa and co-workers reported that the cellular 
bioenergetics (cellular respiration and ATP levels) were inhibited remarkably by large 
SBA-15 nanoparticles, but the inhibition was greatly reduced by smaller MCM-41 type 
nanoparticles.26  These differences in the disruption of cellular bioenergetics are 
believed to be caused by the different surface areas, number of surface silanol groups, 
and/or particle sizes of both types of material.  A recent study by Kohane and 
collaborators on the systemic effects of MCM-41 (particle size ~ 150 nm) and SBA-15 
(particle size ~ 800 nm) MSNs in live animals revealed interesting findings regarding 
their biocompatibility.27  While large doses of mesoporous silicas administered 
subcutaneously to mice appear to be relatively harmless, the same doses given 
intravenously or intraperitoneally were lethal.27  A possible reason for the severe 
systemic toxicity of MSNs when injected intravenously could be the interactions of the 
nanoparticles with blood cells.  
 Our initial studies on the biocompatibility of MCM-41 type MSNs with red blood 
cells (RBCs), the dominant (99%) cell type in blood, suggested that this material was 
innocuous in comparison to the highly hemolytic amorphous silica.30  These results were 
later confirmed by Lin and Haynes, who demonstrated that the hemocompatibility of 
MSNs also depended on the size of the nanoparticles.31  These findings were mainly 
based on hemolysis assays performed by UV-Vis spectroscopy.  The lack of hemolysis, 
however, does not necessarily warrant the absence of interactions between the particles 
and the RBCs, which could lead to more subtle side effects.  Such side effects could 
eventually be the ones responsible for the enhanced systemic toxicity observed upon 
intravenous injection of these materials.27 Therefore, an in depth study of other possible 
biological side effects of these materials must be performed if they are intended to be 
applied as vehicles for drug delivery.   
 In general, our knowledge of the biocompatibility, bioretention, and biodistribution 
of MSNs does not match with the rapid pace of research on their syntheses in numerous 
forms and structures.  To date, efforts have focused predominantly on exploiting 
multifunctional nanoparticles as intravascular drug carriers with different particle sizes 
ranging from a few tens of nanometers4,24,32 up to hundreds of nanometers,3,5 various pore 
diameters ranging from 2 to 10 nm5,11,33 and assorted surface functionalities from small 
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organic groups (e.g., amino,34,35 carboxyl,35 thiol,35 phosphate,19 etc) to large molecules 
(e.g., dendrimers,36 polyethyleneimine (PEI),25,37 poly(ethylene glycol) (PEG),38 
phospholipids,39 etc).  Unfortunately, these endeavors are limited by a poor 
understanding of particle interactions with cells in circulation.  
 Herein, we report our investigations on the interactions of the two most common 
types of MSNs (MCM-41 and SBA-15) with RBC membranes using fluorescence and 
electron microscopies and cell biology techniques.  In addition to studying the effects of 
particle size and surface area on the hemolytic behavior of MSNs, we explored the effects 
that the chemical nature and degree of surface functionalization of the particles has on 
their interactions with RBCs.  Understanding these effects will not only offer a guide for 
the rational design of biocompatible particles, but will also provide an insight into how to 
control the circulation properties of MSNs in the bloodstream.  In fact, a prolonged 
circulation of polymeric nanoparticles has been recently demonstrated by means of their 
non-covalent attachment to the RBC membrane.40  Attachment to the RBC membrane, 
however, may affect one of its most important properties, namely its deformability (i.e. 
the ability of an erythrocyte to deform so it can flow through microcirculation).  To the 
best of our knowledge, this problem has not yet been addressed for any drug delivery 
system.  In this work, we examined the effect of RBC-MSN interactions on membrane 
deformability by the Nucleopore filtration technique,41 and established how size and 
surface properties can alter this important property.  Overall, we propose three 
fundamental criteria to assess the hemocompatibility of nanoparticles: (1) hemolytic 
potential, (2) propensity to induce RBC membrane deformation or morphological 
alteration, and (3) tendency to impair RBC deformability.  The evaluation of these 
conditions will enable a more adequate estimation of the hemocompatibility of many 
types of nanomaterials.  This study suggests a minimal set of criteria that must be met 
before performing in vitro studies involving the intravascular administration of 
nanoparticles. 
 
2.  Results and Discussion 
2.1.  Size- and surface-dependent MSN interaction with RBC membranes 
 While particle size effect of MCM-41 type MSNs has already been established with 
larger particles producing lower hemolysis on RBC,31 the question remains whether the 
typically larger SBA-15 type MSNs as hemocompatible.  A more critical issue is that the 
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mechanism of how MSNs of different sizes and surface areas correlate and contribute to 
their hemocompatibility is unclear, although several biological rationales have been 
suggested.30,31  To address these questions, we prepared two types of MSNs: MCM-41 
and SBA-15, as described in the Methods section.  Scanning electron microscopy (SEM) 
and transmission electron microscopy (TEM) images showed particle sizes of 100 to 200 
nm for the MCM-41-type MSNs (referred to as s-MSN, Figure 1a,d) and ~600 nm by 
~300 nm for the SBA-15-type MSNs (referred as l-MSN, Figure 1b,e).  The 
hydrodynamic particle size distributions of the materials suspended in phosphate-buffered 
saline (PBS) (100 µg mL-1) were determined by dynamic light scattering (DLS), giving 
average sizes of 122 nm for s-MSN and 531 nm for l-MSN (Figure 1c).  XRD patterns 
showed that both s-MSNs and l-MSNs exhibit 2D hexagonal pore arrangements (Figure 
1f). 
 
 
Figure 1. Scanning electron (top) and transmission electron (bottom) images of (a, d) 
s-MSN and (b, e) l-MSN.  (c) Hydrodynamic size distributions of s-MSN (blue) and 
l-MSN (red) suspended in PBS (100 µg mL-1) measured by dynamic light scattering.  (f) 
X-ray diffraction patterns of s-MSN (blue) and l-MSN (red). 
 
(a) (b) 
(d) 
(c) 
(e) (f) 
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Figure 2. Hemolysis assay for s-MSN (green lines) and l-MSN (red lines), using water as 
a positive control (blue lines) and PBS as a negative control (dashed black lines).  The 
materials were suspended at 50 (a, c) and 100 µg mL-1 (b, d).  The mixtures were 
centrifuged to detect the presence of hemoglobin in the supernatant visually (a, b) and by 
absorption at 541 nm (c, d). 
 
 The hemolysis assay was used to evaluate the hemolytic behaviors of s-MSN and 
l-MSN on human RBCs.  Human RBCs were first isolated by centrifugation and purified 
by five successive washes with sterile isotonic PBS, then diluted to 5% hematocrit with 
PBS before incubating with MSN suspensions of various concentrations.  Controls were 
prepared in the same manner as the above RBC samples except adding water (positive 
control) and PBS (negative control) instead of the MSN suspensions.  After a two-hour 
incubation at room temperature, the samples were spun down for the detection of 
hemoglobin released from hemolyzed RBCs.  Surprisingly, contrary to the recently 
reported trend regarding size,31 MSNs with larger particle size exhibited a higher 
hemolytic activity than the small particles (Figure 2).  The hemolytic activity of l-MSNs 
was first observed at 50 µg mL-1 with 5% hemolysis detected, while a good 
hemocompatibility (< 2% hemolysis) of s-MSN was confirmed at concentrations as high 
as 100 µg mL-1. While a larger particle size may be preferable for hemocompatible MSNs 
(a) (b) 
(c) (d) 
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below 225 nm,31 increasing particle size of MSNs beyond this range will not necessarily 
improve the hemocompatibility as one might intuitively expect.  In addition to particle 
size, other factors such as the surface area are also expected to affect the hemolytic 
potential of MSNs. 
 
 
Figure 3. Scanning electron images of RBCs (5% hematocrit) incubated for 2 h at room 
temperature with (A) PBS as control, (B) 100 µg mL-1 of s-MSN and (C) 100 µg mL-1 of 
l-MSN.  Images increase in magnification from left to right with features highlighted 
with white squares or arrows.  The nanoparticles attached on cell surface are 
distinguished by the particle shape and surface textural difference between the particles 
and RBCs.  (Additional high magnification images are shown in Figure S2.) 
 
A 
B 
C 
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Figure 4. Transmission electron images of RBCs (5% hematocrit) incubated for 2 h at 
room temperature with 100 µg mL-1 s-MSN (top) and l-MSN (bottom).  Images increase 
in magnification from left to right.  The presence of MSNs is confirmed by the visible 
pores in the higher magnification micrographs. 
 
 To elucidate the mechanism of the observed difference in hemolysis and investigate 
the underlying particle size and surface effects, the interaction of MSNs with RBCs were 
visualized by SEM (Figure 3) and TEM (Figure 4).  A small proportion of s-MSNs were 
found to adsorb to the surface of RBC.  The cell membrane did not show any alteration 
upon particle binding and RBCs maintained normal biconcave shape compared to control 
RBCs (Figure 3B and Figure 4 top).  In contrast, a large proportion of l-MSNs attached 
to RBC membranes and induced a strong local membrane deformation, which frequently 
resulted in particle encapsulation by RBCs (Figure 3C and Figure 4 bottom).  The 
membrane wrapping around l-MSNs led to an echinocytic (spiculated) shape 
transformation of RBCs and a reduction in the ratio of surface area to volume.42  This 
inability to maintain their normal surface area and control their cell volume can ultimately 
lead to the destruction of these cells,42 which explains the observed high hemolytic 
activity of l-MSNs. 
 Two main processes are involved in the interaction of MSN with the membrane of 
RBC: (1) binding of the silanol-rich surface of MSNs with the phosphatidyl choline-rich 
RBC membrane,30 and (2) bending of the RBC membrane to adapt to the rigid surface of 
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MSNs (Scheme 1).43-47  The occurrence of the interaction depends on whether the 
amount of energy released from the binding of the MSNs with the RBC membrane (Ei) is 
able to overcome the amount of free energy required to bend the membrane and adapt to 
the surface of MSNs (Eb).  The former energy is associated with the external surface 
area (i.e., accessible silanols) of MSN,30 while the latter is proportional to the curvature or 
inversely proportional to the square of the radius (r) of the particle.43,44,47  The external 
surface areas of s-MSNs and l-MSNs, calculated from the t-plots of their N2 adsorption 
isotherms,48 were 81.6 and 155.4 m2 g-1, respectively.  The relatively large external 
surface area of l-MSN (40% of total surface area) in comparison to that of s-MSN (8% of 
total surface area) implies that l-MSN can have a larger binding energy (Ei) available for 
pulling the membrane to the particle surface.  In addition, since surface curvature 
decreases with particle size, the bending energy required to wrap the large particles (Eb) is 
lower than the one needed to wrap the smaller particles.43  This combination makes 
membrane wrapping and engulfment of l-MSN thermodynamically favorable.  On the 
contrary, in order for the RBC membranes to wrap around smaller s-MSNs, they would 
have to attain a larger curvature (steeper angles over smaller areas) than they need for 
wrapping around the larger particles.43  This would require investing a much higher Eb 
compared to the small amount of Ei, which thermodynamically prevents the membrane 
deformation or engulfment of s-MSN by RBC, and explains the lower hemolytic activity 
of s-MSNs.  Similar explanations on the effect of particle size on membrane wrapping 
have been reported elsewhere.43,44  Hence, the interaction of MSNs with RBC 
membranes and the hemolytic activity depends on not only particle size but on their 
external surface area as well. 
 
2.2.  Size- and surface-dependent engulfment of MSNs by RBCs 
 Though the in vitro endocytosis of MSN has been systematically investigated with 
various mammalian cell lines,4,11,17,34,36,49-52 little is known about the uptake of 
nanoparticles by RBCs.  This is partly because the interactions between RBC and MSN 
are still poorly understood.  Before investigating the internalization of MSNs by RBC, it 
is necessary to establish the concentration at which the plasma membrane maintains its 
integrity and RBCs retain normal biconcave shape.  To do so, the RBCs were incubated 
with l-MSNs at different concentrations; and the hemolytic effects as well as the resulting 
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Scheme 1. A schematic illustration of the size- and surface-dependent interaction of MSN 
and RBC membrane.  MSN with radius r can be wrapped around or engulfed by RBC if 
the energy (Ei) released from RBC-MSN interaction is greater than the energy (Eb) 
required for membrane bending. 
 
cell morphologies were examined by UV-Vis spectroscopy (Figure S3 in Supporting 
Information) and SEM (Figure S4).  The hemolysis percentage of RBCs increased from 
1% to 11% as the concentration of l-MSN raised from 20 to 100 µg mL-1, and growing 
proportions of spiculated RBCs were observed with increasing concentrations of l-MSN.  
As shown in Figure S4, almost 90% of RBCs exhibited spiculated shape with 100 µg 
mL-1 of l-MSN.  The proportion of spiculated RBCs decreased to 50% when 50 µg mL-1 
of l-MSN was used.  Interestingly, only minor shape modifications (less than 10% 
spiculated cells) in RBCs were observed after incubation with 20 µg mL-1 of l-MSN, even 
if many particles were adsorbed to the membranes or underwent internalization (Figure 
S4 left).  Therefore, the cellular uptake process was examined at a concentration of 20 
µg mL-1 of l-MSN (Figure 5).  It should be noted that the images in Figure 5 correspond 
to different cells at different stages of nanoparticle encapsulation.  A plausible 
interpretation of our observations is as follows.  The particle interacts with an initially 
flat cell membrane.  Driven by a local reduction in free energy (Scheme 1), the 
phospholipids in the immediate neighborhood of the site of contact are drawn to the 
surface of the particle, leading to membrane wrapping and eventual encapsulation.  Such 
internalization is different from phagocytosis or endocytosis, since it appears to be driven 
by the balance of two opposing forces rather than by an active uptake of nutrients by the 
cell.  It should be stressed that even if almost no hemolysis or spiculation is observed at 
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this concentration we cannot yet exclude the potential side effects of the internalization of 
l-MSN into RBC.  Nevertheless, this preliminary study on MSN engulfment by RBC is 
an important step toward establishing the plausibility of using MSNs as tools for the 
treatment of RBC related diseases or intravascular drug delivery.  We are currently 
conducting more studies to understand and control the internalization of MSNs and the 
delivery of therapeutic agents into RBCs to be published in subsequent manuscripts.  
 
Figure 5. Cellular uptake process (left to right) examined by transmission electron 
microscopy of RBCs (5% hematocrit) incubated with 20 µg mL-1 l-MSN.  Images 
increase in magnification from top to bottom, with features highlighted in white arrows.  
These images (left to right) correspond to different cells at different stages of nanoparticle 
encapsulation.   
 
2.3.  Surface functionality effects on RBC-MSN interaction 
 The results from the size- and surface-dependent interactions of MSNs with RBCs 
have demonstrated a superior hemocompatibility of s-MSNs over l-MSNs.  This does 
not imply, however, that s-MSNs lack any interaction with the membranes of RBCs.  
While the interactions of MSNs with the membranes of RBCs is known to be dependent 
on the presence of silanol groups on the surface of the particles,30,31 there is no 
quantitative information on the magnitude of this association.  Given the interest of 
utilizing s-MSNs for intravenous drug delivery it is necessary to be able to measure and 
control the degree of the abovementioned interactions and, thus, controlling the 
circulation of the particles in the bloodstream.40,53  
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 To study these interactions, s-MSNs were first labeled with fluorescein 
isothiocyanate (FITC), which enabled their tracking by flow cytometry and confocal 
fluorescence microscopy.  FITC-s-MSNs were then functionalized with different 
amounts of aminopropyl (AP), polyethylene glycol (PEG) and carboxyl (CA) groups, as 
described in the Methods section.  These functionalized materials are referred as 
APx-FITC-s-MSN, PEGx-FITC-s-MSN and CAx-FITC-s-MSN, respectively; where the 
subscript x corresponds to the number of mmol introduced per gram of material.  The 
amount of functional groups (AP, PEG and CA) grafted on MSNs was quantified by TGA 
shown in Figure S5 bottom and summarized in Table S1.  The quantification of 
nanoparticle attachment to the membrane of RBCs was performed by flow cytometry.  
Diluted suspensions of RBCs (5×106 cells mL-1) were mixed with equal volumes of 
nanoparticle suspensions to reach a final concentration of 10 µg mL-1 of MSNs and 
incubated at room temperature for 2 h before flow cytometry analysis.  As shown in 
Figure 6, the functionalized nanoparticles exhibited lower affinity to RBC than 
FITC-s-MSNs, furthermore, the affinity decreased with increasing degree of functionality.  
This trend was observed for each functionalized material, independent of the surface 
charge.  In particular, AP and PEG groups (~25% of RBC bound with 
AP1.5-FITC-s-MSN and ~20% with PEG1-FITC-s-MSN) showed a significantly better 
ability to reduce the MSN binding with RBC than CA groups (~65% of RBC bound with 
CA1.5-FITC-s-MSN).  The inhibitory effect of PEG on the adsorption of MSN to RBC 
was not surprising, since PEGylation of nanoparticles is generally used to block 
nonspecific binding of nanoparticles to proteins.54  On the contrary, the reduction of 
MSN binding to RBC due to aminopropyl group functionalization, was completely 
unexpected, since amines are well known to facilitate adsorption of several biomolecules 
to the surface of nanoparticles and facilitate many nanoparticle-cell interactions.34,55  
The reduced binding of AP-FITC-s-MSN to RBC could be explained by the electrostatic 
interaction between amino groups on the surface of MSNs and surface silanols,56 which 
diminishes the accessibility of silanol groups to the cell membrane. 
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Figure 6. Flow cytometry measurement of RBCs (5×106 cells mL-1) incubated with 10 µg 
mL-1 of (a) APx-FITC-s-MSN, (b) PEGx-FITC-s-MSN and (c) CAx-FITC-s-MSN.  
 
 
Figure 7. Confocal fluorescence micrographs (top) and dot plots from the flow cytometry 
analyses (bottom) of PKH26 labeled RBCs (5×106 cells mL-1) incubated with 10 µg mL-1 
of (a, f) FITC-l-MSN, (b, g) FITC-s-MSN, (c, h) AP1.5-FITC-s-MSN, (d, i) 
PEG1-FITC-s-MSN and (e, j) CA1.5-FITC-s-MSN.  The axes correspond to the intensity 
of red fluorescence due to PKH26 labeling (horizontal axis) and green fluorescence due 
to the attachment of FITC-MSNs onto PKH26-RBCs (vertical axis).  The plot was gated 
to show PKH26 labeled RBCs in area Q4 and FITC-fluorescent PKH26-RBCs in area Q2.  
Individual channels for the merged confocal images and enlarged dot plots with 
PKH26-RBC control are shown in Figure S7 and Figure S8, respectively.  
 
 The results obtained by flow cytometry were further confirmed by examination of the 
mixtures of the derivatized MSNs with RBCs under confocal fluorescence microscopy.  
For this purpose, RBCs were first labeled with PKH26 red fluorescent dye (Sigma) and 
incubated with FITC labeled particles at the same conditions as in the flow cytometry 
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experiment.  FITC-l-MSNs, FITC-s-MSNs and CA1.5-FITC-s-MSNs (Figure 7a,b,e) 
were easily observed associated to PKH26-labeled RBCs.  Conversely, only a small 
proportion of AP1.5-FITC-s-MSNs (Figure 7c) and PEG1-FITC-s-MSNs (Figure 7d) were 
found co-localized with PKH26-RBCs, while most of the particles were observed in the 
extracellular space.  A series of movies showing each one of these combinations of 
MSNs and RBCs were prepared from micrographs taken at different z-positions by 
changing the focal plane every 0.5 µm, these movies can be found in the Supporting 
Information.  The different affinities of each MSN for the RBCs were also confirmed by 
the different shifts of the green fluorescence intensities in the 2D dot plots from flow 
cytometry (Figure 7, bottom). 
 
2.4.  Effect of RBC-MSN interaction on RBC deformability 
 The attachment of nanoparticles to the surface of red blood cells has been suggested 
for extending the circulation time and sustained release of therapeutic agents.40,53  Such 
attachment, however, could have an impact on the properties of the membrane affecting 
the normal function of RBCs.  Surprisingly, this potential problem has not been 
addressed for any nanoparticle-based drug carrier, to the best of our knowledge.  One of 
the key properties of RBCs (6-8 µm in diameter) is their ability to undergo deformation to 
traverse the capillaries of the microvascular system (2-3 µm in diameter).  This 
remarkable deformability of RBCs is critical for effective blood flow, and depends 
strongly on the flexibility of the cell membrane.  This is the reason why it is important to 
assess the effects of MSN attachment on the deformability of RBCs. 
 To study the deformability of RBCs, we used a literature reported method consisting 
of filtering the cells through polycarbonate membranes with straight channels of 3 µm 
pore diameter (Nucleopore).41  This technique is generally accepted as a relative 
indication of RBC deformability.41,57-59  We measured the filterability of fresh human 
RBCs (5% hematocrit) previously incubated with varying concentrations (10, 20, 50 µg 
mL-1) of MSN under a constant negative pressure (-20 cm H2O).  The time it took each 
RBC suspension to flow through the membrane was recorded and the deformability index 
(DI) was expressed as the volume (mL) of red blood cells filtered per minute.  As shown 
in Figure 8a, the deformability of RBC decreased with increasing concentrations of all 
MSN materials.  The RBC deformability was severely impaired by l-MSN at 
concentrations as low as 10 µg mL-1.  This result is not surprising given the strong 
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affinity and shape altering effects already described for l-MSN.  As expected, the 
incorporation of AP and PEG groups to the surface of s-MSN preserved the elasticity of  
 
 
Figure 8. (a) Deformability Index (DI) of RBCs incubated with s-MSN (blue), 
AP1.5-s-MSN (green), PEG1-s-MSN (black), CA1.5-s-MSN (purple) and l-MSN (red).  (b) 
Flow cytometry analyses of RBCs incubated with FITC-l-MSN (red), FITC-s-MSN (blue), 
AP1.5-FITC-s-MSN (green), PEG1-FITC-s-MSN (black), and CA1.5-FITC-s-MSN 
(purple). 
 
RBCs better than the non-functionalized s-MSN and the CA-s-MSN, especially at the 
higher concentrations (> 20 µg mL-1).  These results correlate well with the observed 
effects on the degree of RBC-MSN interactions (Figure 8b).  These observations suggest 
that the attachment of MSNs to the surface of RBCs restrict the flexibility of the 
membrane and lead to impairment in the deformability of RBCs.  Conversely, the 
attachment of functional groups to the surface of MSNs reduces the affinity of the 
particles to the membrane of RBC and allows the cells to preserve their deformability. 
 
3.  Conclusion 
 In this study, we investigated the interactions between MSNs of different particle 
sizes and surface properties and RBC membranes by using fluorescence and electron 
microscopies and cell biology techniques.  We compared the size- and 
surface-dependent hemocompatibility of two types of MSN materials (MCM-41 and 
SBA-15) and showed, for the first time, how MSNs are engulfed by RBCs.  This size- 
and surface-dependent process is the resultant of two opposing forces, namely: the 
attractive interaction between MSNs and RBCs, and the bending of the cell membrane.  
(b)(a) 
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These results suggest that only small MCM-41 type MSN materials (100-200 nm) may be 
considered as potentially safe candidates for intravascular drug delivery.  It must be 
noted that although RBCs are the dominant cells in blood, the interactions of these 
nanoparticles with other blood cells and components60,61 should be also evaluated to 
ensure the safe use of these materials for biomedical applications.  In addition, we 
demonstrated that the biocompatibility of these MSN materials with RBCs strongly 
depends on their surface derivatization to minimize their interaction with red blood cells.  
Blocking the surface silanols of the particles with organic groups reduces their 
interactions with the membranes of RBCs.  Minimizing these interactions has a dramatic 
effect on preserving the deformability of RBCs, which is necessary to ensure effective 
blood circulation.  These findings suggest that it is possible to gain control over the 
interactions of MSNs with RBC membranes in order to regulate their circulation half 
lives for various therapeutic purposes, while minimizing their toxicity by carefully 
choosing and tuning their surface functionalities.  As new MSN-based drug delivery 
systems burgeon from many international research groups, our results will provide a 
practical guide to size and surface considerations when designing MSN-based drug 
carriers for delivery, diagnostic, and therapeutic applications.   
 
4.  Methods 
 Synthesis of Mesoporous Silica Nanoparticles.  s-MSN was prepared by our 
previously reported method.33  In brief, N-cetyltrimethylammonium bromide (CTAB, 
1.00 g, 2.74 mmol) was dissolved in 480 mL nanopure water, followed by the addition of 
3.5 mL sodium hydroxide aqueous solution (2.0 M), and the mixture was heated to 80 °C.  
Tetraethoxysilane (TEOS, 5.0 mL, 22.4 mmol) was added dropwise to the surfactant 
solution under vigorous stirring.  The reaction mixture was stirred at 80 °C for another 2 
h.  The resulting white solid was filtered, washed thoroughly with water and methanol, 
and dried under high vacuum at 80 °C overnight.  The fluorescent labeled MSN 
(FITC-s-MSN) was synthesized by reacting fluorescein isothiocyanate (FITC, 15 mg, 
38.5 µmol) with (3-aminopropyl)trimethoxysilane (APTMS, 10 µL, 57.3 µmol) for 2 
hours in dimethyl sulfoxide (DMSO), and adding the resulting product following the 
addition of TEOS in the above synthesis.  The unlabeled FITC was removed by soxhlet 
extraction with methanol.  The amount of FITC labeled on FITC-s-MSN was quantified 
to be 20-30 µmol g-1 by TGA.  The functionalization of s-MSN and FITC-s-MSN with 
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aminopropyl (AP), polyethylene glycol (PEG) and carboxylate (CA) groups was 
performed by refluxing a suspension of the as-made material (200 mg of s-MSN or 
FITC-s-MSN) with APTMS, 2-[methoxy(polyethylenoxy)-propyl]trimethoxysilane 
(PEG-silane) and 3-(triethoxysilyl)propylsuccinic anhydride of various amount (x mmol) 
in anhydrous toluene (50 mL) for 20 h, followed by filtration and washing with toluene 
and methanol, and dried under high vacuum overnight.  The succinic anhydride groups 
were hydrolyzed by boiling the materials in water for 6 hours and measured by FTIR.  
The CTAB surfactant was removed by refluxing the materials in 0.37% HCl methanol, 
followed by filtration and washing with abundant methanol and dried under high vacuum.  
The amount of functional groups (AP, PEG and CA) grafted on MSNs was quantified by 
TGA shown in Figure S5 bottom and summarized in Table S1. 
 l-MSN was prepared by a modified literature procedure.5  Pluronic P104 (courtesy 
of BASF, 7.0 g) was dissolved in a mixture of water (164 g) and HCl (109 g, 4M) and 
stirred at 55 °C for 1 hour.  Tetramethyl orthosilicate (10.64 g) was quickly added into 
the solution at 55 °C.  After continuous stirring for 24 hours, the reaction mixture was 
moved to a teflon-lined, high-pressure autoclave for further hydrothermal treatment at 
150 °C for 24 h.  The product was isolated by filtration, washed with copious water and 
methanol, and dried at 80 °C in air.  The Pluronic P104 surfactant was removed by 
calcination at 550 °C for 6 hours.  The l-MSN was fluorescently labeled (FITC-l-MSN) 
by reacting FITC (15 mg, 38.5 µmol) with APTMS (10 µL, 57.3 µmol) for 2 hours in 
dimethyl sulfoxide (DMSO), and adding the resulting product to a suspension of l-MSN 
(1 g) in anhydrous toluene (100 mL) for 20 h, followed by filtration and washing with 
toluene and methanol.  The unlabeled FITC was removed by soxhlet extraction with 
methanol as the solvent.  The amount of FITC labeled on FITC-l-MSN was quantified to 
be around 30 µmol g-1. 
 The products were characterized by X-ray diffraction in a Rigaku Ultima IV 
diffractometer, nitrogen sorption analysis in a Micromeritics Tristar 3000 surface area and 
porosity analyzer using Brunauer-Emmett-Teller (BET) equation to calculate apparent 
surface area and pore volume and the Barret-Joyner-Halenda (BJH) method to calculate 
pore size distribution, thermogravimetric analysis (TGA) in a TGA 2950 
thermogravimetric analyzer with a temperature ramp of 5 °C/min in air, dynamic light 
scattering size analyses of particle suspensions in a Malvern Nano HT Zetasizer, scanning 
electron microscopy (SEM) of samples coated with gold in a FEI Quanta 250 FEG 
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microscope, and transmission electron microscopy (TEM) of samples supported on 
copper grids in a Tecnai G2 F20 microscope operated at 200 kV.  FTIR spectroscopy 
was performed using a Nicolet Nexus 470 (Madison, EI), equipped with a cooled CT/A 
detector and an Ever-Glo source. 
 Isolation and labeling of red blood cells (RBCs).  Ethylenediamine tetraacetic 
acid (EDTA)-stabilized human blood samples were freshly collected in the Occupational 
Medicine Office of Iowa State University and Ames Laboratory.  Whole blood was 
centrifuged at 1600 rpm for 5 min and the plasma, buffy coat, and top layer of cells were 
decanted.  The remaining packed RBCs were washed five times with sterile isotonic 
PBS.  For labeling with PKH26 (Red fluorescent cell linker kit, Sigma, USA), 100 µL of 
packed RBCs were resuspended in 1 ml diluent C™ and mixed with 1 ml diluent C™ 
containing 4 µM PKH26.  Cells were incubated for 5 min at room temperature in the 
dark.  The reaction was stopped by adding 1 mL plasma (heat inactivated for 1 hour at 
65°C beforehand) for 1 minute and centrifuged at 1600 rpm for 5 min.  The stained 
RBCs were washed five times with PBS to remove free pKH26 dye. 
 Hemolysis assay.  After cell washing, 200 µL of packed RBC was diluted to 4 mL 
with PBS (5% hematocrit).  The diluted RBC suspension (0.2 mL) was then mixed with 
s-MSN and l-MSN suspensions in PBS (0.8 mL) at various concentrations.  PBS and 
water (0.8 mL) were used instead of MSN suspensions as negative and positive control, 
respectively.  The mixture was gently vortexed and incubated at room temperature for 2 
h, followed by centrifuge (1600 rpm, 5 min) and the absorbance of the supernatant at 541 
nm was measured by UV-Visible spectrometry.  The percent hemolysis of RBCs was 
calculated using the following formula: percent hemolysis = ((sample absorbance - 
negative control absorbance)/(positive control absorbance - negative control absorbance)) 
× 100. 
 Scanning electron microscopy (SEM).  The diluted RBC suspension (5% 
hematocrit, 0.2 mL) was mixed with s-MSN and l-MSN suspensions in PBS (0.8 mL) at 
various concentrations, and incubated at room temperature for 2 h.  The samples were 
then fixed by adding a 1% glutaraldehyde solution dropwise over 5 min and further 
incubated at 37 °C for 1.5 h, followed by post-fixation with 1% osmium tetroxide in PBS 
for 1.5 h.  Cells were dehydrated in increasing concentrations of ethanol (50%, 60% 
70%, 80%, 90%, and 100%) for 15 min each.  The cell suspensions were dropped onto 
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glass coverslips, dried, and coated with Au before viewing under a FEI Quanta 250 FEG 
scanning electron microscope. 
 Transmission Electron Microscopy (TEM).  The samples were prepared, fixed 
and dehydrated as above, and stained with 2% uranyl acetate in 70% ethanol at room 
temperature overnight.  The cells were washed three times with acetone and embedded 
in Epon.  The embedded samples were sectioned in 60 nm thick slices on a sliding 
ultramicrotome.  Thin sections supported on copper grids were examined in a Tecnai G2 
F20 microscope operated at 200 kV. 
 Flow cytometry.  After cell washing, 200 µL of RBC suspension at 5×106 cells 
mL-1 were mixed with 200 µL of FITC-MSN suspensions in PBS at 20 µg mL-1, and 
incubated at room temperature for 2 h before flow cytometry analysis in a BD 
FACSCanto instrument.  
 Confocal Fluorescence Microscopy.  200 µL of PKH26 labeled RBC suspension 
at 5×106 cells mL-1 were mixed with 200 µL of FITC-MSN suspensions in PBS at 20 µg 
mL-1, and incubated at room temperature for 2 h.  An aliquot of sample was mounted 
between plastic coverslips and imaged in a Leica SP5 X confocal system. 
 Deformability assay.  1.5 mL of packed RBCs were washed and diluted to 30 mL 
with PBS (5% hematocrit).  The diluted RBC suspension (1 mL) was then mixed with 
MSN suspensions in PBS (4 mL) at various final concentrations of 10, 20 and 50 µg mL-1 
with PBS as control.  The mixture was gently vortexed and incubated at room 
temperature for 2 h before filtering through polycarbonate membrane with straight 
channels of 3 µm pore diameter (Nucleopore, Fisher, USA) under a constant negative 
pressure (-20 cm H2O).  The time for 0.5 mL RBC suspension to pass through the 
membrane was recorded and the deformability index (DI) was calculated as the volume of 
red blood cells filtered per minute.  Data were presented as mean values of triplicate 
experiments.  The present method and apparatus for RBC filterability measurement have 
been described in detail elsewhere.41 
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APPENDIX: Supporting Information 
 
Figure S1. Linear plot of the nitrogen sorption isotherms and pore size distributions of (a) 
s-MSN and (b) l-MSN.  Surface areas of s-MSN and l-MSN were calculated to be 
1051.6 ± 2.2 m2 g-1 and 387.0 ± 1.3 m2 g-1, respectively. 
 
 
Figure S2. Scanning electron micrographs (SEM) of RBCs (5% hematocrit) incubated 
with 100 µg mL-1 s-MSN (top) and l-MSN (bottom).  Images increase in magnification 
from left to right with features highlighted with white squares or arrows, indicating the 
location of particles attached on RBC membrane. 
 
(a) (b)
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Figure S3. Hemolysis assay for l-MSN using water as a positive control (blue lines) and 
PBS as a negative control (dashed black lines).  The materials were suspended at 20 
(green), 50 (yellow) and 100 (red) µg mL-1.  The mixtures were centrifuged to detect the 
presence of hemoglobin (red) in the supernatant visually (a) and by absorption at 541 nm 
(b). 
 
 
Figure S4. Scanning electron micrographs (SEM) of RBCs (5% hematocrit) incubated 
with 20 µg mL-1 (left), 50 µg mL-1(middle), and 100 µg mL-1 of l-MSN (right).  Percent 
of spiculated RBCs were observed to be < 10%, ~50% and ~90% from left to right.  
Images increase in magnification from top to bottom with features highlighted with white 
squares or arrows, indicating the location of particles attached on RBC membrane. 
(a) (b)
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Figure S5. X-ray diffraction patterns (top) and thermogravimetric analysis (bottom) of 
FITC-s-MSN, APx-FITC-s-MSN (left), PEGx-FITC-s-MSN (middle) and  
CAx-FITC-s-MSN (right) (x: amount of organic groups introduced in mmol g-1).  
 
 
Figure S6. (a) X-ray diffraction (XRD) patterns, (b) linear plot of the nitrogen sorption 
isotherms and (c) thermogravimetric analysis (TGA) of s-MSN (blue), AP1.5-s-MSN (red), 
PEG1-s-MSN (black)  and CA1.5-s-MSN (green).  
 
 
 
 
 
 
 
FITC-s-MSN 
AP0.2-FITC-s-MSN 
AP0.5-FITC-sMSN 
AP1-FITC-s-MSN 
AP1.5-FITC-s-MSN 
FITC-s-MSN
PEG 0.2-FITC-s-MSN 
PEG 0.4-FITC-s-MSN 
PEG 0.8-FITC-s-MSN 
PEG 1-FITC-s-MSN 
 
FITC-s-MSN
CA 0.2-FITC-sMSN
CA 0.5-FITC-sMSN
CA 1-FITC-sMSN 
CA 1.5-FITC-sMSN
(a) (b) (c) 
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Table S1. Characteristics of FITC-s-MSN, APx-FITC-s-MSN, PEGx-FITC-s-MSN and 
CAx-FITC-s-MSN (x: amount of organic groups introduced in mmol g-1). 
 
Materials Surface groups(mmol g-1) 
Zeta potential 
(mV) 
Surface area 
(m2 g-1) 
Pore size
(nm) 
FITC-s-MSN 0.02 -27.9 1043.4 ± 4.2 3.0 
AP0.2-FITC--sMSN 0.1-0.2 -22.9 948.3 ± 7.9 2.8 
AP0.5-FITC-s-MSN 0.4-0.6 -10.9 878.7 ± 11.7 2.8 
AP1-FITC-s-MSN 0.6-0.8 +3.2 796.8 ± 1.6 2.8 
AP1.5-FITC-s-MSN 1.2-1.6 +6.87 689.0 ± 29.0 2.7 
     
FITC-s-MSN 0.03 -29.3 1036.4 ± 11.2 2.6 
PEG0.2-FITC-s-MSN 0.03-0.04 -26.1 985.6 ± 9.0 2.6 
PEG0.4-FITC-s-MSN 0.1-0.2 -22.3 839.6 ± 9.3 2.4 
PEG0.8-FITC-s-MSN 0.2-0.3 -20.7 770.8 ± 1.6 2.4 
PEG1-FITC-s-MSN 0.4-0.5 -13.1 628.9 ± 2.6 2.4 
     
FITC-s-MSN 0.03 -28.6 1107.8 ± 8.6 2.7 
CA0.2-FITC-s-MSN 0.07-0.1 -34.3 967.4 ± 2.9 2.5 
CA0.5-FITC-s-MSN 0.3-0.4 -36.1 913.6 ± 19.2 2.4 
CA1-FITC-s-MSN 0.5-0.7 -39.2 863.0 ± 9.2 2.4 
CA1.5-FITC-s-MSN 0.7-1 -42.7 779.2 ± 5.0 2.5 
 
Table S2. Characteristics of s-MSN, AP1.5-s-MSN, PEG1-s-MSN,  CA1.5-s-MSN and 
l-MSN. 
 
Materials Surface 
groups 
(mmol g-1) 
Zeta 
potential 
(mV) 
Surface area
(m2 g-1) 
Pore 
size 
(nm) 
Hydrodynamic 
particle size 
(nm) 
s-MSN  -22.2 1051.6 ± 2.2 3.1 122 
AP1.5-s-MSN 1.1-1.5 +5.79 780.3 ± 9.0 2.4 142 
PEG1-s-MSN 0.3-0.4 -11.6 650.5 ± 2.9 2.7 122 
CA1.5-s-MSN 0.6-0.9 -43.1 792.9 ± 4.4 2.9 142 
l-MSN  -16.5 387.0 ± 1.3 9.0 531 
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Figure S7. Confocal fluorescence micrographs of (A) RBCs (5×106 cells mL-1) incubated 
with 20 µg mL-1 of (B) FITC-l-MSN, (C) FITC-s-MSN, (D) AP1.5-FITC-s-MSN, (E) 
PEG1-FITC-s-MSN and (F) CA1.5-FITC-s-MSN.  The channels from left to right 
correspond to red blood cells stained with PKH26 red fluorescence dye, FITC-MSNs and 
the merged images.   
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Figure S8. Dot plot from the flow cytometry analysis of (a) PKH26 labled RBC 
incubated with (b) FITC-l-MSN, (c) FITC-s-MSN, (d) AP1.5-FITC-s-MSN, (e) 
PEG1-FITC-sMSN and (f) CA1.5-FITC-s-MSN.  The axes correspond to the intensity of 
red fluorescence due to PKH26 labeling (horizontal axis) and green fluorescence due to 
the attachment of FITC-MSNs onto PKH26-RBCs (vertical axis).  The plot was gated to 
show PKH26 labeled RBCs in area Q4 and FITC-fluorescent PKH26-RBCs in area Q2.  
(a) (b) (c) 
(d) (e) (f) 
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CHAPTER 4. MESOPOROUS SILICA NANOPARTICLE 
TETHERED SINGLE SITE PLATINUM CATALYSTS FOR 
THE FUNCTIONALIZATION OF ETHYLENE 
A manuscript submitted for publication in Journal of American Chemical Society 
Jeremy R. Andreatta, Hung-Ting Chen, Xiaoxing Sun, Chih-Hsiang Tsai, Brian G. 
Trewyn, Victor S.-Y. Lin, T. Brent Gunnoe 
 
ABSTRACT 
 Mesoporous silica nanoparticles have been used for tethering a platinum catalyst to 
achieve enhanced thermal stability and longevity. We synthesized and characterized the 
mesoporous silica nanoparticle supported Pt(II) complexes. We then investigated the 
heterogeneous system by comparing it with the homogeneous catalyst on the catalytic 
performance for the hydrophenylation of ethylene and the durability to high temperature. 
 
ARTICLE 
 Alkyl arenes, especially ethyl benzene, are produced on the millions of tons scale per 
annum and serve as important precursors and commodity chemicals for a variety of 
industrial sectors ranging from pharmaceutical to polymers to surfactants. Alkylbenzene 
derivatives account for about 75% of the world wide benzene use, with ethylbenezne (EB) 
being the fate for 54% of the world´s available benzene supply.1 Traditionally, 
Friedel-Crafts (FC) catalysis is utilized for the production of simple alkyl arenes.2 FC 
catalysts suffer from several drawbacks including polyalkylation, lack of regioselectivity 
for dialkylated arenes, inability for selective formation of linear alkyl arenes, use of toxic 
starting materials (e.g. HF as a co-catalyst), and lack of catalyst recyclability. Recent 
developments of zeolite materials have been able to address some of the above problems; 
however, some of the limitations of both FC and zeolite catalytsts are inherent to the 
mechanism. 
 Transition metal mediated insertion of olefins into arene C-H bonds has been 
reported using Ir, Ru, and Pt complexes (Scheme 1).3 The hydroarylation of ethylene 
using [tbpyPtPh(THF)][BArF4] (1) [tbpy = 4,4´-di-tert-butyl-2,2´-bipyridyl,Ph = phenyl, 
BArF4 = tetrakis(3,5-bis(trifluoromethyl)phenyl)borate] as a homogeneous catalyst has 
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been studied in detail and proven to be an effective catalyst for the selective formation of 
ethylbenzene (EtPh).4 One drawback of the homogeneous system is the lack of thermal 
stability and/or catalyst longevity. Herein, we report the synthesis, characterization, and 
catalytic activity of mesoporous silica nanoparticle (MSN) supported bpyPt complexes 
for the hydrophenylation of ethylene. 
 
 
Scheme 1. Transition metal catalyzed hydroarylation of olefins. 
 
 The area of MSN materials, especially as catalyst scaffolds, has recently received 
much attention.5 Examples include supported catalysts for olefin hydrogenation,6-10 Heck 
and Sonogashira reactions,11-14 ring opening of epoxides,15 hydroamination of olefins,16 
and hydrocarboxylation of aryl olefins and alcohols17 among others. In many cases, MSN 
supported catalysts exhibit not only increased stability, but also result in an increase in the 
selectivity versus its homogeneous analog. For example, Tilley and coworkers observed 
marked increases in the production of (Z)-1-phenyl-propene during the partial 
hydrogenation of the parent alkyne.10 Using the general strategies developed for the 
attachment of various single site transition metal catalysts, we report the development of a 
MSN tethered Pt(II) bipyridine catalysts for the hydrophenylation of olefins. 
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Scheme 2. Synthesis of SibpyPt(Ph)2 and attachment via post-synthesis grafting to MSN. 
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 Initial studies focused on the modification of the 2,2´-bipyridine (bpy) ligand 
architecture at the 4 and 4´ positions while maintaining a similar electronic environment 
about the platinum center. The synthesis of a bpy bearing alkyl siloxane moieties was 
achieved via the lithiation of 4,4´-dimethyl bipyridine followed by the addition of 
chloromethyltriisopropoxysilane (Scheme 2) to yield 4,4´-bis(2-triisopropoxysilyl)ethyl)-
2,2´-bipyridine (Sibpy). 
 Analogous to the synthesis of the 1, the addition of [Pt(Ph)2(SEt2)]2 to the ligand in 
an ether solution afforded the desired SibpyPt(Ph)2 (2) product in about 40 % yield. 
Attachment to the MSN was achieved via post-synthesis grafting in refluxing toluene. 
29Si and 13C solid state NMR (ssNMR), along with TEM, ICP-OES, and N2 sorption were 
used to characterize MSN-2. The TEM image and the low-angle X-ray diffraction pattern 
clearly show that the 2-d hexagonal mesopore structure of MSN-2 remained intact after 
synthesis and metal ligand attachment. Nitrogen sorption analysis of MSN-2 measured a 
BET surface area of 610 m2 g-1, along with a BJH mean pore diameter of 5.8 nm, 
indicating no sign of pore blockage. The catalyst loading of MSN-2 was assessed by 
ICP-OES, which was determined to be 0.038 mmol g-1. The 13C ssNMR spectrum of 
MSN-2 indicates that the Pt-Ph bonds are still present in the product material and a 
comparison of the solution and ssNMR demonstrate good agreement (Figure 1). 
 Initial catalytic studies utilizing MSN-2 under similar reaction conditions for 1 (100 
°C) resulted in approximately 100 turnovers (TOs) of ethylbenzene in 24 hours compared 
to 70 TOs after 16 hours using 1. Additionally, the ratio of dialkylated products to the 
more desired monosubstituted benzene product was almost identical between the two 
systems (~20-25%). As with the homogeneous Pt(II) catalyst, styrene production is 
observed; however, ~5 turnovers of styrene are observed versus the 1-2 that is 
occasionally observed with 1. 
 The heterogeneous catalyst material, MSN-2 was examined over a range of 
temperatures (100 - 200 °C), ethylene pressures (15 – 500 psi), and the number of 
equivalents (relative to Pt concentration) of HBArF4 (1 -10 equiv.). Optimal conditions for 
catalysis were obtained at 150 °C, 25 psi ethylene, and 5 equivalents of HBArF4. Under 
optimal reaction conditions, approximately 140 TOs of ethylbenzene 12 TOs of styrene 
are observed using the MSN tethered Pt catalyst. 
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Figure 1. Comparison of 13C NMR spectra of 2 (maroon) and MSN-2(blue). 
 
 Additionally, control reactions using MSN, HBArF4, Pt(0) on silica, and a 
combination of MSN and HBArF4, and Pt(0) and HBArF4 were examined for any activity 
towards the hydrophenylation of ethylene. In each case, catalysis was not observed. 
 
 
Figure 2. Plot of the production of ethylbenzene versus time using MSN-2. 
 
 Catalyst stability was also examined. The homogeneous (tbpy)Pt(II) catalyst showed 
appreciable degradation after 16 h at 100 °C. Under optimal reaction conditions, the MSN 
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tethered catalyst demonstrated activity for 72 hours (Figure 2). Interestingly, up to 40 
TOs of styrene are observed after 72 hours of reactivity. 
 In conclusion, we have tethered a (tbpy)Pt(II) catalyst onto the surface of mesoporous 
silica nanoparticles via a post-synthesis method. The heterogeneous MSN supported Pt(II) 
catalyst exhibited a dramatically increased thermal stability with no obvious change in 
catalytic activity. 
74 
 
REFERENCES 
(1)  Perego, C.; Ingallina, P. Green Chem. 2004, 6, 274. 
(2)  Olah, G. A.; Molnár, Á. Hydrocarbon chemistry; 2nd ed.; Wiley-Interscience: New 
York, 2003. 
(3)  Andreatta, J. R.; McKeown, B. A.; Gunnoe, T. B. J. Organomet. Chem. 2011, 696, 
305. 
(4)  McKeown, B. A.; Foley, N. A.; Lee, J. P.; Gunnoe, T. B. Organometallics 2008, 27, 
4031. 
(5)  Slowing, I. I.; Vivero-Escoto, J. L.; Trewyn, B. G.; Lin, V. S. Y. J Mater Chem 
2010, 20, 7924. 
(6)  Dufaud, V.; Beauchesne, F.; Bonneviot, L. Angew Chem Int Edit 2005, 44, 3475. 
(7)  Lin, W. B.; Mihalcik, D. J. Angew Chem Int Edit 2008, 47, 6229. 
(8)  Lin, W. B.; Mihalcik, D. J. Chemcatchem 2009, 1, 406. 
(9)  Huang, Y.; Xu, S.; Lin, V. S. Y. Chemcatchem 2011, 3, 131. 
(10)  Choi, Y. S.; Moschetta, E. G.; Miller, J. T.; Fasulo, M.; McMurdo, M. J.; Rioux, R. 
M.; Tilley, T. D. Acs Catal 2011, 1, 1166. 
(11)  Tsai, F.-Y.; Wu, C.-L.; Mou, C.-Y.; Chao, M.-C.; Lin, H.-P.; Liu, S.-T. 
Tetrahedron Letters 2004, 45, 7503. 
(12)  Tsai, F. Y.; Lin, B. N.; Huang, S. H.; Wu, W. Y.; Mou, C. Y. Molecules 2010, 15, 
9157. 
(13)  Sharma, K. K.; Biradar, A. V.; Das, S.; Asefa, T. Eur J Inorg Chem 2011, 2011, 
3174. 
(14)  Bahramian, B.; Bakherad, M.; Keivanloo, A.; Bakherad, Z.; Karrabi, B. Appl 
Organomet Chem 2011, 25, 420. 
(15)  Das, S.; Asefa, T. Acs Catal 2011, 1, 502. 
(16)  Duncan, C.; Biradar, A. V.; Asefa, T. Acs Catal 2011, 1, 736. 
(17)  Mukhopadhyay, K.; Sarkar, B. R.; Chaudhari, R. V. Journal of the American 
Chemical Society 2002, 124, 9692.
75 
 
APPENDIX: Supporting Information 
 
Experimental Procedure 
1.1 Materials. Tetramethyl orthosilicate (TMOS) (98 %) was purchased from Aldrich. 
Non ionic surfactant pluronic 104 (P 104) was purchased from BASF Corporation with a 
composition of (EO)27(PO)61(EO)27. Nanopure water (17.9 MHz) used for MSN synthesis 
was prepared from a Barnstead E-pure water purification system. 
1.2 Synthesis of MSN-10.1 P 104 (7.0 g, 1.186 mmol) was added to 1.6 M HCl (273.0 g). 
After stirring at a speed of 400 rpm in a lightly covered 500 ml Erlenmeyer flask at 55 °C 
for 1 h, tetramethylorthosilicate (TMOS) (10.64 g, 69.9 mmol) was added and stirred for 
additional 24 h. The resulting mixture was subjected to hydrothermal treatment at 150 °C 
for 24 h in a 450 ml parr reactor. After cooling, the white solid was collected by filtration, 
washed with nanopure water and methanol and dried in air. Removal of surfactant (P 104) 
was done by calcination at 550 °C for 6 h in a programmable oven at a ramp rate of 1.5 
°C min -1. 
1.3 Synthesis of G-alkyl-2BpyPt-TMOS-MSN.2 MSN-10 was dried under vacuum at 90 
°C for 4 h prior to grafting. For grafting 100 mg of MSN-10 was suspended in 20 ml of 
dry toluene and 160 mg (0.2 mmol) of 4,4'-bis((2-triisopropoxysilyl)ethyl) 2,2'-bipyridine 
Pt diphenyl was added to it. The mixture was refluxed at 100 °C for 24 h under argon 
atmosphere. The resulting mixture was filtered, washed with toluene and methanol, and 
dried under vacuum overnight. 
1.4 Structural Characterization. X Ray Diffraction. Powder X-ray diffraction (XRD) 
measurements were performed using Rigaku Ultima IV diffractometer using a Cu Kα 
radiation source. Transmission Electron Microscopy. The TEM samples were prepared by 
placing a small aliquot of an aqueous suspension on a lacey carbon film coated 400 mesh 
copper grid and drying it in air. The TEM images were obtained on a Tecnai F2 
microscope operated at 200 kV. Scanning Electron Microscopy. Particle morphology was 
determined by SEM using a Hitachi S 4700 FE-SEM system with 10 kV accelerating 
voltage. Surface Characterization. The surface area and average pore diameter were 
measured using N2 adsorption/desorption measurements in a Micromeritics ASAP 2020 
BET surface analyzer system. The data were evaluated using Brunauer−Emmett−Teller 
(BET) and Barrett−Joyner−Halenda (BJH) methods respectively to calculate surface area 
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and pore distributions. Samples were prepared by degassing at 100 °C for 6 h before 
analysis. 
1.5 Functional group and metal loading characterization. Solid State NMR (SS NMR). 
Surface ligand loadings were determined by 29Si DPMAS. Pt loading was determined by 
running ICP-OES measurements over Optima 8300 PerkinElmer ICP-OES spectrometer. 
 
 
Figure 1. Powder X-ray diffraction pattern of MSN-2. 
 
Table 1. 
Sample 
SBET 
(m2/g) 
VP 
(cm3/g)
WBJH
(Å) 
Loading of Bpy-Pt 
complex by 29Si NMR 
(mmol/g) 
Loading of Pt 
by ICP-OES 
(mmol/g) 
G-alkyl-2BpyPt-
TMOS-MSN 
407 0.85 49 0.04 0.038 
The BET surface area (SBET), the mesopore volume (Vp), and the mean mesopore width 
(WBJH) were obtained from the nitrogen adsorption/desorption data. The amounts of 
organic functional groups incorporated to the silica materials were estimated from the 29Si 
DPMAS and ICP-OES. 
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Figure 2. N2 adsorption/desorption isotherms and pore size distribution of MSN-2. 
 
 
Figure 3. (a) SEM and (b) TEM image of MSN-2. 
(a)  (b)
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Figure 4. 13C solid state NMR of G-alkyl-2BpyPt-TMOS-MSN, on the right, assignments 
of the peaks are shown. 
 
FOOTNOTES: 
1.  Valenstein, J. S.; Kandel, K.; Melcher, F.; Slowing, I. I..; Lin, V. S. –Y.; Trewyn, B.G. ACS 
 Appl. Mater. Interfaces 2012, 4, 1003−1009  
2.  In G-alkyl-2BpyPt-TMOS-MSN, G stands for grafting, alkyl is the chain attached to the 
 bipyridyl moiety, 2 denotes that the ligand is bitethered, on the surface of mesoporous silica, 
 Bpy stands for the bipyridyl moiety, Pt is the metal co-ordinated, TMOS 
 (tetramethylorthosilicate) is the silica source used for MSN synthesis.
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CHAPTER 5. ONE-POT OXIDATIVE ESTERIFICATION 
OF ALLYL ALCOHOL CO-CATALYZED BY ALCOHOL 
DEHYDROGENASE ENZYME AND MESOPOROUS 
SILICA NANOPARTICLE SUPPORTED GOLD 
NANOPARTICLES 
Xiaoxing Sun, Justin S. Valenstein, and Brian G. Trewyn 
 
ABSTRACT 
 Supported Au-nanoparticle catalysts used for the oxidative alcohol esterification 
reaction often suffer from certain deficiencies such as slow alcohol oxidation rate and 
poor reactivity in aqueous environments. We designed a co-catalyst system that combines 
the advantages of a biocatalyst, alcohol dehydrogenase, and an inorganic catalyst to 
accelerate oxidation reactions tandemly. We developed a mesoporous silica nanoparticle 
supported Au nanoparticles (Au-MSN) catalyst. We identified several factors that affect 
the catalytic performance of the co-catalyst system. We examined the catalytic 
performance of this co-catalyst system on the one-pot esterification of allyl alcohol. We 
envision that this system could lead to the development of a variety of enzyme-metal 
catalyst pairs for a number of reactions. 
 
1. Introduction 
Carboxylic esters are some of the most industrially important products for the 
synthesis and development of fine chemicals, pharmaceuticals and polymers.1 The 
traditional synthesis methods for carboxylic esters not only require multiple reaction steps 
and harsh reaction conditions, but also produce a large amount of waste.2-4 Therefore, the 
development of environmentally benign methods has become a demanding and 
challenging subject in organic synthesis to address the increasing economical and 
ecological concerns regarding the conventional methods. Among many synthetic routes 
that have been investigated, supported Au-nanoparticle (Au NP) catalyzed oxidative 
esterification may be the most preferred and promising one, as reported by several 
research groups.5-10 Because the whole process involves only molecular oxygen as a 
green oxidant instead of the stoichiometric environmentally harmful oxidants, and avoids 
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employing strong acids and excessive reactants in the reaction. Moreover, in comparison 
with many other metal catalysts, Au catalyst exhibits excellent activity and selectivity for 
the alcohol oxidative esterification without extra ligands,11 which might be attributed to a 
number of factors including metal–support interactions and the Au nanoparticles size 
effect.9,12 For example, Christensen and coworkers reported the aerobic oxidative 
esterification of alcohols over Au/TiO2 catalyst.10 Miyamura et al. synthesized methyl 
esters through the aerobic oxidation of alcohols over polymer-incarcerated gold 
nanoparticles.6 Costa et al. performed a one-pot oxidative esterification of benzyl alcohol 
to methyl benzoate over the Au/MgO catalyst and reached a virtually quantitative yield.8 
It is noteworthy that Yang and coworkers recently demonstrated that the activity of 
supported Au nanoparticle catalyst is strongly dependent on the Au nanoparticle size. 
Mesoporous silica materials are more advantageous than other supports due to their 
ability to manipulate the growth of Au nanoparticles by controlling the amount of Au 
loaded into the mesopore architecture.7 Moreover, the large surface area of mesoporous 
silica material provides better diffusion of substrates and accessibility to the catalyst 
sites.13 
 However, most of the Au nanoparticle catalyzed carboxylic ester synthetic 
procedures were performed in methanol solutions to yield only methyl esters. Direct 
oxidative esterification of alcohols carried out in aqueous solution is rarely reported 
although aqueous reactions are remarkably safe, and economically and environmentally 
beneficial.14 In addition, it has been established that the reaction mechanism is divided 
into three steps,15 the dehydrogenation of the alcohol that produces the corresponding 
aldehyde, the aldehyde transformation to its hemi-acetal form and the further oxidation of 
the hemi-acetal to the carboxylic ester. The rate determining step (RDS) has been 
demonstrated to be the α-hydrogen abstraction from alcohol and it limits the overall 
catalytic performance of supported Au nanoparticle catalyst. Therefore, this major 
challenge of overcoming the slow RDS requires the Au nanoparticle catalysts for alcohol 
oxidative esterification reactions to work under either high temperature or high pressure 
to accelerate the slow alcohol oxidation kinetics, which can be extremely hazardous due 
to the risk of vigorous explosions.16 Additionally, high pressure and high temperature 
reactions are energy and capital intensive processes and identifying new processes that 
avoid these is critical to maintain sustainability. 
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 Herein, we present the development of a co-catalyst system comprising alcohol 
dehydrogenase (ADH) enzyme and mesoporous silica nanoparticles supported Au 
nanoparticles (Au-MSN). We demonstrated that ADH enzyme was capable of converting 
allyl alcohol to its corresponding aldehyde, so as to accelerate the slow RDS at room 
temperature. We also proved that the Au-MSN catalyzed the conversion of the aldehyde 
to the carboxylic ester in aqueous solution without additional acid or base. We further 
investigated the catalytic performance of our co-catalyst system for the one-pot synthesis 
of allyl acrylate ester through aqueous oxidative esterification reaction. As shown in 
Figure 1, ADH enzyme efficiently aids the oxidation of allyl alcohol to acrolein,17 and 
Au-MSN subsequently oxidizes acrolein in fast kinetics, generating allyl acrylate, an 
important chemical in the polymer industry. We compared a number of experimental 
conditions and determined several factors that affect this tandem reaction kinetics. 
 
Figure 1. Schematic representation of the ADH enzyme and Au-MSN co-catalyst system 
 
2. Materials and Methods 
2.1 Reagents and materials 
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Pluronic 104 (P104) was a gift courtesy of BASF. Other reagents were purchased 
from Sigma-Aldrich, Inc. All chemicals were used as received without further 
purification.  
 
2.2 Synthesis of MSN 
The MSN was prepared via our previously reported method.18 Typically, 7.0 g P104 
surfactant was dissolved in 273.0 g HCl solution (1.6 M) and stirred at 55 °C for 1 hr, 
followed by a rapid addition of 10.64 g tetramethylorthosilicate. After continuous stirring 
at 55 °C for 24 hr, the mixture was transferred into a Teflon-lined, high-pressure 
autoclave for hydrothermal treatment at 150 °C for 24 hr. The solid product was filtered 
and washed with copious amounts of water and methanol, and dried under vacuum for 24 
hr. Surfactant was removed by calcination at 550 °C for 6 hr.  
 
2.3 Synthesis of Au(en)2Cl3 
 Au(en)2Cl3 was synthesized based on a literature procedure.19 Ethylenediamine (6.7 
mmol) was added to a 10 ml aqueous solution of HAuCl4·3H2O (2.54 mmol). The 
solution was stirred at room temperature for 30 min. Anhydrous ethanol (70 mL) was 
added into the solution to form a light-yellow precipitate. The solid product was filtered 
and washed with ethanol and dried under vacuum for 24 hr.  
 
2.4 Synthesis of Au-MSN 
 Au-MSN was prepared by our previously reported method.20 In brief, 0.372 g (0.085 
mmol) Au(en)2Cl3 was dissolved in 150 ml deionized water. The pH value of this solution 
was adjusted to 10.0 using NaOH. Subsequently, 2.0 g of surfactant removed MSN was 
added. The pH value of the mixture immediately dropped to around 6 and was tuned to 
reach a pH of 9.0 with NaOH. The mixture was stirred at room temperature for 2 hr. The 
solid product was isolated by filtration, washed with water, and dried under vacuum. This 
process was performed for three cycles to reach a desirable loading of Au(en)2Cl3. Finally, 
Au-MSN was generated by the reduction of Au(en)2Cl3 loaded MSN, which was carried 
out under H2 flow at 200 °C for 5 hr.  
 
2.5 Enzymatic assay of alcohol dehydrogenase 
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 The enzymatic reactivity of alcohol dehydrogenase enzyme catalyzed conversion of 
allyl alcohol to acrolein was determined based on the method of Vallee and Hoch.21 
Typically, an alcohol dehydrogenase enzyme stock solution was prepared by dissolving 
the enzyme in a phosphate buffer (10 mM, pH 7.5) to reach an enzyme concentration of 1 
mg ml-1. The enzyme stock solution was further diluted to the enzyme working solution, 
with an enzyme concentration of 0.2 mg ml-1 in sodium phosphate buffer (10 mM with 
0.1% w/v Bovine Serum Albumin). A 15 mM solution of β-Nicotinamide adenine 
dinucleotide (NAD+) was prepared by dissolving NAD+ (0.5 g) in deionized water (50 
ml). In a 96-well plate, 50 μl allyl alcohol, 70 μl NAD+ solution and 10 μl enzyme 
working solution was pipetted and sodium pyrophosphate buffer solution (50 mM, pH 8.8) 
was added until a total volume of 250 μl was reached. The mixture was immediately 
measured for UV-vis absorbance at 340 nm on a microplate reader (Biotek Synergy MX). 
 To investigate the effect of Au-MSN on enzyme denaturation, 30 μl Au-MSN 
suspension (2.5 mg ml-1 in 10 mM sodium pyrophosphate buffer) was mixed with enzyme 
working solution at different weight ratios (18:1, 12:1 and 9:1). The mixture was then 
stirred for 30 min and centrifuged at 800 rpm for 4 min. 10 μl of supernatant was used in 
an enzyme assay test instead of the enzyme working solution.  
 
2.6 Aerobic oxidative esterification of allyl alcohol and acrolein by Au-MSN 
 A mixture of allyl alcohol (171 mg, 3 mmol), acrolein (168 mg, 3 mmol) and 
Au-MSN catalyst (0.015 mmol, 0.5 mol% Au) in 0.6 ml sodium pyrophosphate buffer 
solution (50 mM, pH 8.8) was prepared in a reaction vial. Anisole (20.0 mg, 0.184 mmol) 
was added as an internal standard. The vial was then purged and balloon filled with pure 
oxygen. The reaction mixture was stirred at room temperature for various reaction time 
periods (1 hr, 3 hr, 6 hr, 12 hr and 24 hr), followed by toluene extractions (0.2 ml × 3). 
The extractions were analyzed using GC-MS.  
 
2.7 Aerobic oxidative esterification of allyl alcohol by ADH and Au-MSN 
 A mixture of allyl alcohol (854 mg, 15 mmol), NAD+ (100 mg, 0.15 mmol), alcohol 
dehydrogenase enzyme (3 mg), bovine serum albumin (0.5 mg) and Au-MSN catalyst 
(0.015 mmol, 0.5 mol% Au) in 4 ml sodium pyrophosphate buffer solution (50 mM, pH 
8.8) was prepared in a reaction vial. Anisole (20.0 mg, 0.184 mmol) was added as an 
internal standard. The vial was then purged and balloon filled with pure oxygen. The 
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reaction mixture was stirred at room temperature for 24 hr, followed by toluene 
extractions (0.5 ml × 3). The extraction solution was analyzed using GC-MS. 
 
2.8 Characterization methods 
 The X-ray powder diffraction (XRD) patterns were measured by Rigaku Ultima IV 
X-Ray Diffractometer using a Cu Kα radiation source. The low angle diffraction was 
measured with a 2θ angle ranging from 0.8 to 10 degrees to evaluate the long-range order 
of the materials. The high angle diffraction pattern was obtained with a 2θ angle ranging 
from 10 to 90 degrees to investigate the degree of crystallinity of Au inside the mesopores 
of MSN. The surface analysis was performed by nitrogen sorption isotherms on a 
Micromeritics Tristar 3000 analyzer. The surface area was calculated by the 
Brunauer-Emmett-Teller (BET) method. The pore size distribution was calculated by the 
Barrett-Joyner-Halenda (BJH) method using the desorption branch of isotherm. 
Transmission electron microscopy (TEM) was completed on a Tecnai G2 F20 electron 
microscope operated at 200 kV. The metal content loading of the Au-MSN was quantified 
by a Hewlett-Packard 4500 ICP-MS. The ester yield was quantified with an Agilent 6890 
gas chromatograph coupled to an accurate mass time-of-flight (TOF) mass spectrometer. 
 
 
Figure 2. (a) SEM image and (b) TEM image of Au-MSN 
 
3. Results and Discussion 
3.1. MSN characterization 
 Full characterizations of Au-MSN were performed by various techniques. The 
synthesized material exhibited typical type IV isotherm behavior with an approximate 
(a)  (b) 
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BET surface area of 294 m2 g-1 and a pore volume of 0.87 cm3 g-1 (Figure 3, Table 1). 
Although both values decreased after Au loading, both are still sufficient for mass 
transport and catalysis. BJH pore size distributions showed that a negligible decrease in 
pore diameters was observed for the materials after Au impregnation. These results 
suggest that the Au nanoparticles formed by in situ reduction are accessible and do not 
block the mesopore channels. The powder X-ray diffraction patterns are shown in Figure 
4. The low angle pattern indicated that the 2D hexagonal mesopore structure of MSN 
remained intact after Au loading. The high angle pattern demonstrated the presence of 
crystalline Au on the MSN, as indicated by the good match with the standard pattern of 
crystalline Au.22 In compliance with the X-ray diffraction pattern, TEM image of 
Au-MSN also indicates a successful loading of Au nanoparticles, represented by the dark 
spots scattered all over the mesoporous silica nanoparticles in Figure 2b, suggesting a 
homogeneous distribution with no apparent aggregation. EDX results also confirmed the 
elemental existence of Au. The actual loading of Au content (12.4 wt%) was determined 
by ICP-MS analysis. Scanning electron microscopy (SEM) showed that Au-MSN 
nanoparticles have consistent morphology and particle sizes at around 600 nm (Figure 
2a).  
 
Table 1. Summary of physical properties of MSN and Au-MSN 
Material 
SBET 
(m2 g-1) 
Pore Volume 
(cm3 g-1) 
Pore Size (nm) 
Au Loading 
wt% 
MSN 385 1.04 11.0 0 
Au-MSN 294 0.83 10.7 12.4 
a. Specific surface area (SBET), pore volume and pore diameter were obtained from N2 
sorption analysis. SBET was calculated by BET method and the pore diameter was 
calculated by BJH method. b. The weight percentage (wt%) of Au content on Au-MSN 
was determined by ICP-MS analysis. 
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Figure 3. (a) N2 adsorption/desorption isotherms and (b) pore diameter distribution of 
Au-MSN 
(a) 
(b) 
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Figure 4. (a) Low-angle and (b) high-angle powder X-ray diffraction patterns of 
Au-MSN. The red lines indicate the standard pattern of crystalline gold. 
 
3.2. ADH enzyme catalyzed alcohol oxidation 
 The enzymatic activity and catalytic efficiency of ADH on the allyl alcohol oxidation 
reaction was examined by means of ADH enzyme assay tests, as described in the 
experimental section. The enzyme assay test is based on the different UV-vis absorption 
behaviors of NAD+ and its reduced form, NADH, where NADH has a strong absorption 
of UV-vis light at the wavelength of 340 nm while light absorbance at the same 
wavelength is very weak for NAD+. In an ADH enzyme catalyzed alcohol oxidation 
(b) 
(a) 
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reaction, the production of NADH is proportional to the consumption of NAD+ and the 
generation of aldehyde.23, 24 Therefore, we can monitor the reaction kinetics by measuring 
the UV-vis light absorbance values. 
 We investigated the effect of allyl alcohol concentration, NAD+ loading amount and 
ADH enzyme concentration on the enzyme activity separately. To evaluate the allyl 
alcohol concentration effect, the enzyme assay tests were performed in a 96-well plate, 
NAD+ solution (15 mM, 70 μl), enzyme working solution (0.2 mg ml-1, 5 μl) and various 
amount of allyl alcohol (37.5 μl, 50 μl and 62.5 μl) was pipetted and sodium 
pyrophosphate buffer solution (50 mM) was added until a total volume of 250 μl was 
reached. As shown in Figure 5a, ADH enzyme activity was depressed upon increased 
allyl alcohol concentrations, which is in accordance with the report of Bradbury and 
Christensen that allyl alcohol inhibits ADH enzyme activity,25 although allyl alcohol itself 
is an ADH enzyme substrate with high specificity.17 We also determined that this 
inhibition effect can be alleviated by decreasing the allyl alcohol concentration below 
25% (v/v).  
 Similar assay tests were carried out to examine the effect of NAD+ amount on the 
enzymatic reaction kinetics. In a 96-well plate, allyl alcohol (25 μl), enzyme working 
solution (0.2 mg ml-1, 5 μl) and various amounts of NAD+ solution (15 mM, 10 μl, 20 μl 
and 50 μl) was pipetted and sodium pyrophosphate buffer solution (50 mM) was added 
until a total volume of 250 μl was reached. It is interesting to note that the production of 
NADH can be tuned by the amount of NAD+ substrate (Figure 5b), where the 
introduction of more NAD+ led to the conversion of more NADH, as well as a higher 
yield of acrolein (aldehyde). 
 In addition, the reaction kinetics is closely associated to the enzyme concentrations. 
In a 96-well plate, allyl alcohol (36 μl), NAD+ solution (15 mM, 50 μl) and various 
amount of enzyme working solution (0.2 mg ml-1, 2 μl, 5 μl and 10 μl) was pipetted and 
sodium pyrophosphate buffer solution (50 mM) was added until a total volume of 250 μl 
was reached. As illustrated in Figure 5c, higher ADH enzyme concentration was able to 
catalyze the alcohol oxidation reaction at a faster rate than that of lower ADH enzyme 
concentration. In summary, we expect that these fundamental studies on the factors that 
affect ADH enzymatic reaction kinetics would provide basic guidelines when designing 
other enzyme involved catalysts. 
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Figure 5. ADH enzyme assay test results at various conditions, (a) various allyl alcohol 
concentrations (v/v), 15% (green circle), 20% (blue triangle), 25% (red square) and blank 
(black dot). (b) Various amounts of NAD+, 0.75 μmol (green circle), 0.30 μmol (blue 
triangle), 0.15 μmol (red square) and blank (black dot). (c) Various ADH enzyme 
concentrations, 8 μg ml-1 (green circle), 4 μg ml-1 (blue triangle), 1.6 μg ml-1 (red square) 
and blank (black dot). (d) Various ADH enzyme to Au-MSN weight ratios, 1:18 (green 
circle), 1:12 (blue triangle), 1:9 (red square) and blank (black dot). 
 
 Complementary to the enzyme assay tests, a millimole-scale quantitative analysis of 
ADH enzyme catalyzed allyl alcohol oxidation reaction was explored to provide direct 
evidence of aldehyde production. A reaction mixture (1 ml, 50 mM sodium 
pyrophosphate buffer) comprising allyl alcohol (171 mg), NAD+ (20 mg) and ADH 
enzyme (0.6 mg) was prepared and allowed to stir at room temperature for 1 hr. Acrolein 
(aldehyde) was then extracted from the mixture with toluene and analyzed by GC-MS. 
Consistent with data obtained from enzyme assay tests, ADH enzyme exhibited high 
activity and selectivity for the allyl alcohol oxidation reaction, where a 95% acrolein yield 
(a)  (b) 
(c)  (d) 
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was obtained. These results suggest that ADH enzyme is capable of oxidizing alcohol in 
fast kinetics with high specificity. 
 The fact that MSN as well as Au nanoparticles would undermine the enzymatic 
activity through a non-specific adsorption effect when incubated with enzymes has been 
reported by several research groups.26,27 Therefore, it is important to analyze the influence 
of Au-MSN on the ADH activity before combining the enzyme and Au-MSN in one 
system. As detailed in the experimental section, ADH enzyme was incubated with 
Au-MSN at three different weight ratios (1:9, 1:12 and 1:18) for 30 min at room 
temperature. The supernatant was then used for the assay tests. As shown in Figure 5d, 
the ADH activity was depressed dramatically upon incubation with Au-MSN at a weight 
ratio of 1:18 presumably due to enzyme denaturation. However, adjusting the enzyme to 
Au-MSN weight ratio to 1:9 can diminish the detrimental influence of the inorganic 
catalyst. This data demonstrated that the enzyme and Au-MSN ratio is another factor that 
would impact the performance of the co-catalyst system. 
 
3.3. Au-MSN catalyzed aldehyde esterification 
 To investigate the catalytic efficiency of Au-MSN on the acrolein to acrylate ester 
transformation, the aerobic oxidative esterification of allyl alcohol and acrolein was 
carried out in sodium phosphate buffer solution using Au-MSN as a catalyst at room 
temperature. A control experiment showed that MSN without Au loading was 
catalytically inactive in this reaction. As illustrated in Figure 6, we can clearly observe 
that the ester yield increased over reaction time, from 7.2% at 1 hr to 34.8% at 24 hr (0.5 
mol% catalyst, blue triangle). The reaction kinetic study also suggests that the reaction 
rate slightly decreased over time. Moreover, the amount of Au-MSN catalyst affected the 
ester productivity, where 34.8% of ester yield was obtained with a 0.5 mol% loading of 
Au-MSN, as opposed to only a 6.6% ester yield when a 0.02 mol% loading of Au-MSN 
was introduced over the same period of 24 hr.  
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Figure 6. Production of allyl acrylate ester versus time using 0.02 mol% Au-MSN (black 
square), 0.08 mol% Au-MSN (red dot), and 0.5 mol% Au-MSN (blue triangle) 
 
Table 2. Catalytic performance of the co-catalyst system for allyl alcohol oxidative 
esterification under various conditions. 
Trial NAD+ (mmol) ADH (mg) Au-MSN (mg) Ester Yield (%)
1 0.3 3 0 n.d. 
2 0.3 0 24 2.2 
3 0.3 3 24 26.1 
4 0.15 3 24 9.7 
5 0.3 2 12 n.d. 
a. Conditions: allyl alcohol (1 ml, 15 mmol); sodium pyrophosphate buffer solution (50 
mM, pH 8.8, 4 ml); O2 (1 atm) were consistent along all trials with various amounts of 
NAD+, ADH enzyme and Au-MSN. Ester yield was determined by GC-MS. n.d. – not 
detectable.  
 
3.4. One-pot aerobic alcohol oxidative esterification reaction results 
 Finally, to evaluate the performance of the constructed co-catalyst system on the 
one-pot alcohol oxidative esterification, a reaction mixture containing allyl alcohol, 
NAD+, ADH enzyme and Au-MSN was prepared and stirred for 24 hr, as described in the 
experimental section. The resulting mixture was extracted with toluene and subsequently 
analyzed by GC-MS. Either ADH enzyme or Au-MSN alone exhibited very low 
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reactivity for ester productions (Trial 1 and 2). In contrast, an enhanced ester yield of 
26.1% was measured using the ADH enzyme and Au-MSN co-catalyst system (Trial 3), 
which can be attributed to the tandem oxidative mechanism as we have proposed. It is 
also noteworthy that increasing the amount of substrate or catalyst caused elevation of the 
ester yield (Trial 3, 4 and 5), but the solubility issue of NAD+ prevents further 
enhancement of reactivity through simply adding more NAD+ in this experiment. 
Furthermore, the co-catalyst system shows comparable reactivity to a previously reported 
method by conducting the reaction at 85 °C, where a 17.5% yield of allyl acrylate ester 
was produced.28 Therefore, this co-catalyst system served as a feasible tool for the 
one-pot aqueous oxidative esterification of alcohol. Further interests on metal active sites 
distribution, metal-support interactions and suppressing the nonspecific adsorption effect 
between enzyme and Au-MSN with polyethylene glycol (PEG) coating or pre-adsorbed 
bovine serum albumin (BSA) are still under investigation for the development of catalytic 
efficiency. 
 
4. Conclusion 
 A co-catalyst system consisting ADH enzyme and Au-MSN has been developed for 
the first time and applied in the oxidative esterification of allyl alcohol. The reaction 
kinetics and mechanism were discussed and we have identified fundamental factors for 
designing similar systems. We found that our co-catalyst system revealed superior ester 
productivity over each catalyst alone. Furthermore, we envision that the concept of 
employing a biocatalyst and a supported inorganic catalyst to establish a synergic effect 
could extend to other reactions. 
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CHAPTER 6. LUCIFERASE AND LUCIFERIN CO-
IMMOBILIZED MESOPOROUS SILICA NANOPARTICLE 
MATERIALS FOR INTRACELLULAR BIOCATALYSIS 
A paper published in Journal of American Chemical Society, 2011, 133, 18554-18557 
Xiaoxing Sun, Yannan Zhao, Victor S.-Y. Lin, Igor I. Slowing, and Brian G. Trewyn 
 
 
ABSTRACT  
 We report a gold nanoparticle-capped mesoporous silica nanoparticle (Au-MSN) 
platform for intracellular co-delivery of an enzyme and a substrate with retention of 
bioactivity.  As a proof-of-concept demonstration, Au-MSNs are shown to release 
luciferin from the interior pores of MSN upon gold nanoparticle uncapping in response to 
disulfide-reducing antioxidants and co-deliver bioactive luciferase from the PEGylated 
exterior surface of Au-MSN to HeLa cells.  The effectiveness of luciferase-catalyzed 
luciferin oxidation and luminescence emission in the presence of intracellular ATP was 
measured by a luminometer.  Overall, the chemical tailorability of the Au-MSN platform 
for retaining enzyme bioactivity, the ability to co-deliver enzyme and substrate, and the 
potential for imaging tumor growth and metastasis afforded by intracellular ATP- and 
glutathione-dependent bioluminescence make this platform appealing for intracellular 
controlled catalysis and tumor imaging.   
 
ARTICLE 
 The intracellular delivery and controlled release of multiple biogenic molecules, such 
as genes, enzymes, proteins, and other molecules of pharmaceutical interest,1-5 provides a 
powerful tool for therapeutics and fundamental study of biological processes such as 
enzyme-catalyzed reactions.  While intracellular enzyme delivery has been studied using 
nanocarriers,2-4 the co-delivery of enzyme and substrate for enzymatic reactions mediated 
by intracellular factors has not yet been reported.  Modulation of enzymatic reactions by 
cellular factors provides a potent means to gain information of cellular processes, such as 
signal transduction, DNA replication and metabolism.  These cellular factors can be 
considered to be biological markers and therapeutic targets for disease diagnosis and 
treatment.6-8  For example, one of the key metabolites involved in maintaining a reduced 
intracellular redox milieu is the tripeptide, glutathione (GSH).9  GSH has long been 
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suggested to be part of signaling cascades transuding environmental signals to the nucleus 
and its elevated concentration in many types of tumors is often associated with an 
increased resistance to chemo- and radiotherapy.8  Likewise, as biological energy, ATP 
is involved in a multitude of important intracellular physiological processes, such as 
protein metabolism and cell apoptosis, the level of which is a measure of tumor cell 
viability and growth.6  Therefore, intracellular co-delivery of enzymes and substrates for 
cellular factor (e.g. GSH and ATP)-mediated enzymatic reactions would not only afford 
novel biocatalysis inside live cells but also find application in monitoring tumor growth 
and metastasis.  Two major challenges, however, are 1) the design of nanomaterials for 
intracellular controlled release of multiple biogenic species with preserved bioactivity, 
and 2) the development of methods for imaging and quantification of cellular 
factor-mediated catalytic reactions.   
 Recently, mesoporous silica nanoparticles (MSNs) demonstrated to be excellent 
candidates as vehicles for co-delivery applications,10,11 owing to the co-existence of both 
interior pore and exterior particle surfaces for loading various guest molecules.  This 
unique feature provides the possibility of using MSN for controlled release and 
co-delivery of enzymes and substrates for intracellular enzymatic reactions.  With 
respect to the challenge of imaging and quantification, most studies on nanoparticle-based 
tumor imaging have focused on their cellular uptake and have relied heavily on 
fluorescence readout, which cannot provide biologically relevant information on cellular 
processes.  Bioluminescence has gained favor in the last decade as an attractive 
approach for tumor imaging.12-17  This technique is based on light emission by the 
luciferase-catalyzed oxidation of the luciferin substrate, which occurs in an 
ATP-dependent manner.18,19  A vast number of experiments have been carried out 
examining tumor growth and the effect of therapeutics with the use of tumor cell lines 
that have been genetically engineered to produce luciferase.12-17  However, the detection 
of photons is dependent on the circulatory half-life of injected luciferin substrate and its 
perfusion into the tumor.20  The fast elimination of luciferin from the circulation makes 
utilizing it in many clinical applications challenging.20  Both the sophisticated gene 
engineering and the short circulatory half-life of luciferin call for novel nanomaterials for 
intracellular co-delivery of luciferase and luciferin, which would offer additional 
advantage of improving tumor uptake via the enhanced permeability and retention (EPR) 
effect.21 
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Figure 1. (a) Schematic representation of gold nanoparticle-capped mesoporous silica 
nanoparticles (Au-MSNs) for intracellular co-delivery of luciferase and luciferin. 
Transmission electron micrographs are shown in (b) PEGlyated linker-MSN and (c) 
luciferin-loaded Au-MSN. High magnification image of luciferin-loaded Au-MSN is 
shown in Figure S3d in the SI. 
 
 Herein, we report the development of a gold nanoparticle-capped MSN (Au-MSN) 
system and investigate the intracellular co-delivery of luciferase and luciferin, as a model 
enzyme and substrate pair.  As depicted in Figure 1a, luciferin is loaded in the 
mesopores of MSN and encapsulated with disulfide-linked gold nanoparticles that 
physically block luciferin from leaching out.  Luciferase is physisorbed to the 
PEGylated external surface of Au-MSN through electrostatic interactions as previously 
(a) 
(b) (c) 
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demonstrated.22  Luciferin molecules trapped inside the pores are released upon 
uncapping by intracellular disulfide-reducing antioxidants such as GSH or cysteine, or the 
introduction of dithiothreitol (DTT).23  The released luciferin is in turn converted by 
co-delivered luciferase to oxyluciferin in presence of intracellular ATP and co-factor 
Mg2+, along with the release of energy in the form of photons, measurable with a 
luminometer.  
 We first synthesized 3-(propyldisulfanyl)ethylamine (0.9 mmol g-1) functionalized 
mesoporous silica nanosphere (linker-MSN) material via a method that we previously 
reported.23,24  As described in the Supporting Information (SI), the material was 
PEGylated by grafting 2-[methoxy(polyethylenoxy)-propyl]trimethoxysilane to yield the 
PEGylated (0.1 mmol g-1) linker-MSN with an average particle diameter of 160 nm and 
an MCM-41-type channel-like mesoporous structure (BJH pore diameter = 2.5 nm) 
(Figure 1b). 
 We then functionalized the surface of the gold nanoparticles with a carboxylic 
acid-terminated polyethylene glycol (PEG) linker (Figure 1a) through exchange of 
1-propanethiol protected gold nanoparticle25 with PEG-functionalized thiol ligand in 
dichloromethane (see SI).  The PEG-functionalized gold nanoparticles (PEG-AuNPs) 
are negatively charged (ζ-potential at -39.6 mV) in PBS (pH 7.4) with an average particle 
diameter of 3 nm as determined by transmission electron microscopy (TEM) shown in 
Figure S3b. 
 Before constructing the enzyme-substrate Au-MSN system, the influence of MSN 
and Au NP on the enzymatic activity of luciferase was analyzed by means of a luciferase 
activity assay.26,27  As presented in Figure S4, the luciferase activity is depressed 
dramatically when incubated with linker-MSNs and 1-propanethiol stabilized gold 
nanoparticles, with activities of ~20% and below 15%, respectively, after only 1 h 
incubation.  However, nearly 75% and ~ 63% of luciferase activity were observed after 
3 h of contact with PEGylated linker-MSNs and PEG-Au NPs, respectively.  The 
enzymatic activity of luciferase was also found to be dependent on the incubation time.  
A slight decrease in luciferase activity was found when the incubation time increased 
from 3 to 24 h, in which nearly 60% and ~62% of activity were observed for PEGylated 
linker-MSNs and PEG-Au NPs, respectively.  These data demonstrated that surface 
PEGylation plays a crucial role in improving the biocompatibility of MSN and Au NP for 
the retention of enzyme bioactivity, which is consistent with other literature reports.22,28 
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Figure 2. (a) Cumulative release of luciferin from luciferin-loaded Au-MSN suspension 
(1 mg mL-1) after addition of 1 mM dithiothreitol (DTT) at 23 h.  (b) Resultant 
luminescence from luciferase-luciferin Au-MSN suspension (1 mg mL-1) in presence of 
ATP (80 µM) and Mg2+ (8 mM) after addition of 0.1 (blue), 0.5 (green), 1 (red) and 10 
(black) mM DTT at 60 min. 
 
 Having demonstrated the surface biocompatibility of the materials, we utilized the 
Au-MSN platform to adsorb and encapsulate the enzymatic substrate, luciferin.  To do 
so, the mesopores of PEGylated linker-MSN (25 mg) were loaded with luciferin (33 μM) 
in PBS buffer (pH 7.4), then capped with PEG-Au NPs (25 mg) through amide bond 
formation between the carboxylic acid groups of PEG-Au NP and amino groups of 
PEGylated linker-MSN (Figure 1a), giving rise to the desired luciferin-loaded Au-MSN 
(Figure 1c).  The loading of luciferin was determined to be 13.1 μmol g-1 by 
fluorescence emission spectroscopy (see SI). 
 Transmission electron microscopy (TEM) imaging provides visual evidence on the 
mesopore capping with PEG-Au NPs.  Figure 1b and 1c shows the TEM image of 
PEGylated linker-MSN before and after capping with PEG-AuNPs.  In the case of the 
uncapped MSN (Figure 1b), the hexagonally packed mesoporous channels are clearly 
visable.  In contrast, the TEM image of luciferin-loaded Au-MSN (Figure 1c) shows 
dark spots on MSN surface, representing the attachment of gold nanoparticles on the 
exterior surface of MSN.  
 To determine if the release of luciferin from the luciferin-loaded Au-MSN could be 
induced by disulfide cleavage as desired for intracellular controlled release, 
(a)  (b) 
100 
 
luciferin-loaded Au-MSN (1 mg mL-1) was suspended in PBS buffer (pH 7.4) for 23 h 
before addition of 1 mM DTT.  As shown in Figure 2a, the Au-MSN drug delivery 
system exhibited less than 5.0% of drug release in PBS buffer over of the initial 23 h 
period.  The result suggests a good capping efficiency of the gold nanoparticles for 
encapsulation of the luciferin molecules against leaching.  Addition of 
disulfide-reducing molecules, DTT (1 mM) triggered the release of the 
mesopore-entrapped luciferin.  The rate of luciferin release slightly decreased over time 
until reaching 100% of the total cumulative release (1.44 µmol g-1) in 8 h.  In addition, 
the controlled release of luciferin mediated by the Au-MSN system would offer the 
advantage of improving the circulatory half-life of luciferin and also promote tumor 
uptake via EPR effect, as required in various in vitro and in vivo luminescence assays.  
In addition, the disulfide linkage design renders the release of luciferin predominately 
inside the cells.9,23,24 
 
  
Figure 3. (a) Cytotoxicity study of Hela cells (4×105 cells mL-1) after 24 h incubation 
with different concentrations (20, 50, 100 μg ml-1) of luciferase-luciferin Au-MSN 
suspensions. (b) Endocytosis kinetics measurement of Hela cells incubated with 50 μg 
ml-1 luciferase-luciferin FITC-Au-MSNs.  The cellular uptake percentage at each time 
point was normalized to that at 6 h of contact (63% FITC-positive cells). 
 
 The most advantageous feature of this Au-MSN platform is the potential to deliver 
different biogenic species simultaneously in a controlled fashion.  To construct the 
enzyme-substrate co-delivery system, luciferase was immobilized on the external surface 
of Au-MSNs by incubating luciferin-loaded Au-MSNs (1 mg ml-1) with luciferase (1 mg 
(a) (b) 
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ml-1) in PBS buffer (pH 7.4) for 2 h, followed by centrifugation and freeze drying.  The 
loading of luciferase was measured to be 29.7 µmol g-1 by luciferase activity assay (see 
SI).  This system will henceforth be referred to as luciferase-luciferin Au-MSN.  To 
examine the applicability of this controlled release co-delivery system, DTT-stimulated 
luciferase-luciferin reaction was conducted in situ, as described in the SI.  The 
luminescence intensity remained at background level over a period of 60 minutes before 
the addition of disulfide bond reducing agents, suggesting a “zero premature release” 
property of this system.  After addition of DTT (1 mM), luciferin was released and 
converted to oxyluciferin in a luciferase-catalyzed light-emitting reaction.  As shown in 
Figure 2b, the pattern of luminescence as a function of time was similar for all DTT doses 
(0.1, 0.5, 1 and 10 mM).  The highest luminescence signal was detected in 5 minutes and 
gradually decayed, reaching background after approximately 180 min.  The observed 
luminescence strongly depends on the concentration of DTT.  An increase in the 
luminescence signal was observed with growing DTT dose up to 1 mM, suggesting a 
dose-dependent controlled release profile.  Importantly, when 10 mM DTT was 
introduced to the system, the luminescence showed a 15% reduction in intensity 
compared to the signal triggered by 1 mM DTT, which can be attributed to the 
denaturation of luciferase by high DTT concentrations.29  Hence, the effectiveness of the 
luciferase-luciferin reaction on the Au-MSN platform depends on the strength of the 
reducing environment to which it is exposed. 
 Prior to functional biological studies of the luciferase-luciferin Au-MSNs, it is 
necessary to evaluate the cellular uptake and cytotoxic effects of the material.  To do so, 
we first assessed the cellular uptake of fluorescein isothiocyanate (FITC)-labeled 
luciferase-luciferin Au-MSNs (denoted as luciferase-luciferin FITC-Au-MSNs) by human 
cervical carcinoma (Hela) cells over time.  The cells were incubated in the presence of 
the nanoparticles (50 μg mL-1) for increasing periods of time.  The percentage of cells 
internalizing luciferase-luciferin FITC-Au-MSNs were then monitored by flow cytometry, 
using the trypan blue exclusion method for quenching the fluorescence of extracellular 
particles.30  As shown in Figure 3b, the percent of FITC-positive cells increased with 
time, reaching over 80% of total cellular uptake at 3h of contact and a plateau in 
approximately 6 h.  Taking into account the aforementioned incubation time effect on 
luciferase activity (Figure S4), 3 h of contact was selected for the following biological 
experiments.  We performed confocal fluorescence microscopy (Figure 4a-c) and TEM 
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(Figure 4d-f) analysis of Hela cells 3 h after treatment with 50 μg mL-1 of 
luciferase-luciferin FITC-Au-MSNs and luciferase-luciferin Au-MSNs, respectively.  
Indeed, the nanoparticles were easily visable inside the cells confirming uptake of the 
materials.  Finally, the toxicity of the luciferase-luciferin Au-MSNs was assessed by 
Guava ViaCount cytometry assay with Hela cells.  Following 24 h treatment, we 
observed minimal toxicity (> 95% of cell viability) at concentrations of the material as 
high as 100 μg ml-1 (Figure 3a), in consistence with the good biocompatibility of 
MSN23,31 and gold nanoparticles.32  
 
 
Figure 4. (a) Fluorescence confocal micrographs of Hela cells (4×105 cells mL-1) 
internalized with luciferase-luciferin FITC-Au-MSN (50 μg mL-1, green) for 3 h.  Cell 
nuclei were stained with DAPI (blue).  (b) Corresponding bright field image of Hela 
cells.  (c) Fluorescence confocal and bright field merged image.  (d-f) Transmission 
electron micrographs of Hela cells (4×105 cells mL-1) internalized with 
luciferase-luciferin Au-MSN (50 μg mL-1) for 3 h.  Images increase in magnification 
from left to right. 
 
 To demonstrate that the enzyme-substrate Au-MSN system can deliver both the 
enzyme luciferase and the substrate luciferin for intracellular ATP- and redox 
(d) (e) (f) 
10 µm  10 µm 10 µm 
(a) (b) (c) 
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potential-mediated biocatalysis, the luciferase-luciferin Au-MSN (50 μg mL-1) was 
internalized by Hela cells.  After 3 h incubation, the intracellular luciferase-catalyzed 
luciferin conversion and light emission was assessed by means of intracellular luciferase 
activity assay (see SI).  As shown in Figure 5a, a burst of luminescence was observed 
immediately and slowly decayed over the next 30 min.  Neither the untreated Hela cells 
nor the cells treated with free solution of luciferase and luciferin (10- and 15-fold of 
loading amount, respectively) generated detectable luminescence, which is consistent 
with the low extracellular ATP level33,34 and the membrane impermeability of 
luciferase.35  Therefore, the observed luminescence can be attributed to the capability of 
our Au-MSN system for intracellular co-delivery of enzyme and substrate.  Furthermore, 
our model system provides a means to further regulate the enzymatic reaction inside live 
cells.  As a first demonstration of intracellular catalysis with tunability, the enzymatic 
reaction efficiency was increased by enhancing the intracellular reducing environment.  
As shown in Figure 5b, addition of 1 mM DTT after the decay of the initial intracellular 
disulfide-reducing antioxidant triggered luminescence and led to a 5-fold signal in 10 min 
compared to the highest initial luminescence, followed by a gradual decay, in accord with 
the in situ controlled release experiment shown Figure 3b.  Therefore, this system 
renders the possibility to serve as not only a universal enzyme-substrate carrier for 
intracellular controlled catalysis but also a unique reporter to monitor intracellular 
redox-potential for the study of drug delivery, cell viability and tumor growth. 
 In conclusion, the present study has introduced a novel approach to intracellular 
co-delivery of enzyme and substrate enabling the system to be utilized in intracellular 
controlled catalysis.  Although we have demonstrated only the co-delivery of luciferase 
and luciferin in this study, the concept for delivering multiple biogenic agents using such 
systems could also be extended to other enzymatic reactions by exchanging the enzyme 
and substrate pair.  In addition, it has been recently observed that MSNs are able to 
undergo exocytosis and harvest intracellular biomolecules,36 hence, we envision that our 
system could not only conduct biocatalysis inside live cells but also sequester the product 
out of cells for a variety of biotechnological applications.  
 The luciferase-luciferin Au-MSN system was designed to allow imaging and 
quantification of the intracellular catalysis for system optimization, which also affords a 
unique route toward monitoring tumor growth and metastasis by means of 
bioluminescence and using intracellular ATP and GSH levels as indicators.  Compared 
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with traditional bioluminescence assays, which generally employ gene engineering and 
multiple luciferin injection, only one system needs to be delivered for this strategy.  
Rapid readouts of the luminescence arising from the nanoparticle internalization and 
intracellular GSH-mediated luciferase-luciferin reaction provide a unique platform for 
evaluating tumor development and a convenient way of monitoring response to 
treatments and measuring therapeutic efficacy, which is of importance for medical 
diagnosis, drug screen and development. 
 
 
Figure 5. (a) Resultant luminescence from Hela cells (4×105 cells mL-1) measured after 3 
h incubation with luciferase-luciferin Au-MSNs (50 µg mL-1, black) and with free 
luciferase (1 mg mL-1) and luciferin (40 µM) solution (red), as compared to untreated 
cells (blue).  (b) Observed luminescence after addition of 1 mM dithiothreitol (DTT) at 
30 min  to Hela cells (4×105 cells mL-1) preincubated with luciferase-luciferin Au-MSNs 
(50 µg mL-1) for 3 h. 
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APPENDIX: Supporting Information 
 
1.  Materials Syntheses 
1.1 Synthesis of thiol-functionalized mesoporous silica nanoparticle (SH-MSN) 
 SH-MSNs were synthesized by co-condensation method that we reported 
previously.1  N-Cetyltrimethylammonium bromide (CTAB; 1.0 g) was dissolved in 480 
mL of nanopure water.  NaOH (aq) (2.0 M, 3.5 ml) was introduced to the CTAB 
solution at 353 K.  Tetraethoxysilane (TEOS, 5.0 ml, 22.4 mmol) and 
3-mercaptopropyltrimethoxysilane (MPTMS, 1.0 ml, 5.4 mmol) was added dropwisely to 
the CTAB solution under vigorous stirring.  The mixture was allowed to react for 2 h to 
generate a white precipitate.  This solid crude product was filtered, washed with 
nanopure water and methanol, and dried under high vacuum to yield the as-synthesized 
SH-MSN.  Surface thiol groups were quantified to be 1.75 mmol g-1 by 
thermogravimetric analysis (TGA).  
 
1.2 Synthesis of PEGylated SH-MSN 
 As-synthesized SH-MSN (1.0 g) was suspended in anhydrous toluene (80 ml), 
followed by the addition of 2-[methoxy(polyethylenoxy)-propyl]trimethoxysilane 
(PEG-silane, 1.0 mmol).  The dispersion was refluxed for 20 hours.  The solid was 
filtered, washed with toluene and methanol and dried under high vacuum.  The 
surfactant was removed by refluxing the material (1.0 g) in 1.0 ml of HCl (37.4%) and 
100 ml of methanol for 6 h.  After that, the material was washed extensively with 
methanol and placed under high vacuum to remove remaining solvent.  Surface PEG 
groups were quantified to be 0.15 mmol g-1 by TGA.  
 
1.3 Synthesis of PEGylated 3-(Propyldisulfanyl)propylamine-MSN (PEGylated 
linker-MSN)   
 Surfactant-free PEGylated SH-MSN (0.20 g) and 2-aldrithiol (0.75 g) was dissolved 
in ethanol (80 ml).  The mixture was stirred at room temperature for 24 h to undergo the 
disulfide bond exchange reaction.  The solid was collected, washed with ethanol and 
dried under high vacuum.  The white powder was resuspended in 30 ml ethanol, 
followed by the dropwise addition of aminoethanethiol (0.18 g) in 20 ml ethanol solution.  
The mixture was stirred at room temperature for 24 h followed by centrifugation and 
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washing with copious ethanol to generate the PEGlyated linker-MSN.  
3-(Propyldisulfanyl)propylamine groups on MSN surface were quantified to be 0.9 mmol 
g-1 by TGA.  
 
1.4 Synthesis of 1-propanethiol stabilized gold nanoparticles (Au NPs) 
 The 1-propanethiol stabilized gold nanoparticles were synthesized according to a 
literature reported procedure.2  HAuCl4 (354.4 mg) was dissolved in H2O (30 ml), mixed 
with a solution containing N(C8H17)4Br (2.187 g) and toluene (80 ml).  The two phase 
mixture was vigorously stirred for 20 min and the organic phase was collected, followed 
by the addition of 1-propanethiol (68.5 mg) and NaBH4 solution.  The solution was 
stirred at room temperature for 3 h and the organic phase was separated.  The solvent 
was removed under reduced pressure and the remaining product was mixed with 400 ml 
ethanol.  The mixture was kept at -18°C until dark brown solid precipitated.  Finally, 
the dark brown solid was centrifuged and washed with ethanol several time to afford 
1-propanethiol stabilized gold nanoparticles. 
 
1.5 Synthesis of 2-(2-{2-[2-(2-[2-(11-mercapto-undecyloxy)-ethoxy]-ethoxy)-ethoxy]-
ethoxy}-ethoxy)-ethoxy-acetic acid (thiolalkyl-EG6-COOH) stabilized gold 
nanoparticles (PEG-Au NPs) 
    The thiolalkyl-EG6-COOH stabilized gold nanoparticles were synthesized through 
ligand-exchange reaction according to a modified literature reported procedure.3  
1-propanethiol stabilized gold nanoparticles (20 mg) were dissolved in 20 ml 
dichloromethane.  Thiolalkyl-EG6-COOH (474 mg) was dissolved in dichloromethane 
and added into the gold nanoparticles solution.  The mixture was stirred at room 
temperature for 24 h.  The solid was centrifuged, washed with dichloromethane and 
dried under high vacuum.  A 500 µg mL-1 suspension of PEG-Au-MSN in PBS (pH 7.4) 
was prepared and ζ-potential of PEG-Au-NPs was measured to be -39.6 mV on a Malvern 
Nano HT Zetasizer. 
 
2.  Characterization 
2.1 Powder X-Ray Diffraction 
 X-ray diffraction patterns of the MSN materials were obtained in a Rigaku ultima IV 
X-ray diffractometer using Cu Kα irradiation. 
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Figure S1. Low angle X-Ray Diffraction patterns of SH-MSN (dotted line) and 
PEGylated linker-MSN (solid line). 
 
2.2 Nitrogen adsorption/desorption isotherms 
 Surface analysis of the MSN materials was performed by nitrogen sorption isotherms 
in a Micromeritics Tristar 3000 sorptometer. The surface areas were calculated by the 
Brunauer–Emmett–Teller (BET). 
 
 
Figure S2. (a) BET nitrogen adsorption/desorption isotherms and (b) BJH pore size 
distributions of PEGylated linker-MSN.  Surface area and pore diameter of PEGylated 
linker-MSN were calculated to be 929 m2 g-1 and 2.5 nm, respectively. 
 
2.3 Transmission Electron Microscopy (TEM) 
 The TEM examination was completed on a Tecnai G2 F20 electron microscope 
operated at 200 kV to examine at electron optical magnification of 64,000 to 550,000.  
SH-MSN
PEGylated linker-MSN
(a) (b)
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Figure S3. TEM micrographs of (a) PEGylated linker-MSN, (b) PEG-Au NP, (c-d) 
luciferin-loaded Au-MSN. 
 
3. Loading and releasing experiments 
3.1 Mesopores capping with PEG-Au NPs 
 PEGylated linker-MSN (25.0 mg) was suspended in 10 ml PBS (pH 7.4), PEG-Au 
NPs (25.0 mg) were added to the above suspension along with the addition of 
N-hydroxysuccinimide (NHS, 10 mg) and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC, 10 mg).  The mixture was stirred for another 24 h 
followed by filtration and washing with PBS (×8), giving rise to the desired Au-MSNs. 
 
3.2 Loading of luciferin and capping with PEG-Au NPs 
 PEGylated linker-MSN (25.0 mg) was suspended in 10 ml PBS (pH 7.4) containing 
35.7 μM D-luciferin, and incubated at room temperature with stirring for 24 h.  PEG-Au 
NPs (25.0 mg) were added to the above suspension along with the addition of 
(a) (b)
(c) (d)
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N-hydroxysuccinimide (NHS, 10 mg) and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC, 10 mg).  The mixture was stirred for another 24 h 
followed by filtration and washing with PBS (×8), giving rise to the desired 
luciferin-loaded Au-MSNs.  The loading of luciferin (13.1 µmol g-1) was measured by 
fluorescence microscopy (FluoroMax-2, λex 330 nm, λem 535 nm) and calculated by 
subtracting the amount of luciferin remaining in the phosphate buffer and the combined 
washings from the amount of luciferin initially added to the reaction. 
 
3.3 Controlled release of luciferin 
Luciferin-loaded Au-MSNs (10 mg) were pre-treated by a solution (1 ml) of 
luciferase (1 mg), ATP (0.08 μmol) and Mg2+ (8 μmol) to consume the physisorbed 
luciferin that is tolerant to PBS washing.  The pre-treated luciferin-loaded Au-MSNs (5 
mg) were then suspended in 5 ml PBS and stirred at room temperature.  The amount of 
luciferin leaching was monitored by fluorescence measurement (FluoroMax-2, λex 330 
nm, λem 535 nm) over a period of 23 h.  Dithiothreitol (DTT) was then added to the 
above suspension with final concentration of 1 mM.  The release of luciferin triggered 
by DTT was monitored at different time intervals by fluorescence microscopy. 
 
3.4 Loading of luciferase 
The Au-MSNs (1 mg, section 3.1) or pre-treated Luciferin-loaded Au-MSN (1 mg, 
section 3.2) was suspended in 1 ml PBS (pH 7.4) containing 1 mg ml-1 of luciferase, and 
incubated at room temperature for 2 h.  The resulting luciferase@Au-MSNs or 
luciferase-luciferin Au-MSNs were washed with PBS (×3) and freeze dried.  A loading 
of luciferase (29.7 µmol/g) on luciferase-luciferin Au-MSNs was measured by luciferase 
activity assay as described below, and calculated by subtracting the amount of luciferase 
remaining in the phosphate buffer and the combined washings from the amount of 
luciferase initially added to the material suspension. 
 
3.5 Luciferase activity assay 
The biological acitivty of luciferase was measured according to a standard luciferase 
activity assay as reported previously.4,5  Free luciferase or luciferase-luciferin Au-MSNs 
of different concentrations were added to a solution of MgSO4 (8 mM), ATP (80 μM) and 
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luciferin (40 μM).  Luminescence intensity was measured immediately by a 
luminometer in a microplate reader (Synergy MX). 
 
3.6 Surface property effect on bioactivity of luciferase 
 Free luciferase (1 mg mL-1) was incubated with 0.5 mg mL-1 of SH-MSN, PEGlyated 
linker-MSN Au NPs or PEG-Au NPs for different period of time (1, 3, 24 h) at room 
temperature.  The biological activity of the treated luciferase was measured by luciferase 
activity assay as described above, and compared with untreated luciferase. (Figure S4)  
 
Figure S4. Normalized bioactivity of luciferase (1 mg mL-1) upon incubation with 0.5 mg 
mL-1 of (a) linker-MSN (white), PEGlyated linker-MSN (gray), (b) Au NPs (white), and 
PEG-Au NPs (gray) for different period of time (1, 3, and 24 h), as compared to the 
bioactivity of untreated luciferase (1 mg mL-1, black). 
 
4. Biocompatibility studies 
Reagents and materials for biological studies 
 HeLa cell line was obtained from American Tissue Culture Collection (ATCC). 
Formaldehyde solution (37%, w/w) was purchased from Fisher. 4,6-Diamidino-2-
phenylindole dihydrochloride (DAPI) and trypan blue solution (0.4%, w/w) were 
purchased from Sigma–Aldrich. Trypsin (1×, 0.25%) in 0.1% EDTA-Na without calcium 
and magnesium was purchased from Fisher Scientific. 
 
Cell line maintenance 
 Human liver, skin fibroblast and HeLa cells were maintained in T75 flasks using the 
base medium DMEM (Dulbucco’s modified Eagle’s medium) supplemented with 2 mM 
l-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 1 mg/mL gentamycin. 
(a) (b)
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To make the complete growth medium, 10% fetal bovine serum is added for liver and 
skin fibroblast cells culture, and 10% equine serum is added for HeLa cells. Rat islet 
tumor cells were maintained in T75 flasks using ATCC formulated RPMI-1640 medium 
supplemented with 10% fetal bovine serum. HeLa cells were split every 2–3 days. Human 
liver, skin fibroblast and rat islet tumor cells were split every 3-4 days. 
 
4.1 Cellular uptake study 
 Luciferase-luciferin Au-MSNs were labeled with fluorescein isothiocyanate (denoted 
as luciferase-luciferin FITC-Au-MSNs) for flow cytometry measurement and confocal 
fluorescence microscopy imaging.  FITC-labeled SH-MSNs were employed as the 
starting material for the preparation of luciferase-luciferin FITC-Au-MSNs and 
synthesized by co-condensation reaction1 of TEOS (22.4 mmol), MPTMS (5.4 mmol) and 
fluorescein-linked 3-aminopropyltrimethoxysilane (FITC-APTMS, 40 µmol). 
Hela cells were seeded in six-well plates at the concentration of 1x105 cells/mL and 
incubated at 37°C under 5.5% CO2 in the standard growth media.  After 24 h incubation, 
the growth media were replaced by suspensions of 50 μg ml-1 luciferase-luciferin 
FITC-Au-MSNs in serum-free medium, and the cells were incubated for specific times 
(1,0 30, 60, 180, 360 and 540 min).  The suspensions were then discarded, and the cells 
were harvested by trypsinization and resuspended in trypan blue solution for flow 
cytometry analysis.  Flow cytometry was performed in a BD FACSCanto instrument.  
The percent of cells internalizing luciferase-luciferin FITC-Au-MSNs (FITC-positive 
cells) was plotted as a function of incubation time, as shown in Figure S5. 
For confocal microscopy, glass cover slips were set in the bottom of the wells of the 
plates, followed by addition of the cell suspensions.  After cell attachment, the cells 
were incubated with 50 μg ml-1 luciferase-luciferin FITC-Au-MSNs for 3 h.  The nuclei 
were then stained with Hoechst 33258 (blue) dye.  The cells were imaged in a Leica SP5 
X confocal system with Leica AFS Lite 2.1.0 imaging processing software under an 
oil-immersion 100x objective. 
For transmission electron microscopy (TEM), the trypsinized cells were fixed by 3% 
glutaraldehyde solution after 3 h incubation with 50 μg ml-1 luciferase-luciferin 
FITC-Au-MSNs.  After 1 h incubation with 3% glutaraldehyde at 37°C, the samples 
were post-fixed with 1% osmium tetroxide in PBS for 1.5 h.  Cells were then dehydrated 
in increasing concentrations of ethanol (50%, 60% 70%, 80%, 90%, and 100%) for 15 
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min each and stained with 2% uranyl acetate in 70% ethanol at room temperature 
overnight.  The cells were washed three times with acetone and embedded in Epon.  
Embedded samples were sectioned in 60 nm thick slices on a sliding ultramicrotome.  
Thin sections supported on copper grids were examined with a Tecnai G2 F20 
transmission electron microscope operated at 200 kV. 
 
Figure S5. Endocytosis kinetics measurement of Hela cells incubated with 50 μg ml-1 
luciferase-luciferin FITC-Au-MSNs.  The cellular uptake percentage at each time point 
was normalized to that at 6 h of contact (63% FITC-positive cells).  
 
4.2 Cell viability study 
 HeLa cells were seeded in 6-well plates at the concentration of 1x105 cells/mL and 
were incubated for 24 h in standard culture medium at 37 °C in 5% CO2. After 24 h 
incubation, the growth medium was replaced by suspensions of 20, 50 and 100 μg ml-1 
luciferase-luciferin Au-MSNs in the standard medium, and the cells were incubated for 
24 h. As a control experiment, the cells were incubated with standard growth medium 
without luciferase-luciferin Au-MSNs for another 24 h. Finally, the cytotoxicity of the 
material with Hela cells was evaluated by Guava ViaCount cytometry assay (Guava 
Technologies, Inc.; Hayward, CA).  Cell viability % = (number of viable cells after 
treatment with luciferase-luciferin Au-MSNs / number of viable cells from untreated 
control sample)×100%. (Figure S6)  
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Figure S6. Cytotoxicity study of luciferase-luciferin Au-MSN with Hela cells.  Hela 
cells were incubated with different concentrations (20, 50, 100 μg ml-1) of 
luciferase-luciferin Au-MSN suspensions for 24 h before measuring cell viability by 
Guava ViaCount cytometry assay. 
 
 
Figure S7. Luminescence from Hela cells (4×105 cells mL-1) measured after 3 h 
incubation with luciferase-luciferin Au-MSNs (50 µg mL-1, black dot) and with 
luciferase@Au-MSNs (50 μg mL-1, green triangle), as compared to untreated cells (blue 
square). 
 
4.3 Intracellular luciferase activity assay 
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 Hela cells were seeded in 96-well plates at the concentration of 1x105 cells ml-1 and 
incubated at 37°C under 5.5% CO2 in the standard growth media.  After 24 h incubation, 
the growth media were replaced by suspensions of 50 μg ml-1 luciferase-luciferin 
Au-MSNs in serum-free medium, and the cells were incubated for either 3 h or 6 h.  A 
solution of MgSO4 (8 mM) was then added and luminescence intensity was measured by 
a luminometer on a microplate reader (Synergy MX), as shown in Figure S7 and S8. 
 
 
Figure S8. Observed luminescence after addition of 1 mM dithiothreitol (DTT) to Hela 
cells (4×105 cells mL-1) preincubated with luciferase-luciferin Au-MSNs (50 µg mL-1) for 
3 h (red dot) and 6 h (blue square). 
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CHAPTER 7. GENERAL CONCLUSIONS 
 
  This dissertation summarizes the research accomplished during my doctoral studies. 
The central theme is focused on the applications of mesoporous silica nanoparticles 
(MSNs) in the field of drug delivery as well as catalysis. Contributions in both fields have 
been made by Dr. Lin’s and Dr. Trewyn’s group, using MSNs to serve as multiple 
biomolecules intracellular delivery vehicles, or as solid supports for noble metal catalyst 
complexation. Unique features of MSNs, such as large surface area, tunable pore 
diameter, controllable particle size and morphology, excellent biocompatibility, offer 
great advantages over other materials. 
 Recent advancement of hybrid MSNs materials as non-invasive, biocompatible drug 
delivery devices has been well established in pharmaceutical research. The flexibility to 
functionalize both interior pore and exterior particle surface of MSNs with organic 
components has led to the fabrication of numerous MSNs based nanovalve and capping 
systems. Thus, drug molecules can be encapsulated in the pores and released in a 
controlled fashion by physical, chemical or biological external or internal stimuli. 
Although the biocompatibility of MSNs has not been fully unveiled, paradigms of 
successful in vivo drug delivery systems using MSNs have been demonstrated. 
Investigations conducted on the hemocompatibility of MSNs showed that the interactions 
of MSNs with human red blood cells (RBC) membranes are particle size- and 
surface-dependent. Moreover, hemocompatibility of MSNs can be regulated by surface 
modification. In addition, it is discovered for the first time that MSNs were internalized 
by RBC, rendering the possibility of delivering drug molecules into non-phagocytic cells 
with MSNs.  
 MSNs material has also been extensively applied in the field of catalysis as solid 
scaffolds. A Pt(II) complex catalyst was tethered onto MSNs via a post-synthesis method. 
A detailed study suggests that the assembly exhibited preserved catalytic activity and 
dramatically improved thermal stability comparing to the homogeneous catalyst. 
Furthermore, this MSNs supported noble metal catalyst can function synergically with 
other catalysts, especially biocatalysts. In an alcohol oxidative esterification reaction, 
with the aid of alcohol dehydrogenase (ADH) to efficiently oxidize alcohol to aldehyde, 
MSNs supported Au nanoparicles (Au-MSN) were able to subsequently convert aldehyde 
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to esters with fast kinetics. The fundamental studies would enable this co-catalyst system 
to extend to a variety of catalyst pairs for a great scope of reactions. 
 Taking advantage of the excellent endocytosis efficiency of MSNs, catalysis 
reactions can take place intracellularly using cell components as substrates. An 
intracellular co-delivery system was designed based on a gold nanoparticles-capped 
MSNs platform. Luciferin was trapped inside the pore channels and released upon gold 
nanoparticle uncapping after cell internalization. Luciferase enzyme with preserved 
bioactivity was co-delivered simultaneously. Successful intracellular catalysis reaction 
was indicated by the emission of luminescence signals during the oxidization of delivered 
luciferin and intracellular ATP by luciferase enzyme. This co-delivery system could play a 
significant role in intracellular controlled catalysis and tumor imaging. 
 In summary, MSNs material shows its versatility in a wide range of applications. 
However, applications are not limited to what have been discussed in this dissertation. 
We envision that in the future, multi-functional MSNs assemblies can be developed to 
accomplish multiple tasks simultaneously. 
